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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 13, Revision 2 
(FGE.13Rev2): 
Furfuryl and furan derivatives with and without additional side-chain 
substituents and heteroatoms from chemical group 141 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3  
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT  
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to evaluate 27 flavouring substances in the Flavouring Group 
Evaluation 13, Revision 2, using the Procedure in Commission Regulation (EC) No 1565/2000. Three 
of the substances [Fl-no: 13.125, 13.155 and 13.162] were considered to have genotoxic potential. The 
remaining 24 substances were evaluated through a stepwise approach (the Procedure) that integrates 
information on structure-activity relationships, intake from current uses, toxicological threshold of 
concern, and available data on metabolism and toxicity. The Panel concluded that the 24 substances do 
not give rise to safety concerns at their levels of dietary intake, estimated on the basis of the MSDI 
approach. Besides the safety assessment of these flavouring substances, the specifications for the 
materials of commerce have also been considered. Adequate specifications including complete purity 
criteria and identity for the materials of commerce have been provided for all 24 flavouring substances 
evaluated through the Procedure.  
© European Food Safety Authority, 2011 
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SUMMARY 
The present revision of FGE.13, FGE.13Rev2, concerns, in total, the evaluation of 27 candidate 
flavouring substances; two more than in the previous revision of this FGE. New data included are 
additional data submitted on 5-hydroxymethylfurfural (5HMF) [FL-no: 13.139] in response to 
genotoxicity data requested in FGE.13, consideration of additional data on the stereoisomeric 
composition for two substances [FL-no: 13.185 and 13.199] and inclusion of two more candidate 
substances [FL-no: 13.130 and 13.155]. Also the evaluation of substance [FL-no: 13.135] has been re-
considered. 
Three of the 27 flavouring substances possesses a chiral centre [FL-no: 13.127, 13.185 and 13.199]. 
Industry has informed that the commercial substances are the racemates in all three cases. Two of the 
27 substances can exist as geometrical isomers [FL-no: 13.011 and 13.129] and in both cases Industry 
has informed that the commercial substances are the (E)-isomers.  
Eight of the candidate substances are classified into structural class II [FL-no: 13.122, 13.130, 13.136, 
13.139, 13.145, 13.155, 13.125 and 13.162] and 19 candidate substances are classified into structural 
class III [FL-no: 13.011, 13.102, 13.108, 13.113, 13.114, 13.124, 13.127, 13.129, 13.132, 13.133, 
13.135, 13.141, 13.143, 13.144, 13.146, 13.149, 13.178, 13.185 and 13.199]. 
Nineteen of the flavouring substances in the present group have been reported to occur naturally in a 
wide range of food items. For seven flavouring substances, no data on natural occurrence have been 
reported. 
In its evaluation, the Panel as a default used the “Maximised Survey-derived Daily Intakes” (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe. However, when the 
Panel examined the information provided by the European Flavouring Industry on the use levels in 
various foods, it appeared obvious that the MSDI approach in a number of cases would grossly 
underestimate the intake by regular consumers of products flavoured at the use level reported by the 
Industry, especially in those cases where the annual production values were reported to be small. In 
consequence, the Panel had reservations about the data on use and use levels provided and the intake 
estimates obtained by the MSDI approach. 
In the absence of more precise information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a “modified Theoretical Added Maximum Daily Intake” 
(mTAMDI) approach based on the normal use levels reported by Industry. In those cases where the 
mTAMDI approach indicated that the intake of a flavouring substance might exceed its corresponding 
threshold of concern, the Panel decided not to carry out a formal safety assessment using the 
Procedure. In these cases the Panel requires more precise data on use and use levels. 
According to the default MSDI approach, the 27 flavouring substances in this group have intakes in 
Europe from 0.0012 to 37 microgram/capita/day, which are below the thresholds of concern for both 
structural class II (540 microgram/person/day) and structural class III (90 microgram/person/day) 
substances.  
On the basis of the reported annual production volumes in Europe (MSDI approach), the total 
estimated combined intake of candidate and supporting substances would be 885 and 60 
microgram/capita/day for structural class II and III, respectively. The total combined daily per capita 
intake of 885 microgram exceeds the threshold of concern of 540 microgram/person/day for structural 
class II substances. However, 50 % of the combined daily per capita intake of 885 microgram comes 
from furfural for which, together with the furfural component of furfural diethyl acetal, an ADI of 0.5 
mg/kg bw has been established by EFSA. The total combined intake for the class III substances of 60 
microgram/capita/day does not exceed the threshold for the structural class of 90 
microgram/person/day. 
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Genotoxicity studies were only available on some of the candidate substances included in main group 
I or on related supporting substances. For subgroup Ia, data on in vitro genotoxicity were provided for 
the two candidate substances 5HMF [FL-no: 13.139] and furoic acid [FL-no: 13.136] as well as for 
five supporting substances. Data on in vivo genotoxicity were provided for one candidate substance 
[FL-no: 13.139] and for two of the supporting substances. For the candidate substance in group Ib, in 
vitro and in vivo genotoxicity data were available for one supporting substance. For subgroup Ic, data 
on in vitro genotoxicity were provided for two supporting substances. For one of these, also data on in 
vivo genotoxicity were provided. In addition, data for a supporting substance for subgroup Ib 
contribute to the evaluation of the genotoxic potential of substances in subgroup Ic due to structural 
similarity of metabolites of the Ic candidates with the substances in subgroup Ib. 
In subgroup Ia the data available do not indicate a concern for genotoxicity. For the one candidate 
substance in subgroup Ib [FL-no: 13.155] and the two candidate substances in subgroup Ic [FL-no: 
13.125 and 13.162], metabolism studies on closely related substances indicate a potential for DNA-
binding of metabolites. In addition, in several in vitro studies with related substances, indications for 
genotoxic activity were obtained. These data preclude the evaluation through the Procedure of the 
three candidate flavouring substances in subgroup Ib and Ic. 
No genotoxicity data were available on candidate substances or on structurally related substances in 
main group II. The lack of data on the sulphur-containing candidate substances from main group II, or 
on the related supporting substances, does not allow concluding on their genotoxicity, but would not 
preclude the evaluation of these substances through the Procedure. 
The metabolism of non-sulphur-containing furfuryl alcohol derivatives in FGE.13 [FL-no: 13.127, 
13.129, 13.130, 13.132 and 13.133] includes the formation of furfural, a known reactive aldehyde, that 
may lead to hepatotoxicity. Furfural will be further metabolised to furoic acid [Fl no: 13.136] and 
furanacrylic acid, the hydrolysis product of [FL-no: 13.011]. In addition the two furoate esters [FL-no: 
13.102 and 13.122] and furoic acid itself [FL-no: 13.136], which is the main metabolite of furfural, 
may be metabolised to CO2, with the opening of the furan ring, producing reactive intermediates. 
Therefore, it is concluded that the candidate substances included in subgroup Ia cannot be predicted to 
be metabolised to innocuous compounds. In addition, 5HMF [FL-no: 13.139] has a free aldehyde 
function (cf. furfural) and can be anticipated to be reactive. In addition, this substance may be 
bioactivated to reactive intermediates by sulphotransferases for which genotoxicity has been reported. 
However, the available genotoxicity and carcinogenicity data for this substance do not indicate a 
concern for this substance. Extensive ring-opening with formation of intermediates reactive towards 
DNA has been reported for 2-alkyl-substituted furans in subgroup 1c [FL-no: 13.125 and 13.162]. In 
addition, these compounds may be metabolised to ketones (subgroup 1b; [FL-no: 13.155]), for which 
genotoxicity may be anticipated. 
Based on the metabolism of other sulphur-containing compounds, the candidate furfuryl and furan 
monosulphides are expected to be subject to oxidation mainly to sulphoxides and sulphones. Given the 
reactivity of thiol groups, whether free or from di- or trisulphides, and the importance of thiol groups 
in cell physiology, it cannot be excluded that these substances interfere with normal cell function. 
Therefore, it is concluded that none of the candidate substances included in main group II can be 
predicted to be metabolised to innocuous substances.  
Short-term and long-term toxicity studies are available for two candidate substances included in 
subgroup Ia, namely 2-furoic acid [FL-no: 13.136] and 5HMF [FL-no: 13.139] and for three related 
supporting substances. For the candidate substances structurally related to furfuryl alcohol or furfural, 
these studies indicate that the liver is the critical target for their toxicity. EFSA has established an ADI 
value of 0.5 mg/kg/d bw for furfural and the furfural component of furfural diethyl acetal. For 5-
hydroxymethylfurfural [FL-no: 13.139], substance-specific data indicate that the kidney of the male 
mouse was the target organ, and for this substance a BMDL of 14.4 mg/kg bw/day could be derived, 
based on the results of a 13-weeks oral toxicity study.  
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No toxicity data are available on the sulphur-containing furan-derived candidate substances included 
in subgroups IIa-d. However, results from toxicity studies on 14 supporting substances have been 
reported. Many of the available studies were performed either with a single dose level or multiple dose 
levels that produced no effects; the doses producing no adverse effects ranged from 0.45 to 10 mg/kg 
bw/day.  
It was considered on the basis of the default MSDI approach that for the 24 candidate substances [FL-
no: 13.011, 13.102, 13.108, 13.113, 13.114, 13.122, 13.124, 13.127, 13.129, 13.130, 13.132, 13.133, 
13.135, 13.136, 13.139, 13.141, 13.143, 13.144, 13.145, 13.146, 13.149, 13.178, 13.185 and 13.199], 
it could be concluded, at step B4 of the Procedure, that these 24 candidate substances do not pose a 
safety concern when used as flavouring substances at the estimated levels of intake based on the MSDI 
approach. 
The Panel has reservations for three substances [FL-no: 13.125, 13.155 and 13.162] which could not 
be evaluated through the Procedure due to concern of genotoxicity in vitro. For these three substances 
additional date are required. 
For three candidate substances [FL-no: 13.122, 13.136 and 13.139] in structural class II, evaluated 
through the Procedure, the mTAMDI range from 1400 to 3900 microgram/person/day, which are 
above the threshold of concern for this Cramer class. For one substance [FL-no: 13.145] the mTAMDI 
is 160 microgram/person/day, which is below the class threshold of 540 microgram/person/day. For 
substance [FL-no: 13.130], no use levels were provided, so no mTAMDI can be calculated. 
The estimated intakes for 16 [FL-no: 13.011, 13.102, 13.108, 13.113, 13.114, 13.127, 13.129, 13.132, 
13.133, 13.135, 13.141, 13.143, 13.146, 13.149, 13.178 and 13.185] of the 19 substances evaluated 
through the Procedure and assigned to structural class III, based on the mTAMDI, range from 160 to 
3900 microgram/person/day, which are above the threshold of concern for structural class III 
substances of 90 microgram/person/day. For the remaining three substances from structural class III 
[FL-no: 13.124, 13.144 and 13.199] the mTAMDIs range from 49 to 78 microgram/person/day, which 
is below the threshold of concern. 
Thus, for 20 of the candidate substances, evaluated using the Procedure, further information is 
required. This would include more reliable intake data and then, if required, additional toxicological 
data. On the basis of such additional data, these flavouring substances should be reconsidered along 
the steps of the Procedure. Following this procedure additional toxicological data might become 
necessary.  
In order to determine whether the conclusion for the 24 candidate substances evaluated through the 
Procedure can be applied to the material of commerce, it is necessary to consider the available 
specifications. Adequate specifications including complete purity criteria and identity for the materials 
of commerce have been provided for all 24 flavouring substances evaluated through the Procedure.  
For these 24 candidate substances [FL-no: 13.011, 13.102, 13.108, 13.113, 13.114, 13.122, 13.124, 
13.127, 13.129, 13.130, 13.132, 13.133, 13.135, 13.136, 13.139, 13.141, 13.143, 13.144, 13.145, 
13.146, 13.149, 13.178, 13.185 and 13.199] the Panel concluded that they would be of “No safety 
concern at estimated levels of intake as flavouring substances” based on the MSDI approach. 
KEYWORDS 
Furfuryl, furan, flavourings, sulphur-substituted, disulphide, trisulphide, thioester, safety, FGE.13. 
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Furthermore, all substances are divided into 34 chemical groups. Substances within a group 
should have some metabolic and biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
The FGE is revised to include substances for which data were submitted after the deadline as laid 
down in Commission Regulation (EC) No 622/2002 and to take into account additional information 
that has been made available since the previous Opinion on this FGE.  
The revision also includes newly notified substances belonging to the same chemical groups evaluated 
in this FGE. 
After the completion of the evaluation programme the Union List of flavouring substances for use in 
or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
HISTORY OF THE EVALUATION 
The first revision of FGE.13, FGE.13Rev1, included the assessment of seven additional candidate 
substances [FL-no: 13.125, 13.135, 13.141, 13.143, 13.162, 13.185 and 13.199]. For two of these 
substances [FL-no: 13.125 and 13.162] supporting toxicity data on a structurally related substance 
have been submitted. No other data have been provided. The No Observed Adverse Effect Level 
(NOAEL) for the structurally related substance [FL-no: 13.079] turned out to be taken from a study 
with a different substance. This necessitates an update of the evaluation of the flavouring substance 
[FL-no: 13.113], which depends on this NOAEL. For 12 flavouring substances in the original FGE.13, 
the classification according to Cramer et al, 1977 was revised. These revisions were necessary to 
create consistency with the evaluations in FGEs 65 and 67. For the substances involved, the final 
conclusions were not changed. In addition, the Panel noted that substance [FL-no: 13.178] is 
synonymous with [FL-no: 13.192], which is evaluated by the JECFA (JECFA no 1542) at its 69th 
meeting (JECFA, 2009a). For this substance in the JECFA evaluation an MSDI for Europe of 0.24 
microgram per capita per day was given. This figure, which is higher and more recent than the 
exposure estimate in FGE.13 (0.0012 microgram per capita per day), was used in the first Revision of 
the FGE. 
FGE Opinion adopted 
by EFSA 
Link No. of candidate 
substances 
FGE.13 28 April 2005 http://www.efsa.eu.int/science/afc/afc_opinions/1023_en.htm
l 
18 
FGE.13Rev1 26 November 2009 http://www.efsa.europa.eu/en/scdocs/scdoc/1403.htm 25 
FGE.13Rev2   27 
 
The present revision of FGE.13, FGE.13Rev2 includes the consideration of newly submitted sub-
chronic and chronic toxicity data as well as genotoxiciy data on 5-hydroxymethylfurfural [FL-no: 
13.139]. For this substance additional genotoxicity data have been requested in FGE.13. The Panel has 
used the information from the new sub-chronic and chronic toxicity studies for a BMD derivation. 
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New information from Industry on the stereoisomeric composition of two candidate substances [FL-
no: 13.185 and 13.199] has also been included. 
Furthermore, one alpha,beta-unsaturated ketone [FL-no: 13.155] from FGE.221 has been included in a 
new subgroup, as well as seven supporting substances from the same FGE.221 have been included in 
the current FGE.13Rev2. EFSA concluded in November 2008 that the alpha,beta-unsaturated structure 
in conjugation with an aromatic ring system is comparable to the situation in acetophenone, i.e. no 
structural alert for genotoxicity. Industry has submitted additional genotoxicity data on the structurally 
related 2-furyl methyl ketone [FL-no: 13.054]. These data will be considered in this FGE as well.  
In addition, this revision also includes one substance furfuryl butyrate [FL-no: 13.130] for which the 
JECFA did evaluate the specifications, but did not perform a safety evaluation. No toxicity or 
metabolism data were submitted for this substance. 
In the previous versions of this FGE, substance [FL-no: 13.135] (1-(2-furfyrylthio)propanone) was 
incorrectly allocated to a subgroup of thioesters and evaluated as the thioester S-furfuryl-
propanethioate. In the current revision of FGE.13 this candidate substance ([FL-no: 13.135]) is 
allocated to and re-evaluated in subgroup IIa, consisting of sulphides. Since there are no further 
thioester candidates substances left in this FGE, the respective subgroup has been deleted.  
TERMS OF REFERENCE 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 
substances in the Register prior to their authorisation and inclusion in a Union List according to 
Commission Regulation (EC) No 1565/2000 (EC, 2000a). In addition, the Commission requested 
EFSA to evaluate newly notified flavouring substances, where possible, before finalising the 
evaluation programme. 
In addition, in letter of 30 July 2010 the Commission requested EFSA to carry out an evaluation of 
flavouring substance 1-(2-furfyrylthio)propanone [FL-no: 13.135]: 
“The European Commission requests the European Food Safety Authority to carry out a safety 
assessment on the new flavouring substances 5-Pentyl-3H-furan-2-one, 1-(2-furfyrylthio)propanone 
and 5-Ethyl 2,3-dimethyl pyrazine, in accordance with Commission Regulation (EC) No 1565/2000.  
5-Pentyl-3H-furan-2-one [FL-no: 10.070] and 5-Ethyl 2,3-dimethyl pyrazine [FL-no: 14.170] are 
evaluated in FGE.10Rev3 and FGE17Rev3.  
The evaluation programme has been finalised end of 2009. The deadline of the Terms of Reference in 
letter of 30 July 2010 was negotiated to end 2011. 
ASSESSMENT 
1. Presentation of the Substances in Flavouring Group Evaluation 13 Revision 2 
1.1. Description 
The present Flavouring Group Evaluation (FGE.13Rev2), using the Procedure as referred to in the 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) (The Procedure – shown in schematic form 
in Annex I of this FGE), deals with 27 flavouring substances (candidate substances) from chemical 
group 14, Annex I of Commission Regulation (EC) No 1565/2000 (EC, 2000a). All candidate 
substances in FGE.13Rev2 are furan derivatives and can be divided into two main groups (I and II), 
depending on the absence/presence of sulphur-containing substituents. Within these two main groups a 
further differentiation in subgroups is introduced, depending on the nature of the ring substituents and 
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the number and position of the sulphur substituents. The subgrouping of the candidate substances is 
shown below. The candidate substances are structurally related to 53 flavouring substances 
(supporting substances) evaluated by the JECFA at their 55th, 59th, 65th and 69th meetings (JECFA, 
2001a; JECFA, 2002c; JECFA, 2006d; JECFA, 2009a) or EFSA (EFSA, 2004c) [FL-no: 13.126]).   
Main group I. Non-sulphur-containing Furan Derivatives 
Subgroup Ia: Structurally related to furfuryl alcohol 
The ten candidate substances in subgroup Ia are furfuryl alcohol derivatives such as esters of furfuryl 
alcohol [FL-no: 13.127, 13.129, 13.130, 13.132 and 13.133] or ethyl ester of furanacrylic acid [FL-no: 
13.011], furoic acid [FL-no: 13.136] and its esters [FL-no: 13.102 and 13.122] and 5-
hydroxymethylfurfuraldehyde [FL-no: 13.139]. These ten candidate substances are closely related to 
14 supporting substances evaluated at the 55th JECFA meeting (JECFA, 2001a) in a group of 
“Furfuryl alcohol and related substances”. The 14 supporting substances have subsequently been 
considered by EFSA in FGE.66 (EFSA, 2009ap). In addition, the implication for human health of 
dietary exposure to furfural and furfural diethyl acetal [FL-no: 13.126] (a fifteenth supporting 
substance for this group) has been evaluated by the AFC Panel (EFSA, 2004c) and a risk assessment 
report for furfural is available in the framework of Existing Chemical Evaluation, according to EU 
Regulation 73/793/CE (EU-RAR, 2004b). 
Subgroup Ib: Alkoyl-substitutes furans 
This subgroups contains only one candidate substance [FL no: 13.155], which is closely related to 
seven supporting substances evaluated at the 69th JECFA meeting (JECFA, 2009a) in a group of 
“Furan-substituted substances”. These seven supporting substances will be considered by EFSA in 
FGE.67Rev1 (EFSA, 2011i). 
Subgroup Ic: Alkyl-substituted furans 
The two candidate substances in subgroup Ic are alkyl substituted furans [FL-no: 13.125 and 13.162] 
without any further functional groups. These two candidate substances are closely related to seven 
supporting substances evaluated at the 69th JECFA meeting (JECFA, 2009a) in a group of “Furan-
substituted substances”. These seven supporting substances have been considered by EFSA in FGE.67 
(EFSA, 2009ao). 
Main group II. Sulphur-containing Furan Derivatives 
Subgroup IIa: Sulphides 
The seven candidate substances in subgroup IIa are sulphides (or thioethers) [FL-no: 13.114, 13.124, 
13.135, 13.141, 13.143, 13.145 and 13.199]. These seven candidate substances are closely related to 
11 supporting substances evaluated at the 59th JECFA meeting (JECFA, 2002c) in a group of 
“Sulphur-substituted furan derivatives”. These 11 supporting substances have been considered by 
EFSA in FGE.65 (EFSA, 2009an).  
Subgroup IIb: Thiols 
The two candidate substances in subgroup IIb are thiols [FL-no: 13.108 and 13.149]. Candidate 
substance [FL-no: 13.108] is a dihydrofuran derivative, rather than a furan derivative, but is included 
in this subgroup, nonetheless. The two candidate substances are closely related to five supporting 
substances evaluated at the 59th JECFA meeting (JECFA, 2002c) in a group of “Sulphur-substituted 
furan derivatives”. These five supporting substances have been considered by EFSA in FGE.65 
(EFSA, 2009an).  
Subgroup IIc: Disulphides 
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The four candidate substances in subgroup IIc are disulphides [FL-no: 13.113, 13.144, 13.178 and 
13.185]. These four candidate substances are closely related to seven supporting substances evaluated 
at the 59th JECFA meeting (JECFA, 2002c) in a group of “Sulphur-substituted furan derivatives”. 
These seven supporting substances have been considered by EFSA in FGE.65 (EFSA, 2009an). 
Subgroup IId: Polysulphides 
The one candidate substance in subgroup IId is a trisulphide [FL-no: 13.146]. This candidate substance 
is closely related to a tetrasulphide supporting substance evaluated at the 59th JECFA meeting 
(JECFA, 2002c) in a group of “Sulphur-substituted furan derivatives”. This supporting substance has 
been considered by EFSA in FGE.65 (EFSA, 2009an). 
FGE.13Rev2 – Candidate and Supporting substances divided into subgroups of related chemical 
structures. Substances listed in bold are the candidate substances in this FGE. The supporting substances 
from the 55th, 59th, 65th or 69th JECFA and EFSA (EFSA, 2004c) are in normal type face. 
FL-no 
JECFA-no 
EU Register name Structural formula 
Ia Structurally Related to Furfuryl Alcohol 
13.011 Ethyl furfuracrylate O O
O
 
13.102 Butyl 2-furoate 
O
O
O
 
13.122 Ethyl 2-furoate 
O
O
O
 
13.127 Furfuryl 2-methylbutyrate O
O
O
 
13.129 Furfuryl but-2-enoate 
O
O
O
 
13.130 Furfuryl butyrate O O
O
 
13.132 Furfuryl hexanoate 
O
O
O
13.133 Furfuryl isobutyrate O
O
O
 
13.136 2-Furoic acid 
O
OH
O
 
13.139 5-Hydroxymethylfurfuraldehyde 
O
O OH
 
13.001 
745 5-Methylfurfural 
O
O
 
13.002 
746 Methyl 2-furoate 
O
O
O
 
13.003 
747 Propyl 2-furoate 
O
O
O
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FGE.13Rev2 – Candidate and Supporting substances divided into subgroups of related chemical 
structures. Substances listed in bold are the candidate substances in this FGE. The supporting substances 
from the 55th, 59th, 65th or 69th JECFA and EFSA (EFSA, 2004c) are in normal type face. 
FL-no 
JECFA-no 
EU Register name Structural formula 
13.018 
450 Furfural 
O
O
 
13.019 
451 Furfuryl alcohol 
O
OH
 
13.057 
743 Furfuryl isovalerate 
O
O
O
13.062 
740 Furfuryl propionate 
O
O
O
 
13.068 
741 Furfuryl valerate 
O
O
O
 
13.126 Furfuryl diethyl acetal 
O
O
O
 
13.128 
739 Furfuryl acetate 
O
O
O
 
13.005 
749 Hexyl 2-furoate 
O
O
O
13.025 
748 Pentyl 2-furoate 
O
O
O
13.038 
752 2-Phenyl-3-carbethoxyfuran 
O
O
O  
13.067 
742 Furfuryl octanoate 
O
O
O
13.073 
750 Octyl 2-furoate 
O
O
O
Ib Alkoyl-substituted furans 
13.155 2-Methyl-5-propionylfuran O
O
 
13.054 
1503 2-Acetylfuran 
O
O
 
13.066 
1506 3-Acetyl-2,5-dimethylfuran 
O
O  
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FGE.13Rev2 – Candidate and Supporting substances divided into subgroups of related chemical 
structures. Substances listed in bold are the candidate substances in this FGE. The supporting substances 
from the 55th, 59th, 65th or 69th JECFA and EFSA (EFSA, 2004c) are in normal type face. 
FL-no 
JECFA-no 
EU Register name Structural formula 
13.070 
1512 2-Hexanoylfuran 
O
O
 
13.083 
1504 2-Acetyl-5-methylfuran 
O
O
 
13.101 
1505 2-Acetyl-3,5-dimethylfuran 
O
O
 
13.105 
1507 2-Butyrylfuran 
O
O
 
13.163 
1509 2-Pentanoylfuran 
O
O
 
Ic Alkyl-substituted furans 
13.125 2-Ethyl-5-methylfuran 
O
 
13.162 2-Octylfuran 
O
13.029 
1488 2,5-Dimethylfuran 
O
 
13.030 
1487 2-Methylfuran 
O
 
13.092 
1489 2-Ethylfuran 
O
 
13.059 
1491 2-Pentylfuran 
O
 
13.069 
1492 2-Heptylfuran 
O
 
13.103 
1490 2-Butylfuran 
O
 
13.106 
1493 2-Decylfuran 
O
II Sulphur-substituted Furan Derivatives 
IIa Sulphides 
13.114 2,5-Dimethyl-3-(methylthio)furan 
O
S  
13.124 Ethyl furfuryl sulfide S
O
 
13.135 1-(2-furfurylthio)-propanone 
O
S
O  
13.141 Methyl (2-furfurylthio)acetate 
O
S
O
O  
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FGE.13Rev2 – Candidate and Supporting substances divided into subgroups of related chemical 
structures. Substances listed in bold are the candidate substances in this FGE. The supporting substances 
from the 55th, 59th, 65th or 69th JECFA and EFSA (EFSA, 2004c) are in normal type face. 
FL-no 
JECFA-no 
EU Register name Structural formula 
13.143 Methyl 3-(furfurylthio)propionate 
O
OS
O
13.145 Methyl 5-methylfurfuryl sulfide S
O
 
13.199 3-[(2-methyl-3-furyl)thio]-butanal 
o
s O  
13.053 
1076 Methyl furfuryl sulfide 
S
O
 
13.056 
1080 Difurfuryl sulfide 
S
O
O
13.065 
1062 2-Methyl-5-(methylthio)furan 
O S
 
13.152 
1061 2-Methyl-3-(methylthio)furan 
O
S  
13.196 
1084 
4-(Furfurylthio) pentan-2-one  
 
O
S
O
 
13.032 
1077 Furfuryl isopropyl sulfide 
O
S
 
13.075 
1086 2,6-Dimethyl-3-((2-methyl-3-furyl)thio)heptan-4-one 
O
S
O
 
13.077 
1085 3-((2-Methyl-3-furyl)thio)heptan-4-one 
O
S
O
 
13.078 
1087 4-((2-Methyl-3-furyl)thio)nonan-5-one 
O
S
O
 
13.093 
1088 Ethyl 3-(2-furfurylthio)propionate OS
O
O
 
13.151 
1082 2-Methyl-3,5 and 6-(furfurylthio)pyrazine 
2 or 5 or 6 -Methyl-3-(furfurylthio)pyrazine
N
N
S
O
IIb Thiols 
13.149 5-Methyl-2-furanmethanethiol 
O
SH
 
13.108 4,5-Dihydro-3-mercapto-2-methylfuran 
O
SH  
13.026 
1072 2-Furanmethanethiol 
O
SH
 
13.055 
1060 2-Methylfuran-3-thiol 
O
SH  
13.071 
1063 2,5-Dimethylfuran-3-thiol 
O
SH  
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FGE.13Rev2 – Candidate and Supporting substances divided into subgroups of related chemical 
structures. Substances listed in bold are the candidate substances in this FGE. The supporting substances 
from the 55th, 59th, 65th or 69th JECFA and EFSA (EFSA, 2004c) are in normal type face. 
FL-no 
JECFA-no 
EU Register name Structural formula 
13.160 
1090 2-Methyltetrahydrofuran-3-thiol 
O
SH
 
13.193 
1091 2,5-Dimethyltetrahydro-3-furanthiol 
O
SH  
IIc Disulphides 
13.113 2,5-Dimethyl-3-(methyldithio)furan 
O
S
S
 
13.144 Methyl 5-methylfurfuryl disulfide 
O
S
S
 
13.178 3-(Furfuryldithio)-2-methylfuran 
O
O
S
S
 
13.185 2-Furfuryl 3-oxo-2-butyl disulphide O S
S
O
 
13.016 
1066 bis-(2-Methyl-3-furyl) disulfide 
S
S
O
O
 
13.050 
1081 Difurfuryl disulfide S
SO
O
 
13.064 
1078 Methyl furfuryl disulfide 
S
SO
 
13.082 
1065 Propyl 2-methyl-3-furyl disulfide 
O
S
S
 
13.079 
1064 Methyl 2-methyl-3-furyl disulfide 
O
S
S
 
13.197 
1079 Furfuryl propyldisulfide 
O
S
S
 
13.015 
1067 bis-(2,5-Dimethyl-3-furyl) disulfide 
O
S
S
O
 
IId Polysulphides 
13.146 Methyl furfuryl trisulfide S
S
S
O
 
13.017 
1068 bis-(2-Methyl-3-furyl) tetrasulfide S
SS
S
O
O
 
 
The 27 candidate flavouring substances under consideration, as well as their chemical Register names, 
FLAVIS- (FL-no), Chemical Abstract Service- (CAS-), Council of Europe- (CoE-) and Flavor and 
Extract Manufactures Association- (FEMA-) numbers, structure and specifications, are listed in Table 
1. 
A summery of the safety evaluation of the candidate substances under consideration in the present 
evaluation are listed in Table 2a. 
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The hydrolysis products of the candidate esters are listed in Table 2b. 
The names and structures of the supporting substances are listed in Table 3, together with their 
evaluation status (CoE, 1992; JECFA, 2001a; JECFA, 2002c; JECFA, 2006b; JECFA, 2009c;SCF, 
1995). 
1.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. Their 
flavour may be different, they may have different chemical properties resulting in possible variation of 
their absorption, distribution, metabolism, elimination and toxicity. Thus, information must be 
provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number etc.). 
Three of the 27 candidate substances possess a chiral centre [FL-no: 13.127, 13.185 and 13.199]. For 
all three substances the Industry has informed that the commercial substance is the racemate.  
Two of the 27 candidate substances can exist as geometrical isomers [FL-no: 13.011 and 13.129] and 
in both cases Industry has informed that the commercial substance is the (E)-isomer (see Table 1). 
1.3. Natural Occurrence in Food 
Nineteen of the 27 candidate substances have been reported to occur in milk, bread, coffee, cocoa, 
grain, a wide range of fruits and vegetables, meat, beer, various types of alcoholic beverages, soy 
protein, honey and/or almond.  
Quantitative data on the natural occurrence in food have been reported for 12 of these substances. 
These reports include: 
 Butyl 2-furoate [FL-no: 13.102]: Less than 0.01 mg/kg in papaya. 
 Ethyl 2-furoate [FL-no: 13.122]: Up to 0.05 mg/kg in beer, up to 0.3 mg/kg in brandy, less 
than 0.01 mg/kg in guava fruit, 0.0004 mg/kg in kiwi fruit, up to 0.05 mg/kg in papaya, 0.1 
mg/kg in rum, trace amount in port, up to 0.04 mg/kg in wine. 
 Ethyl furfuryl sulfide [FL-no: 13.124]: 0.01 mg/kg in coffee. 
 2-Ethyl-5-methylfuran [FL-no: 13.125]: 0.011 mg/kg in shrimps. 
 Furfuryl but-2-enoate [FL-no: 13.129]: Up to 0.2 mg/kg in coffee. 
 Furfuryl butyrate [FL-no: 13.130]: up to 0.8 mg/kg in coffee. 
 2-Furoic acid [FL-no: 13.136]: 0.01 mg/kg in asparagus (cooked), up to 0.8 mg/kg in beer, up 
to 80 mg/kg in coffee, less than 0.05 mg/kg in guava fruit, less than 0.05 mg/kg in papaya 
fruit, 0.4 mg/kg in rum. 
 5-Hydroxymethylfurfuraldehyde [FL-no: 13.139]: 0.03 mg/kg in milk, up to 19.1 mg/kg in 
wheaten bread, up to 35 mg/kg in coffee, up to 8 mg/kg in beer, up to 11.6 mg/kg in brandy, 
up to 680 mg/kg in sherry, up to 10.1 mg/kg in whisky, up to 27.3 mg/kg in wine, up to 63 
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mg/kg in port, 9 mg/kg in almond (roasted), 0.2 mg/kg in cloudberry, up to 450 mg/kg in 
prune. 
 Methyl 5-methylfurfuryl disulfide [FL-no: 13.144]: Up to 0.03 mg/kg in coffee. 
 Methyl 5-methylfurfuryl sulfide [FL-no: 13.145]: Up to 0.2 mg/kg in coffee. 
 5-Methyl-2-furanmethanethiol [FL-no: 13.149]: Up to 0.2 mg/kg in coffee. 
 2- Methyl-5-propionylfuran [FL-no: 13.155]: Up to 4.2 mg/kg in coffee. 
Seven of the substances, have not been reported to occur naturally in any food items according to 
TNO (TNO, 2000; TNO, 2009), see Table 1.3.  
1.3 Candidate substances not reported to occur in nature (TNO, 2000; TNO, 2009) 
FL-no: Name: 
13.108 4,5-dihydro-3-mercapto-2-methylfuran 
13.135 1-(2-furfurylthio)propanone 
13.141 methyl (2-furfurylthio)acetate 
13.143 methyl 3-(furfurylthio)propionate 
13.178 3-(furfuryldithio)-2-methylfuran 
13.185 2-furfuryl 3-oxo-2-butyl disulphide 
13.199 3-[(2-methyl-3-furyl)thio]-butanal 
2. Specifications 
Purity criteria for the 27 candidate substances have been provided by the flavouring industry (EFFA, 
2003g; EFFA, 2004y; Flavour Industry, 2009b; JECFA, 2001c). 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC, 
2000a), the information is adequate for all 27 candidate substances.  
For substance [FL-no: 13.185] the Register name and structure and for substance [FL no: 13.178] the 
Register name appeared to be incorrect. Corrected structure and names have been provided (written 
correspondence between EFSA and EFFA). The corrected names and structure have been given in 
Table 1. 
3. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999a). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties 
in the underreporting correction factor and to uncertainties in the percentage of consumers, the 
reliability of intake estimates on the basis of the MSDI-approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI-approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
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Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999a). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI)-approach which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake in most consumers because it is based on the assumption 
that the consumer regularly eats and drinks several food products containing the same flavouring 
substance at the upper use level. 
One option to modify the TAMDI-approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported) (EC, 2000a). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004a). 
3.1. Estimated Daily per Capita Intake (MSDI Approach) 
The Maximised Survey-derived Daily Intake (MSDI (SCF, 1999a)) data are derived from surveys on 
annual production volumes in Europe. These surveys were conducted in 1995 by the International 
Organization of the Flavour Industry, in which flavour manufacturers reported the total amount of 
each flavouring substance incorporated into food sold in the EU during the previous year (IOFI, 
1995). The intake approach does not consider the possible natural occurrence in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the EU population4 (Eurostat, 1998). This is derived for candidate substances 
from estimates of annual volume of production provided by Industry and incorporates a correction 
factor of 0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999a). 
The total annual volume of production of the 27 candidate substances for use as flavouring substances 
in Europe has been reported to be approximately 357 kg (EFFA, 2003g; EFFA, 2004y; Flavour 
Industry, 2009b; EFFA, 2011b) and for 51 (for which european production volumes are available) of 
the 53 supporting substances approximately 7700 kg (cited by (JECFA, 2001b; JECFA, 2003a)). 
On the basis of the annual volumes of production reported for the 27 candidate substances, the daily 
per capita intakes for each of these flavourings have been estimated (Table 2a). More than 90 % of the 
total annual volume of production for the candidate substances is accounted for by one candidate 
substance, 4,5-dihydro-3-mercapto-2-methylfuran [FL-no: 13.108]. The estimated daily per capita 
intake of this candidate substance from use as a flavouring substance is 37 microgram, and below 1.2 
microgram for each of the remaining candidate substances (Table 2a). 
3.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995).  
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
                                                     
 
4 EU figure 375 millions (Eurostat, 1998). This figure relates to EU population at the time for which production data are 
available, and is consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No production data 
are available for the enlarged EU. 
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For 26 of the 27 candidate substances information on food categories and normal and maximum use 
levels5,6,7 were submitted by the Flavour Industry (EFFA, 2003g; EFFA, 2004y; EFFA, 2007a; 
Flavour Industry, 2009b). The 26 candidate substances are used in flavoured food products divided 
into the food categories, outlined in Annex III of the Commission Regulation 1565/2000 (EC, 2000a), 
as shown in Table 3.1. For the present calculation of mTAMDI, the reported normal use levels were 
used. In the case where different use levels were reported for different food categories the highest 
reported normal use level was used. No normal and maximum use levels were provided for [FL-no: 
13.130]. 
Table 3.1 Use of the 26 Candidate Substances for which use levels have been provided 
Food category Description Flavourings used 
01.0 Dairy products, excluding products of category 2 All 26 
02.0 Fats and oils, and fat emulsions (type water-in-oil) All 26 
03.0 Edible ices, including sherbet and sorbet All 26 
04.1 Processed fruits All 26 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds Only [FL-no: 13.199] 
05.0 Confectionery All 26 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery All 26 
07.0 Bakery wares All 26 except [FL-no: 13.136] 
08.0 Meat and meat products, including poultry and game All 26 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  All 26 
10.0 Eggs and egg products None 
11.0 Sweeteners, including honey None 
12.0 Salts, spices, soups, sauces, salads, protein products etc. All 26 
13.0 Foodstuffs intended for particular nutritional uses All 26 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products All 26 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts All 26 
15.0 Ready-to-eat savouries All 26 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 1 – 15 All 25 
 
According to the Flavour Industry the normal use levels for the 26 of the 27 candidate substances are 
in the range of 0.001 - 20 mg/kg food, and the maximum use levels are in the range of 0.003 - 100 
mg/kg food (EFFA, 2003g; EFFA, 2004y; Flavour Industry, 2009b).  
The mTAMDI values for the seven candidate substances from structural class II (see Section 5) range 
from 160 to 3900 microgram/person/day. For 19 candidate substances from structural class III the 
mTAMDIs range from 49 to 3900 microgram/person/day. 
                                                     
 
5 ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile of reported 
usages (EFFA, 2002i). 
6 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived 
from 12 model flavouring substances (EFFA, 2004e). 
7 The use levels from food category 5 “Confectionery” have been inserted as default values for food category 14.2 
“Alcoholic beverages” for substances for which no data have been given for food category 14.2 (EFFA, 2007a). 
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For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 6 and Annex II. 
4. Absorption, Distribution, Metabolism and Elimination 
The candidate substances in FGE.13Rev2 are furan derivatives which can be divided into subgroups 
based on their chemical structure (see Table 4.1). 
Table 4.1. Candidate substances divided into subgroups of related chemical structures 
FL-no EU Register name Structural formula Structural class 
1a Structurally Related to Furfuryl Alcohol 
13.011 Ethyl furfuracrylate O O
O
III 
13.102 Butyl 2-furoate 
O
O
O III 
13.122 Ethyl 2-furoate 
O
O
O II 
13.127 Furfuryl 2-methylbutyrate O
O
O III 
13.129 Furfuryl but-2-enoate 
O
O
O III 
13.130 Furfuryl butyrate O O
O
II 
13.132 Furfuryl hexanoate 
O
O
O III 
13.133 Furfuryl isobutyrate O
O
O III 
13.136 2-Furoic acid 
O
OH
O
II 
13.139 5-Hydroxymethylfurfuraldehyde 
O
O OH II 
Ib Alkoyl-substituted furans 
13.155 2-Methyl-5-propionylfuran O
O
II 
Ic Alkyl-substituted furans 
13.125 2-Ethyl-5-methylfuran 
O
II 
13.162 2-Octylfuran 
O
II 
II Sulphur-substituted Furan Derivatives 
IIa Sulphides 
13.114 2,5-Dimethyl-3-(methylthio)furan 
O
S
III 
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Table 4.1. Candidate substances divided into subgroups of related chemical structures 
FL-no EU Register name Structural formula Structural class 
13.124 Ethyl furfuryl sulfide S
O
III 
13.135 1-(2-Furfurylthio)propanone 
O
S
O
III 
13.141 Methyl (2-furfurylthio)acetate 
O
S
O
O
III 
13.143 Methyl 3-(furfurylthio)propionate 
O
OS
O III 
13.145 Methyl 5-methylfurfuryl sulfide S
O
II 
13.199 3-[(2-methyl-3-furyl)thio]-butanal 
o
s
o
III 
IIb Thiols 
13.149 5-Methyl-2-furanmethanethiol 
O
SH III 
13.108 4,5-Dihydro-3-mercapto-2-methylfuran 
O
SH
III 
IIc Disulphides 
13.113 2,5-Dimethyl-3-(methyldithio)furan 
O
S
S
III 
13.144 Methyl 5-methylfurfuryl disulfide 
O
S
S III 
13.178 3-(Furfuryldithio)-2-methylfuran 
O
O
S
S
III 
13.185 2-Furfuryl 3-oxo-2-butyl disulphide O S
S
O
III 
IId Polysulphides 
13.146 Methyl furfuryl trisulfide S
S
S
O
III 
4.1. Main Group I 
4.1.1. Subgroup Ia 
The ten candidate substances in subgroup Ia are furfuryl alcohol derivatives such as esters of furfuryl 
alcohol [FL-no: 13.127, 13.129, 13.130, 13.132 and 13.133], ethyl ester of furanacrylic acid [FL-no 
13.011], furoic acid [FL-no: 13.136] and two esters [FL-no: 13.102 and 13.122] of furoic acid. 5-
Hydroxymethylfurfuraldehyde (5HMF) [FL-no: 13.139] with an additional hydroxymethyl side chain 
at C5 of the furan ring is also included in the subgroup. For a number of candidate and supporting 
substances, including furfural, metabolism data are available. 
The esters of furfuryl alcohol (i.e. candidate substances furfuryl butyrate [FL-no: 13.130], furfuryl 
hexanoate [FL-no: 13.132], furfuryl isobutyrate [FL-no: 13.133], furfuryl 2-methylbutyrate [FL-no: 
13.127] and furfuryl but-2-enoate [FL-no: 13.129]) are expected to be hydrolysed to furfuryl alcohol 
Flavouring Group Evaluation 13, Revision 2
 
 
20 EFSA Journal 2011; 9(8):2313 
and the corresponding aliphatic carboxylic acid based on hydrolysis data (See Annex III for a detailed 
description). 
Furoates (i.e. candidate substances ethyl 2-furoate [FL-no: 13.122] and butyl 2-furoate [FL-no: 
13.102]) are hydrolysed to the candidate substance 2-furoic acid [FL-no: 13.136], which is known as 
the major metabolite from furfural, and to the corresponding aliphatic alcohol. The candidate 
substance ethyl furfuracrylate [FL-no 13.011] is expected to be hydrolysed to furanacrylic acid, a 
known metabolite of furfural, and to ethanol. On the basis of the available results it can be anticipated 
that the substances in this subgroup or their hydrolysis products are rapidly absorbed after oral 
exposure. 
In general, the non-furan containing alcohols and carboxylic acids formed by ester hydrolysis of the 
candidate furfuryl alcohol esters and of the furoic acid esters participate in fatty acid oxidation and the 
citric acid cycle to yield CO2 and water. 
Furfuryl alcohol, furoic acid, furanacrylic acid, 5HMF and their derivatives participate in the same 
pathways as those involved in the detoxication of furfural in rodents. These pathways comprise as first 
step, the oxidation of the alcohol or aldehyde group of furfuryl alcohol and furfural, respectively, to 
furoic acid; furanacrylic acid can also be oxidised to furfural and then to furoic acid. The oxidation 
may be followed by conjugation with glycine, yielding 2-furoylglycine or 2-furanacryloylglycine, or 
by reaction with acetyl-CoA (leading to furanacryloyl-CoA) which can also further be followed by 
conjugation with glycine. The conjugates are readily excreted. However, there is some indication that 
in rats complete oxidation of furan to CO2 can occur; the process requires the opening of the furan 
ring, with production of reactive intermediates. Although it seems that in humans this pathway is of 
minor importance, its presence in humans cannot be ruled out. 
Also for 5HMF, data have shown that for this substance the principal route of metabolism in mice and 
rats is oxidation to the furoic acid derivative followed by glycine conjugation and rapid elimination in 
the urine. However, in addition to this pathway, 5HMF has been shown to be bioactivated in vitro to 
5-[(sulphoxy)methyl] furfural (SMF), through sulphonation of its allylic hydroxyl functional group, 
catalyzed by sulfotransferases. In the resulting ester, the sulphate is a good leaving group, thus 
producing a highly electrophilic allyl carbocation, which could be stabilized by distribution of charges 
on the furan ring. The subsequent interaction of this reactive intermediate with critical cellular 
nucleophiles (i.e. DNA, RNA and proteins) may result in toxic and mutagenic effects. After 
intravenous administration of 5HMF to mice, SMF can be detected in the blood. This is an unstable 
substance with a half-life of only 4.2 minutes. 
4.1.2. Subgroup Ib 
The candidate substance in subgroup Ib [FL-no: 13.155] is an alkoyl-substituted furan which has a 
keto function at the carbon atom directly adjacent to the furan ring (i.e. the C1’-carbon of the ring 
substituent). It is considered that the alpha,beta-unsaturated structure in this substance is structurally 
related and comparable to the structure in acetophenone (EFSA, 2008am). It is anticipated that the 
ketone in the C1 position of the sidechain will undergo reduction to the corresponding secondary 
alcohol which subsequently is excreted after conjugation (JECFA, 2006d). For this substance also ring 
oxidation followed by ring opening may be anticipated (see subgroup Ic). 
4.1.3. Subgroup Ic 
The candidate substances in subgroup Ic [FL-no: 13.125 and 13.162] are substituted furans which in 
contrast to the candidate substances in subgroup Ia do not bear any functional (carbonyl) groups in the 
side chain. Based on the limited data availabe, also for these substances absorption from the GI-tract 
may be anticipated, similar to the subgroup Ia substances. Mono-alkyl furans, such as the candidate 
substance 2-octylfuran [FL-no: 13.162], may be subject to oxidation (possibly epoxidation of the 
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unsubstituted double bond in the furan ring) followed by ring opening and rearrangement to alkyl-
substituted dialdehydes. For several 2-alkyl-substituted furans reactivity of dialdehydes towards 
proteins and DNA has been demonstrated, resulting in toxicity to liver and kidneys. Oxidation of the 
C1’-carbon of the alkyl substituent may result in the formation of an α,β-unsaturated ketone with the 
carbonyl group connected to the aromatic double bonds in the furan ring, similar to acetophenone (see 
also subgroup Ib). No data on metabolism of 2,5-dialkylfurans were available, but for these substances 
oxidation of the side chains may be anticipated. It is not clear if such substances would be subject to 
ring-opening, and in absence of data, this metabolic option should be anticipated. 
4.2. Main group II 
The 14 representatives of subgroup II are all sulphur-containing furan derivatives. The sulphur is 
present in the molecule either as:  
• sulphides (subgroup IIa): [FL-no: 13.114, 13.124, 13.135, 13.141, 13.143, 13.145 and 13.199] 
• a free thiol group (subgroup IIb): [FL-no: 13.108 and 13.149]   
• disulphides (subgroup IIc): [FL-no: 13.113, 13.144, 13.178 and 13.185]  
• trisulphide (subgroup IId): [FL-no: 13.146] 
4.2.1. Subgroup IIa 
Sulphides [FL-no: 13.114, 13.124, 13.135, 13.141, 13.143, 13.145 and 13.199] 
The sulphides [FL-no: 13.114, 13.124, 13.135, 13.145 and 13.199] may undergo sulphur oxidation 
reactions; free thiol groups may also be formed. In addition to this, the sulphides [FL-no: 13.141 and 
13.143] carrying an esterified carboxylic acid group may also be anticipated to be subject to ester 
hydrolysis in the GI-tract or shortly after absorption in e.g. the liver (see Annex III). 
4.2.2. Subgroup IIb 
Thiols [FL-no: 13.108 and 13.149] 
The candidate 4,5-dihydro-3-mercapto-2-methylfuran [FL-no: 13.108], the only compound containing 
a non aromatic ring and a free thiol, is also included in this subgroup.  
Substances bearing a free thiol group [FL-no: 13.108 and 13.149] can directly react with endogenous 
sulphur-containing substances, e.g. glutathione and proteins. Metabolism data on candidate or 
supporting substances are not available, but the metabolic fate of these substances can be estimated 
from general knowledge of thiol metabolism. Free thiol groups can be metabolised by methylation 
after which the sulphur can be further oxidised to give sulphoxides or sulphones, which can be 
excreted unchanged in the urine. Alternatively, conjugation with glutathione may occur, resulting in a 
mixed disulphide, which can be reduced to give free thiols, or oxidised to give thiosulphinates or 
thiosulphones (see Annex III, Fig. III.3). They may also undergo thiol-disulphide exchange either with 
free thiol groups of proteins or with free thiol groups in other endogenous substances. The reaction 
with proteins may affect biochemical functions, thereby triggering adverse effects. 
4.2.3. Subgroup IIc 
Disulphides [FL-no: 13.113, 13.144, 13.178 and 13.185] can be reduced to give the free thiols, or can 
be oxidised to give thiosulphinates or thiosulphones. 
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2-Furfuryl 3-oxo-2-butyl disulphide [FL-no: 13.185] which also carries a keto group in the side chain 
might be subject to keto-reduction after which the resulting hydroxyl group could be conjugated. 
However, there is no data to support this observation.  
4.2.4. Subgroup IId 
Trisulphide [FL-no: 13.146] 
For the one trisulphide candidate substance [FL-no: 13.146] no direct information on metabolism was 
available. However, it has been described that tri and higher sulphides may be cleaved upon reaction 
with GSH, resulting in the formation of reactive perthiols [EFSA, 2010w]. 
An extensive description of the information on metablism of the candidate and supporting substances 
including references has been presented in Annex III. 
4.3. Summary 
The metabolism of non-sulphur-containing furfuryl alcohol derivatives in FGE.13 [FL-no: 13.127, 
13.129, 13.130, 13.132 and 13.133] includes the formation of furfural, a known reactive aldehyde, that 
may lead to hepatotoxicity. Ethyl furfuracrylate [FL-no 13.011] is expected to be hydrolysed to 
furanacrylic acid, a known metabolite of furfural, and to ethanol. In addition the two furoate esters 
[FL-no: 13.102 and 13.122] and furoic acid itself [FL-no: 13.136], which is the main metabolite of 
furfural, may be metabolised to CO2, with the opening of the furan ring, producing reactive 
intermediates. In addition to the above mentioned oxidation pathway of the alcohol function, 5HMF 
[FL-no: 13.139] has been shown to be bioactivated in vitro to a reactive intermediate, SMF, by 
sulphotransferases. The same metabolism has been demonstrated in vivo after intravenous 
administration, but the SMF has a short half-life. This metabolite raises a concern for genotoxicity and 
therefore additional data on genotoxicity of 5HMF need to be present to overcome this concern. 
Extensive ring-opening with formation of intermediates reactive towards DNA has been reported for 
2-alkyl-substituted furans and the two candidate substances in subgroup Ic are two examples of these. 
The same metabolic conversion can be anticipated for the candidate substance in subgroup Ib. 
Therefore, it is concluded that the candidate substances included in main group I cannot be predicted 
to be metabolised to innocuous compounds. 
It is anticipated that the predominant metabolic attack of the sulphur-substituated furans (main group 
II) will be on the sulphur atom(s), and ring opening is not considered to be a major metabolic route. 
Based on the metabolism of other sulphur-containing compounds, the candidate furfuryl and furan 
monosulphides are expected to undergo oxidation mainly to sulphoxides and sulphones. Given the 
reactivity of thiol groups, whether free or from di- or tri-sulphides, and the importance of thiol groups 
in cell physiology, it cannot be excluded that these substances interfere with normal cell function. 
Therefore, it is concluded that none of the candidate substances included in main group II can be 
predicted to be metabolised to innocuous substances. 
A detailed description of the toxicokinetic features of the candidate substances in this FGE is reported 
in Annex III. 
5. Application of the Procedure for the Safety Evaluation of Flavouring Substances 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 6. 
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In Section 4 it has been indicated that the candidate substance 5-hydroxymethylfurfuraldehyde 
(5HMF) [FL-no: 13.139] from subgroup Ia may be metabolised to 5-[(sulphoxy)methyl]furfural 
(SMF), which shows genotoxic potential in vitro. Sufficient data have been provided to mitigate this 
concern with respect to genotoxic potential in vivo.  
Based on genotoxicity data for the substance 2-acetylfuran [FL-no: 13.054] supporting to the 
candidate substance in subgroup Ib [FL-no: 13.155], a concern for genotoxicity is raised for candidate 
substance [FL-no: 13.155].  
For the two substances (2-ethyl-5-methylfuran [FL-no: 13.125] and 2-octylfuran [FL-no: 13.162] from 
subgroup Ic, genotoxicity may be anticipated based on formation of DNA-reactive metabolites and 
based on information available for the candidate substance in subgroup Ib [FL-no: 13.155].  
In absence of sufficient experimental data on genotoxicity on these or structurally related substances, 
the Procedure cannot be applied to the candidate substance in subgroup Ib and the two candidate 
substances in subgroup Ic. A further extensive discussion on the genotoxicity of the candidate 
substances has been presented in Section 8.4. 
Thus, the Procedure for the safety evaluation of flavouring substances as outlined in Annex I has been 
applied to 24 candidate substances from chemical group 14. The stepwise evaluations of the 24 
substances are summarised in Table 2a. 
Step 1 
Five [FL-no: 13.122, 13.130, 13.136, 13.139 and 13.145] of the 24 candidate substances evaluated via 
the Procedure are classified into structural class II and 19 [FL-no: 13.011, 13.102, 13.108, 13.113, 
13.114, 13.124, 13.127, 13.129, 13.132, 13.133, 13.135, 13.141, 13.143, 13.144, 13.146, 13.149, 
13.178, 13.185 and 13.199] are classified into structural class III according to the decision tree 
approach by Cramer et al. (Cramer et al., 1978), see Table 2a. 
Step 2 
Taking into account the metabolic pathways described in Section 4, none of the candidate substances 
is predicted to be metabolised to innocuous products. Therefore, the evaluation of the 24 candidate 
substances proceeds via the B-side of the evaluation scheme. 
Step B3 
The five candidate substances, which have been assigned to structural class II, have estimated 
European daily per capita intakes (MSDI) ranging from 0.0024 to 0.39 microgram (Table 2a). These 
intakes are below the threshold of concern of 540 microgram/person/day for structural class II. The 
estimated daily per capita intakes of the 19 candidate substances assigned to structural class III range 
from 0.0012 to 37 microgram, which are also below the threshold of concern for the structural class of 
90 microgram/person/day. Therefore, the safety evaluation proceeds to step B4 for all 24 candidate 
substances. 
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Step B4 
Subgroup Ia structurally related to furfurylalcohol [FL-no: 13.011, 13.102, 13.122, 13.127, 13.129, 
13.130, 13.132, 13.133, 13.136 and 13.139]:  
Considering that the ten candidate substances of subgroup Ia are metabolised to yield furfural and 
furoic acid or furanacrylic acid, the toxicity of the esters of furfuryl alcohol [FL-no: 13.127, 13.129, 
13.130, 13.132 and 13.133], furoic acid [FL-no: 13.102 and 13.122] and furanacrylic acid [FL-no: 
13.011] is expected to be similar to that of the structurally related supporting substance furfural [FL-
no: 13.018] and of the candidate substance 2-furoic acid [FL-no: 13.136], which is the major 
metabolite of furfural. For furfural [FL-no: 13.018] an ADI value of 0.5 mg/kg/d bw has been recently 
established by EFSA (EFSA, 2004c). The estimated daily per capita intakes based on the MSDI 
approach expressed in microgram/kg body weight (bw)/day of candidate substances in subgroup Ia of 
the present FGE.13Rev2 are more than 30.000 fold below the ADI value. 
For 5HMF [FL-no: 13.139] a substantial amount of substance-specific data are available, including 
13-week subchronic studies and chronic studies in B6C3F1 mice and F344/N rats (NTP, 2010c), see 
Section 8.2). The carcinogenicity study in mice demonstrated that 5HMF may induce liver tumours, 
but these are considered irrelevant for humans. In contrast, no carcinogenic responses have been 
reported in the study with rats. The data have shown that the critical effect is cytoplasmic alterations in 
renal proximal tubule epithelium in mice, observed in the 13-weeks study with mice at 188 mg/kg bw 
for 5 days (d)/week (w) and above with an intermittent dose regimen of five days per week. For this 
effects a BMDL of 20.2 bw for 5d/w can be derived, which would be equivalent to 14.4 mg/kg 
bw/day, when corrected for continuous daily administration (see Section 8.2 and Annex V). When this 
BMDL of 14.4 mg/kg bw/day derived from the 13-weeks study in mice is compared to the MSDI of 
0.39 microgram/capita/day for this substance, a margin of safety of 2.2 × 106 can be calculated. From 
this it is concluded that 5HMF [FL-no: 13.139] does not raise a safety concern as a flavouring 
substance, at its current level of use in foods. 
Since no toxicity data are available on the sulphur-containing candidate substances in main group II, 
the relevant No Observed Adverse Effect Level (NOAEL) values originate from structurally related 
supporting substances. 
Subgroup IIa sulphides [FL-no: 13.114, 13.124, 13.135, 13.141, 13.143, 13.145 and 13.199]: 
The candidate substances ethyl furfuryl sulfide [FL-no: 13.124], methyl 5-methylfurfuryl sulfide [FL-
no: 13.145] and 2,5-dimethyl-3-(methylthio)furan [FL-no: 13.114] are expected to participate in the 
same metabolic pathways as the supporting substance furfuryl isopropyl sulfide [FL-no: 13.032] and 
therefore to have same toxicological properties. No effects were observed for furfuryl isopropyl 
sulfide in a 90-day dietary study with rats at a single dose level (1.34 mg/kg bw/day) (Posternak et al., 
1969). Comparison of the only level tested with no effect taken as a no oberved adverse effect level 
(NOAEL) with the estimated daily per capita intakes based on the MSDI approach and expressed in 
microgram/kg bw/day for ethyl furfuryl sulfide [FL-no: 13.124], methyl 5-methylfurfuryl sulfide [FL-
no: 13.145] and 2,5-dimethyl-3-(methylthio)furan [FL-no: 13.114] provides adequate margins of 
safety > 105. 
After ester hydrolysis, the candidate substances methyl (2-furfurylthio)acetate and methyl 3-
furfurylthio)propionate [FL-no: 13.141 and 13.143] are anticipated to be metabolised and to have 
toxicological properties similar to the supporting substance ethyl-3-(2-furfurylthio) propionate [FL-no: 
13.093]. For this substance an NOAEL of 5.78 mg/kg bw/day has been identified in a 90-day study 
(Bio-Research Laboratory, 1980). Comparison of this NOAEL with the estimated daily per capita 
intakes based on the MSDI approach and expressed in microgram/kg bw/day of methyl (2-
furfurylthio)acetate and methyl 3-furfurylthio) propionate [FL-no: 13.141 and 13.143] provides an 
adequate margin of safety of 3.2 × 107 for both substances. 
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Candidate substances 1-(2-furfurylthio)propanone [FL no: 13.135] and 3-[(2-methyl-3-furyl)thio]-
butanal [FL-no: 13.199] may be evaluated by comparison of their exposure estimates with the NOAEL 
from supporting substance 3-[(2-methyl-3-furyl)thio]-4-heptanone [FL-no: 13.077]. 3-[(2-Methyl-3-
furyl)thio]-4-heptanone was tested in rats at a single dose level of 3.76 mg/kg bw/day in the diet for 90 
days without treatment-related effects (Gallo et al., 1976b). Comparison of the estimated daily per 
capita intake based on the MSDI approach for 3-[(2-methyl-3-furyl)thio]-butanal [FL-no: 13.199] with 
the NOAEL of 3.76 mg/kg bw/day for the supporting substance provided an adequate margin of safety 
of 1.9 × 105. Comparison of the estimated daily per capita intake based on the MSDI approach for 1-
(2-furfurylthio)propanone [FL-no: 13.135] with the NOAEL of 3.76 mg/kg bw/day for the supporting 
substance provides an adequate margin of safety of 2.1 × 107. 
Subgroup IIb thiols [FL-no: 13.108 and 13.149]: 
The candidate substances 5-methyl-2-furanmethanethiol [FL-no: 13.149] is structurally related to the 
supporting substance 2-furanmethanethiol [FL-no: 13.026]. The NOAEL of 2-furanmethanethiol in a 
multiple dose level 91-day oral gavage study with rats was 3 mg/kg bw/day (Phillips et al., 1977). 
Comparison of the NOAEL for 2-furanmethanethiol with the estimated daily per capita intake based 
on the MSDI approach expressed in microgram/kg bw/day of 5-methyl-2-furanmethanethiol [FL-no: 
13.149] provides an adequate margin of safety of 3.7 × 105. 
The candidate substance 4,5-dihydro-3-mercapto-2-methylfuran [FL-no: 13.108] is structurally related 
to the supporting substance 2-methyl-3-thioacetoxy-4,5-dihydrofuran [FL-no: 13.086] from subgroup 
IIe (of FGE13Rev1). Several subchronic studies have been carried out with this supporting substance. 
A NOAEL of 1.4 mg/kg bw/day has been derived in a multiple dose level 13 weeks dietary study with 
rats (Munday & Gellatly, 1973a). Comparison of the NOAEL for 2-methyl-3-thioacetoxy-4,5-
dihydrofuran with the estimated daily per capita intake based on the MSDI approach expressed in 
microgram/kg bw/day of 4,5-dihydro-3-mercapto-2-methylfuran [FL-no: 13.108] provided an 
adequate margin of safety of 2.3 × 103. 
Subgroup IIc disulphides [FL-no: 13.113, 13.144, 13.178 and 13.185]: 
In the previous version of this FGE, the candidate substance 2,5-dimethyl-3-(methyldithio)furan [FL-
no: 13.113] was evaluated against a NOAEL which turned out to belong to a structurally unrelated 
substance. Therefore this evaluation was not valid and thus substance [FL-no: 13.113] had to be 
reconsidered. It may be anticipated that this disulphide will be subject to fission of the disulphide 
bridge. The resulting furan-containing fragment, which is more reactive than the disulphide itself, 
could be evaluated by comparison with the toxicity of 2-methyl-3-furanthiol [FL-no: 13.055] from 
subgroup IIb. The NOAEL of 2-methyl-3-furanthiol in a multiple dose level 90-day oral gavage study 
with rats was 5 mg/kg bw/day (Oser, 1970b). When the NOAEL for 2-methyl-3-furanthiol is 
compared with the estimated daily per capita intake based on the MSDI approach expressed in 
microgram/kg bw/day for 2,5-dimethyl-3-(methyldithio)furan [FL-no: 13.113] an adequate margin of 
safety of 25 × 107 can be calculated. 
For the candidate substances methyl 5-methylfurfuryl disulfide [FL-no: 13.144] and 2-furfuryl 3-oxo-
2-butyl disulphide [FL-no: 13.185] a NOAEL for a comparable substance is not available. However, 
after fission of the disulphide bridge the resulting furan-containing fragment, which is more reactive 
than the disulphide itself, could be evaluated by comparison with the toxicity of furfuryl mercaptan 
[FL-no: 13.026] from subgroup IIb. The NOAEL of furfuryl mercaptan in a multiple dose level 91-day 
oral gavage study with rats was 3 mg/kg bw/day (Phillips et al., 1977). When the NOAEL for furfuryl 
mercaptan is compared with the estimated daily per capita intakes based on the MSDI approach 
expressed in microgram/kg bw/day for methyl 5-methylfurfuryl disulfide [FL-no: 13.144] and 2-
furfuryl 3-oxo-2-butyl disulphide [FL-no: 13.185], adequate margins of safety of 75 × 106 and 16 × 
106, respectively, can be calculated. 
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The Panel noted that the candidate substance 3-(furfuryldithio)-2-methylfuran [FL-no: 13.178] is 
identical to [FL-no: 13.192]. The latter substance has been assigned the JECFA number 1524 in the 
report of the 69th meeting (JECFA, 2009a). For this substance, in the JECFA evaluation, an MSDI for 
Europe of 0.24 microgram per capita per day was given. This figure, which is higher and more recent 
than the exposure estimate in the previous version of this FGE (0.0012 microgram per capita per day), 
will be used in the current revision of this FGE. The candidate substance 3-(furfuryldithio)-2-
methylfuran [FL-no: 13.178] is structurally related to the supporting substance bis(2-methyl-3-furyl) 
disulfide [FL-no: 13.016] which has been tested in two single-dose-level 90-day dietary studies with 
rats at 5 mg/kg bw/day and 0.45 mg/kg bw/day, respectively (Oser, 1970a; Morgareidge and Oser, 
1970e). Treatment-related effects were seen at the intake level of 5.0 mg/kg bw/day, but the intake 
level of 0.45 mg/kg bw/day was determined to be a NOAEL. The disulphide bridge fission products 
are related to [FL-no: 13.026] (of subgroup IIb), for which a NOAEL of 3 mg/kg bw/day has been 
derived. When the estimated daily per capita intake based on the MSDI approach expressed in 
microgram/kg bw/day of 3-(furfuryldithio)-2-methylfuran [FL-no: 13.178] is compared to this 
NOAEL an adequate margins of safety of 7.5 × 105 can be calculated for [FL-no: 13.178].  
Alternatively, the two fission products may be considered separately. These fission products are [FL 
no: 13.055] and [FL-no: 13.026], for which NOAELs of 5 mg/kg bw/day and 3 mg/kg bw/day, 
respectively, have been derived (Oser, 1970b; Phillips et al., 1977). Exposure to [FL-no: 13.178] at the 
level of its MSDI would correspond to exposures to [FL-no: 13.026] and [FL-no: 13.055] of 0.12 
microgram per person per day for both fragments. Comparison of these exposure estimates to the 
NOAELs for these two fragments provides adequate margins of safety of 1.5 × 106 and 2.5 × 106 for 
[FL-no: 13.026] and [FL-no: 13.055], respectively. 
Subgroup IId polysulphide [FL-no: 13.146]: 
The one candidate flavouring substance in this subgroup methyl furfuryl trisulphide [FL-no: 13.146] is 
a trisulphide which may be anticipated to release perthiols upon metabolism. Similar reactive products 
may be anticipated for bis-(2-methyl-3-furyl)tetrasulphide [FL-no: 13.017] for which a NOAEL of 
0.56 mg/kg bw/day in a 90-day study has been derived (Morgareidge and Oser, 1970f). Comparison of 
this NOAEL with the estimated daily per capita intake of methyl furfuryl trisulphide [FL-no: 13.146] 
based on the MSDI approach expressed in microgram/kg bw/day of 0.0024 microgram provides an 
adequate margin of safety of 14 × 106. 
Summary: 
For the ten, seven, two, four and one substances in subgroups Ia [FL-no: 13.011, 13.102, 13.122, 
13.127, 13.129, 13.130, 13.132, 13.133, 13.136 and 13.139], IIa [FL-no: 13.114, 13.124, 13.135, 
13.141, 13.143, 13.145 and 13.199], IIb [FL-no: 13.108 and 13.149], IIc [FL-no: 13.113, 13.144, 
13.178 and 13.185] and IId [FL-no: 13.146], respectively, which have been evaluated through the 
Procedure, it can be concluded at step B4 of the Procedure that these 24 candidate substances do not 
pose a safety concern when used as flavouring substances at the estimated levels of intake based on 
the MSDI approach. 
6. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI 
Approach 
For three candidate substances [FL-no: 13.122, 13.136 and 13.139] in structural class II, evaluated 
through the Procedure, the mTAMDI range from 1400 to 3900 microgram/person/day, which is above 
the threshold of concern for this Cramer class. For one substance [FL- no: 13.145] the mTAMDI is 
160 microgram/person/day, which is below the class threshold of 540 microgram/person/day. For 
substance [FL-no: 13.130] no use levels were provided and no mTAMDI can be calculated. 
The estimated intakes for 16 [FL-no: 13.011, 13.102, 13.108, 13.113, 13.114, 13.127, 13.129, 13.132, 
13.133, 13.135, 13.141, 13.143, 13.146, 13.149, 13.178 and 13.185] of the 19 substances evaluated 
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through the Procedure and assigned to structural class III, based on the mTAMDI, range from 160 to 
3900 microgram/person/day, which are above the threshold of concern for structural class III 
substances of 90 microgram/person/day. For the remaining three substances from structural class III 
[FL no: 13.124, 13.144 and 13.199] the mTAMDIs range from 49 to 78 microgram/person/day, which 
is below the threshold of concern. 
Thus, for 20 of the candidate substances, evaluated using the Procedure, further information is 
required. This would include more reliable intake data and then, if required, additional toxicological 
data. For comparison of the MSDI and mTAMDI values, see Table 6.1. 
 
Table 6.1 Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural 
class 
Threshold of concern 
(µg/person/day) 
13.122 Ethyl 2-furoate 0.39 3900 Class II 540 
13.130 Furfuryl butyrate 0.24  Class II 540 
13.136 2-Furoic acid 0.013 1400 Class II 540 
13.139 5-Hydroxymethylfurfuraldehyde 0.39 1600 Class II 540 
13.145 Methyl 5-methylfurfuryl sulfide 0.0024 160 Class II 540 
13.155 2-Methyl-5-propionylfuran 0.011 420 Class II 540 
13.125 2-Ethyl-5-methylfuran 0.011 420 Class II 540 
13.162 2-Octylfuran 0.011 420 Class II 540 
13.011 Ethyl furfuracrylate 0.12 3900 Class III 90 
13.102 Butyl 2-furoate 0.12 3900 Class III 90 
13.108 4,5-Dihydro-3-mercapto-2-methylfuran 37 160 Class III 90 
13.113 2,5-Dimethyl-3-(methyldithio)furan 0.0012 160 Class III 90 
13.114 2,5-Dimethyl-3-(methylthio)furan 0.0024 160 Class III 90 
13.124 Ethyl furfuryl sulfide 0.18 78 Class III 90 
13.127 Furfuryl 2-methylbutyrate 0.73 3900 Class III 90 
13.129 Furfuryl but-2-enoate 0.11 3900 Class III 90 
13.132 Furfuryl hexanoate 0.58 3900 Class III 90 
13.133 Furfuryl isobutyrate 0.89 3900 Class III 90 
13.135 1-(2-Furfurylthio)propanone 0.61 780 Class III 90 
13.141 Methyl (2-furfurylthio)acetate 0.011 400 Class III 90 
13.143 Methyl 3-(furfurylthio)propionate 0.011 420 Class III 90 
13.144 Methyl 5-methylfurfuryl disulfide 0.0024 78 Class III 90 
13.146 Methyl furfuryl trisulfide 0.0024 160 Class III 90 
13.149 5-Methyl-2-furanmethanethiol 0.37 160 Class III 90 
13.178 3-(Furfuryldithio)-2-methylfuran 0.24 160 Class III 90 
13.185 2-Furfuryl 3-oxo-2-butyl disulphide 0.011 420 Class III 90 
13.199 3-[(2-Methyl-3-furyl)thio]-butanal 1.2 49 Class III 90 
7. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this Flavouring Group Evaluation may also be metabolised 
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through the same pathways, the combined intake estimates presented here are only preliminary. 
Currently, the combined intake estimates are only based on MSDI exposure estimates, although it is 
recognised that this may lead to underestimation of exposure. After completion of all FGEs, this issue 
should be readdressed.  
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances evaluated through the Procedure. 
On the basis of the reported annual production volumes in Europe (EFFA, 2003g; EFFA, 2004y), the 
combined estimated daily per capita intake as flavourings of the five candidate substances assigned to 
structural class II, and evaluated through the Procedure,  is 1 microgram, which does not exceed the 
threshold of concern of 540 microgram/person/day for substances belonging to structural class II. The 
combined daily per capita intake as flavourings of the 19 candidate substances assigned to structural 
class III is 42 microgram, which does not exceed the threshold of concern of 90 microgram/person/day 
for substances belonging to structural class III.  
The 24 candidate substances evaluated through the Procedure, are structurally related to 398 
supporting substances evaluated by the JEFCA at their 55th, 59th and 69th meetings (JECFA, 2001a; 
JECFA, 2002c; JECFA, 2009c) or by EFSA (EFSA, 2004c). The total combined intake of candidate 
and supporting substances (in Europe) would be 885 and 60 microgram/capita/day for structural class 
II and III, respectively.  
The total combined daily per capita intake of 885 microgram exceeds the threshold of concern of 540 
microgram/person/day for structural class II substances. However, 50 % of the combined daily per 
capita intake of 885 microgram comes from furfural for which, together with the furfural component 
of furfural diethyl acetal, an ADI of 0.5 mg/kg bw/day has been established by EFSA (EFSA, 2004c). 
The total combined intake for the class III substances of 60 microgram/capita/day does not exceed the 
threshold for the structural class of 90 microgram/person/day. 
8. Toxicity 
8.1. Acute Toxicity 
Oral LD50 values in rodents have been reported for three candidate substances [FL-no: 13.102, 13.122 
and 13.139] and for five supporting substances for main group I. No acute oral toxicity data were 
available for any of the candidate substances in main group II, but oral LD50 values were found for 12 
supporting substances in this group.  
The reported oral LD50 values for the candidate substances are around 1500 - 2000 mg/kg body weight 
(bw) both in rats and in mice, while the majority of reported rodent oral LD50 values for supporting 
substances falls between 100 and 250 mg/kg bw. 
The acute toxicity data are summarised in Annex IV, Table IV.1. 
8.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
Main group I 
Short-term and long-term toxicity studies are available for two candidate substances included in main 
group I, namely 2-furoic acid [FL-no: 13.136] and 5-hydroxymethylfurfural (5HMF [FL-no: 13.139]) 
and for three supporting substances and one structurally related substance. The data for these 
                                                     
 
8 Of the 53 EFSA considered supporting substances 14 substances have not been considered using the Procedure and for two 
of these no use has been reported for Europe. 
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substances indicate that the liver is the target for their toxicity. EFSA has established an ADI value of 
0.5 mg/kg bw/d for furfural and the furfural component of furfural diethyl acetal (EFSA, 2004c). This 
ADI will be used for the evaluation of the nine furfural-related candidate flavouring substances in 
subgroup Ia [FL-no: 13.011, 13.102, 13.122, 13.127, 13.129, 13.130, 13.132, 13.133 and 13.136]. 
For candidate substance [FL-no: 13.139] specific toxicity data are available in a NTP study report 
(NTP, 2010c) which will be used for the evaluation of this substance. The reported 13-weeks and 
chronic bioassays have been described below, and the results of these studies have been analysed 
using BMDL dose-response modelling (EFSA, 2009bc; EFSA, 2011g); see Annex V for details). 
Data on 5-hydroxymethylfurfuraldehyde (5HMF) [FL- no: 13.139] 
Studies in mice (NTP, 2010c): 
Subchronic study in mice 
Groups of 10 male and 10 female mice (B6C3F1) were administered 0, 47, 94, 188, 375 or 750 mg 
5HMF/kg bw for 5 days (d)/week (w) in deionised water by gavage for 3 months. No treatment-related 
undercurrent death was observed. At term, animals were examined for changes in hematology, clinical 
chemistry, sperm count and motility, vaginal cytology and CNS neuropathological examination. In 
addition, full histopathology was carried out on control and highest does group. Mean body weight 
and body weight gain of 750 mg/kg males was significantly less (< 15 % less) than those of the 
vehicle control group. Female body weights were not affected. There were no treatment-related 
changes in hematology or clinical chemistry parameters or organ weights. 
The absolute kidney weights of 188 mg/kg or greater males and the relative kidney weight of 375 
mg/kg males were significantly less than those of the vehicle controls. The absolute weights of the 
heart and liver were significantly decreased in 750 mg/kg males, and the relative testis weight of 750 
mg/kg males and relative lung weight of 375 mg/kg females were significantly increased, NTP did not 
consider any of these organ weight changes chemical-related. 
The relative epididymis weight of the 750 mg/kg males was significantly increased, but 5HMF did not 
cause any biologically significant changes in the sperm parameters. There were no significant 
differences between dosed and vehicle control groups in vaginal cytology parameters in females. 
There were no significant changes in the histopathology of the reproductive organs for male or female 
mice. 
The incidences of minimal to mild cytoplasmic alterations of the kidney were significantly increased 
in males administered 188 mg/kg or greater. Cytoplasmic alterations were characterized by the 
variable depletion of large, clear cytoplasmic vacuoles in the proximal tubule epithelial cells that were 
readily observed in the proximal tubule epithelial cells of vehicle controls; depletion of cytoplasmic 
vacuoles was most pronounced in 750 mg/kg males. These cytoplasmic vacuoles are typical in the 
kidneys of B6C3F1 mice. No other histopathological changes in any other tissue were observed that 
could be attributed to treatment with 5HMF. This effect has been used for dose-response modelling. A 
BMDL of 20.2 mg/kg bw for 5d/w was derived (see Annex V). 
Chronic study in mice 
Groups of B6C3F1 mice (50/sex/dose) were administered 0, 188, 375 or 750 mg 5HFM/kg bw for, five 
days per week for 104 weeks via aqueous gavage. Survival of both males and female mice in the 750 
mg/kg group was significantly less than that of vehicle control. Mean body weights of 750 mg/kg were 
14 % less than those of the vehicle controls after week 26. Mean body weights of 375 and 750 mg/kg 
females were 9 % and 30 % less, respectively, than those of the vehicle controls after week 36. The 
following histopathological findings were reported: 
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The incidences hepatocellular adenoma in the 188 and 375 mg/kg female mice were significantly 
increased two-fold up to 53 % and 52 % and exceeded the historical control ranges for water gavage 
studies. However, the incidences were within the historical ranges for all routes of administration. No 
increase was observed in the incidence of hepatocellular carcinomas. Conversely, the incidences of 
hepatocellular adenoma and hepatocellular adenoma or carcinoma (combined) were significantly 
decreased in 750 mg/kg males; these decreased incidences of age-related neoplasms were due to early 
and high mortality in this dosed group rather than a direct chemical effect. Because of the reduced 
survival (30 % reduction) of the groups receiving 750 mg 5HMF/kg bw per day, NTP did not include 
the results for these dose groups in the evaluation of carcinogenic potential. 
Incidences of mononuclear cell infiltration and eosinophilic foci were significantly increased in the 
livers of 188 mg/kg females, and the incidences of basophilic foci were significantly increased in 
livers of 188 and 375 mg/kg females. However, the degree of severity of the mononuclear cell 
infiltration was lower in the exposed groups as compared to the control group and the changes in 
incidences of basophilic and eosinophilic foci were not dose related. No such changes were observed 
in the 750 mg/kg dose group. Also, no changes were reported in the livers of male mice. The non-
cancerous histological responses in livers were not dose-related and were only observed in one sex. 
Therefore the Panel is of the opinion that these changes have no toxicological significance. 
A spectrum of non-neoplastic nasal lesions considered to be related to administration of 5HMF was 
observed. The following effects extended into the low dose group in either or both sexes:  
° Olfactory epithelial metaplasia (significantly increased in all dosed groups of males and in 375 
and 750 mg/kg females). Metaplasia consisted of focal, multifocal, or diffuse replacement of 
the segments of the normal pseudostratified olfactory epithelium by tall, ciliated, columnar 
epithelium resembling normal respiratory epithelium. 
° Chronic active olfactory epithelium inflammation (significantly increased in all dosed groups 
of males and in 375 and 750 mg/kg females) consisted of mixed inflammatory cell infiltrates 
of macrophages, lymphocytes and neutrophils in varying numbers in the lamina propria of the 
dorsal aspects of Levels II and III. 
° Bowman gland hyperplasia (was significantly increased in all dosed groups of females and in 
375 and 750 mg/kg males). Bowman’s glands were tortuous with increased numbers of acinar 
profiles (glandular hyperplasia) within the lamina propria. 
° Bowman gland dilatation in all dosed groups of females and in 375 and 750 mg/kg males. 
° Chronic active inflamation of Bowman glands (significantly increased in all dosed groups of 
males and in 375 and 750 mg/kg females). Glandular lumens contained varying numbers of 
macrophages, lymphocytes and neutrophils and degenerate cellular debris with often 
hypertrophic epithelial acinar cells and with focally multilayered and disorganized epithelium. 
 
These effects have been used for dose-response modelling. A BMDL of 62.5 mg/kg bw for 5d/w was 
derived for chronic active inflammation of Bowman glands in males (see Annex V). 
Studies in rats (NTP, 2010c): 
Sub-chronic study in rats 
Groups of 10 male and 10 female rats (F344/N) were administered 0, 94, 188, 375, 750, or 1,500 mg 
5HMF/kg bw for 5 d/w in deionised water by gavage for 3 months. One male and three female rats 
administered 1,500 mg/kg died before the end of the study; the male died as a result of gavage trauma. 
At term, animals were examined for changes in hematology, clinical chemistry, sperm count and 
motility, vaginal cytology and CNS neuropathological examination. In addition, full histopathology 
was carried out on control and highest does group. Mean body weights of 750 and 1,500 mg/kg males 
were significantly less (< 10 % less) than those of the vehicle control group. There were no treatment-
related changes in hematology or clinical chemistry parameters or biologically relevant changes in 
absolute organ weights. 
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There were no relevant changes in organ weights except for relative epidydimus weight in the high 
dose group, but there were no changes in sperm parameters and no histopathological changes in the 
male sex organs were found. 
Based on the NTP report, it seems that the effects on oestrus cyclicity are the most critical in this 
study. Female rats (only 0, 375, 750 and 1500 mg/kg groups were examined) had elongated estrous 
cycles in the 750 and 1500 mg/kg females (not statistically significant) and fewer females in these 
groups had regular cycles. Statistical significance for the proportion of regular cycling females was 
only reached for the 1500 mg/kg dose group, but this may be related to the fact that estrous cycle 
length was unclear in more animals from the high dose group than in females from the control group. 
Females in the 375, 750 and 1500 mg/kg groups had a significantly increased probability of extended 
dioestrus. The Panel noted that determination of stage in oestrus cycle appeared problematic in several 
animals in particular in the control group. The “% time in dioestrus” parameter was ca. 20 – 40 % less 
in the control group females than the treatment groups females. However, for the control the diagnoses 
of estrous stage was unclear in ca. 20 % of the cycle time, while this percentage was much less in the 
treatment groups (down to 0 % in the high dose group). There were no histopathological changes in 
the female sex organs. 
No other histopathological changes in any other tissue were observed that could be attributed to 
treatment with 5HMF. 
NTP considered the toxicity of 5HMF as “minimal” except for the high dose group females (three 
animals had died). The Panel noted that statistically significant changes in estrous cyclicity were only 
observed in the 1500 mg/kg dose group. Given the reported problems with the diagnosis of estrous 
cyclicity in the females and the absence of any further histopathological changes, the Panel questions 
the relevance of the reported findings. Since in the other studies carried out by NTP effects were 
observed at lower dose levels, the Panel did not consider these changes useful for further examination 
using dose-response modelling. 
Chronic study in rats 
Groups of F344/N rats (50/sex/dose) were administered 0 (vehicle control), 188, 375 and 750 mg 
5HMF/kg bw per day, five days per week for 104 weeks via aqueous gavage. Survival of the 188 and 
750 mg/kg per day male groups was higher than that of vehicle controls. Survival in the 375 mg/kg 
males and in all female dose groups was comparable to the respective vehicle control groups. Mean 
body weights of all test groups were comparable to vehicle controls throughout the study. The 
following histopathological findings were reported: 
 
Two cases of hepatocellular adenoma occurred in 375 mg/kg males, but none in the high dose group. 
Males of the 188 and 375 mg/kg per day males showed increased incidences of C-cell adenoma or 
carcinoma (combined) of the thyroid gland, but without clear dose-response relationship. No other 
carcinogenic effects were observed (NTP, 2010c). 
 
Incidences of olfactory epithelium degeneration were increased in all dosed groups of male and female 
rats and were significantly increased in 750 mg/kg males (incidence: 29/49; grade 1.5) and in 188 and 
375 mg/kg females (incidences 35/49 and 35/49, respectively; grade 1.2 for both groups), but not in 
the high dose females (incidence 28/49, grade 1.3). Degeneration of the olfactory epithelium was 
graded minimal to mild in all groups (grade 1.1 to 1.5 in a scale of 1 to 4). A similar degree of 
olfactory epithelium degeneration (grade 1.1) was observed in the control group, but at a lower 
incidence (males: 18/50, grade 1.1; females: 21/50, grade 1.2). In the male and female high dose 
groups (750 mg/kg) a variety of other histological changes in the nose were observed (e.g. increased 
incidences of mild respiratory epithelium, squamous metaplasia, increase incidences of suppurative 
inflammation and chronic active inflammation of the nose).  
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The incidence of clear cell foci was significantly increased in the livers of 750 mg/kg bw/day males. 
Incidences of minimal chronic active inflammation of the liver were increased in all dosed groups of 
males (incidences 25/50, 34/50, 30/50 and 38/50 in 0, 188, 375 and 750 mg/kg groups, respectively) 
and the increase in 750 mg/kg bw /day males was statistically significant. The Panel noted that the 
dose response was not very strong. 
 
Based on the minimal changes in respiratory epithelium and the reported changes in the livers of male 
rats, the Panel concluded that the effects in the high dose group may be considered as adverse, 
resulting in an NOAEL of 375 mg/kg bw for 5d/w. Since in other studies (e.g. the mouse studies) 
effects were reported to occur at lower dose levels, the data from the NTP chronic rat bioassay have 
not been used for dose-response modelling. 
 
Evaluation of NTP’s subchronic and chronic bioassays with 5HMF in rodents 
carcinogenicity 
According to NTP, in the above described chronic bioassays with rats and mice, there was no evidence 
of carcinogenic activity of 5HMF in male or female F344/N rats administered 188, 375 or 750 mg/kg 
bw for 5d/w under the conditions of the 2-year gavage study. There was no evidence of carcinogenic 
activity in male B6C3F1 mice administered 188 or 375 mg/kg bw for 5d/w. There was some evidence 
of carcinogenic activity of 5HMF in female B6C3F1 mice, based on increased incidences of 
hepatocellular adenoma in the 188 and 375 mg/kg groups. The Panel considered, the about two-fold 
increase (not dose-related) of these benign hepatocellular tumours observed in B6C3F1 female mice to 
be irrelevant for humans, in view of the recognized high genetic susceptibility of this strain to 
hepatocarcinogenesis and the known high back-ground incidence of these tumours in this mouse 
strain. Therefore, these studies do not give rise to concern with respect to the carcinogenic potential of 
5HMF. 
Non-neoplastic lesions 
Administration of 5-hydroxymethylfurfuraldehyde (5HMF) [FL- no: 13.139] produced a mild toxic 
response in mice. The only histologic lesion related to chemical administration were cytoplasmic 
alterations in the renal proximal tubule epithelium at 188 mg/kg or above in male mice in a sub-
chronic bioassay. Although this effect was not observed in the chronic study in mice, or in the sub-
chronic or chronic studies in rats, the Panel was not convinced that this result could be dismissed as 
being non-adverse. In addition, in this assay also kidney weight changes were observed at dose levels 
of 188 mg/kg bw and above. In other tissues (liver, heart, testes, lungs) also weight changes were 
observed but at higher dose levels. Although the study authors (NTP 2010c) considered these weight 
chages of little relevance, the Panel noted a dose-relationship and decided not to dismiss these 
observations. The Panel used the data on the histopathological changes in the kidneys as a basis for 
dose-response modelling, since for this effect the dose-response in the data was the most pronounced. 
A BMDL of 20.2 mg/kg bw for 5d/w was derived (see Annex V). 
Considerations were made by the Panel on the occurence of histopathological changes in the upper 
respiratory tract (i.e. nose) observed in both mouse and rat. Similar changes are frequently observed in 
animal species following administration of inhaled products but less common in studies performed by 
other routes of exposure. The Panel has derived a BMDL of 62.5 mg/kg bw for 5d/w for the nasal 
effets in the mouse. However, extraplotation to humans of these injuries is complicated by the 
complexity and diversity of this upper airway among animal species. Though important local 
bioactivations are known to occur  in the olfactory mucosa, in absence of characteristic, site-specific, 
distibution pattern of the lesion, the predominantly chronic inflammatory description of the finding is 
rather suggestive of a mild irritant effect of the substance that could have rich significant concentration 
in the upper airways (e.g. regurgitation or presence of potential irritant substances from metabolism in 
the faces or urine in the cage or in the litter). Although the effect is adverse in rodent species, the Panel 
considered it unlikely to be of human relevance (Harkema et al, 2006).  
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For the evaluation of 5HMF the Panel has used the BMDL of 20.2 mg/kg bw for 5d/w based on renal 
histopathology in the mouse. The Panel noted that this BMDL is sufficiently low to cover also the 
organ weight changes in kidneys and other tissues at dose levels of 188 mg/kg bw and above.  
Main group II 
No toxicity data are available on candidate substances included in main group II, however, results 
from toxicity studies on 14 supporting substances and one structurally related substance have been 
reported. 
Toxicity studies on supporting substances used for deriving the NOAELs used in the Procedure are 
briefly reported in the following. 
Furfuryl mercaptan [FL-no: 13.026] 
Groups of 15 Wistar rats of each sex were given daily doses of 0, 1, 3 or 30 mg/kg bw furfuryl 
mercaptan, dissolved in corn oil by stomach tube for 13 weeks. At the highest dose level, a decrease in 
body weight gain was associated with a reduced food intake. Significant differences in absolute and 
relative organ weights (i.e. brain, kidneys, stomach, heart and liver) were reported for the 30 mg/kg 
bw group at 13 weeks. Haematological examination revealed increases in haemoglobin concentration 
and packed cell volume at the highest dose level at study termination. Histopathological examination 
showed no abnormalities related to the treatment. Based on organ weight changes evidenced at the 
highest dose group, 3 mg/kg bw/day can be considered as a NOAEL (Phillips et al., 1977).  
Furfuryl isopropyl sulfide [FL-no: 13.032] 
Groups of 16 Charles River CD rats of each sex were given ad libitum access to water and food. The 
test material (98 % purity) was incorporated into the diet of the treatment group. The concentration of 
the test material in the diet was adjusted during the study to maintain constant levels of dietary intake 
of about 1.30 mg furfuryl isopropyl sulfide/kg bw/day (Posternak et al., 1969). The authors stated that 
no major differences were observed between groups of treated and control animals, based on 
measurements of growth, food intake, haematological and clinical chemistry parameters, organ 
weights and gross and histopathologic examinations. However, no numeric data were reported. The 
only level tested (1.34 mg/kg bw/day) has been taken as a NOAEL (Posternak et al., 1969). 
Bis(2-methyl-3-furyl)disulfide [FL-no: 13.016] 
Groups of 15 Wistar rats of each sex were administered bis(2-methyl-3-furyl)disulfide dissolved in 
acetone and blended into the diet to give an intended daily dose of 3.96 mg/kg bw for 90 days. The 
actual mean intake calculated over the period of the study was 5.0 mg/kg bw/day. Control group 
received diet mixed with the vehicle only. Dietary acetone was evaporated before presentation to the 
animals. Body weight gain in treated animals was 37 % and 15 % less in males and females, 
respectively, than that for corresponding controls. Absolute liver and kidney weights were lower but 
their relative weights were significantly greater in treated animals than in control. Haematological 
examinations, blood chemical determinations, urine analysis and gross and histopathological 
examinations, showed no differences between treated and control animals. The author concluded that 
administration of 5.0 mg/kg bw/day of the test substance for 90 days was associated with retarded 
growth rates in both sexes accompanied by decreased efficiency of food utilization and elevated 
relative liver and kidney weights in males (Oser, 1970a).  
Using the same protocol, the test material was tested in a 90-day study performed at a lower dose level 
(mean intake over the period of the study was 0.45 mg/kg/day). The results of this study indicated that 
there were no effects observed in the treatment group when compared to the control with respect to the 
above mentioned parameters. Therefore, 0.45 mg/kg bw/day can be considered the NOAEL for bis(2-
methyl-3-furyl)disulfide (Morgareidge and Oser, 1970e). 
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2-Methyl-3-thioacetoxy-4,5-dihydrofuran [FL-no: 13.086] 
Groups of eight male and eight female Wistar rats were fed for 13 weeks on diets containing 2-methyl-
3-thioacetoxy-4,5-dihydrofuran spray dried with maltodextrin, to give intakes of 1.4, 2.8, 5.55, 8.3, 
13.85 or 27.7 mg/kg bw/day. Sixteen male and 16 female rats were fed a control diet. Parameters 
studied included body weight gain, food intake, food utilization, water intake, serum chemistry, 
haematology, organ weights, macroscopic appearance at post-mortem examination and 
histopathology. Separate groups of six animals per sex were dosed and monitored similarly, but were 
killed at week 6. Treatment and dose-related haemolysis of red blood cells was observed in animals 
receiving 2.8 mg/kg bw/day and above, particularly in females, as evidenced by significantly reduced 
hematocrit values, generally accompanied by decreased haemoglobin levels, increased spleen weights 
and microscopic changes in the spleen and liver were observed. No other adverse effects were 
demonstrated. The haemolytic changes were not apparent in animals receiving 1.4 mg/kg bw/day, 
other than a significant decrease in haemoglobin in the female rats, which was not seen at the next 
higher dose level of 2.8 mg/kg bw/day. The report concluded that the no-effect level was 1.4 mg/kg 
bw/day (Munday & Gellatly, 1973a). 
Ethyl 3-(furfurylthio)propionate [FL-no: 13.093] 
Ethyl 3-(furfurylthio) propionate was added to the diet of groups of 10 male and 10 female rats (strain 
not given) at concentrations calculated to result in an average daily intake of 5.8 or 17 mg/kg bw for 
90 days. Body weight, food intake and food use efficiency were recorded weekly. No significant 
difference was found in these parameters between treated animals at either dose and controls (no 
numeric data were provided, nor for the haematological, biochemical and organ weight results 
described in the following text). Minor variations in haematological parameters at weeks 7 and 13 
were judged by the study authors to be of no toxicological significance. Blood chemistry showed a 
significant (but less than 2-fold) increase in aspartate aminotransferase (AST (SGOT)) after 13 weeks  
in high dose females, while blood urea nitrogen (BUN) was statistically increased in females 
(presumed both dose levels) at 6 weeks but not at 12 weeks. Urine analyses conducted at weeks 7 and 
13 gave normal values. The weights of the liver and kidneys at necropsy were normal, and gross and 
microscopic examination revealed no dose-related effects, other than an increased incidence of 
histiocytic myocarditis with occasional concomitant myocardial degeneration in high dose males and 
females. The cardiac changes were seen at lower incidence in the lower dose animals and in controls, 
and the authors concluded that this was due to a treatment-related exacerbation of a pre-existing 
endemic cardiac infection (Bio-Research Laboratory, 1980). Although the changes in AST and the 
reported cardiac changes may be linked and may not be truly adverse, as it appears that they are linked 
to a pre-existing inflammatory condition, the level of 5.78 mg/kg bw/day has been taken as a NOAEL 
for this study (Bio-Research Laboratory, 1980). 
3[(2-Methyl-3-furyl)thio]-4-heptanone [FL-no: 13.077] 
Groups of 15 male and 15 female weanling Wistar rats were administered 3[(2-methyl-3-furyl)-thio]-
4-heptanone dissolved in acetone and blended into a basal laboratory diet to give a daily dose 
approximating to 3.76 mg/kg bw for 90 days. Controls received the basal laboratory diet mixed with 
acetone. The acetone was evaporated from the diets before presentation to the animals. Samples of 
each diet were taken weekly to assess the stability and concentration of the test material. Daily 
observations of appearance, behaviour, appetite, elimination, gross signs of adverse effects and 
mortality showed no differences among test and control animals. Weekly measurement of body weight 
and food consumption also showed no significant differences between test animals and controls. 
Haematological, blood chemical and urine analyses performed during weeks 6 and 12 on eight males 
and eight females from each group gave normal values. No differences in absolute or relative weights 
of the liver or kidneys were found at necropsy. No evidence of gross or histological alteration was 
seen in tissues from major organs of eight male and eight female rats or in the livers and kidneys of the 
remaining seven animals. The only level tested (3.76 mg/kg bw/day) has been taken as a NOAEL 
(Gallo et al., 1976b). 
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2-Methyl-3-furanthiol [FL-no: 13.055] 
Groups of 15 male and 15 female weanling Wistar rats were administered the test substance 2-methyl-
3-furanthiol [FL no: 13.055] dissolved in acetone and blended into a basal laboratory diet to give a 
daily dose approximating to an intake of 5.0 mg/kg bw/day for 90 days. Controls received the basal 
laboratory diet admixed with acetone. The acetone was evaporated from the diets before presentation 
to the animals. Samples of each diet were taken weekly to assess the stability and concentration of the 
test material. Daily observations of appearance, behaviour, appetite, elimination, gross signs of 
adverse effects and mortality showed no differences among test and control animals. Weekly 
measurement of body weight and food consumption also showed no significant differences between 
test animals and controls. Haematological, blood chemical and urine analyses performed during weeks 
6 and 12 on eight males and eight females from each group gave normal values. No differences in 
absolute or relative weights of the liver or kidneys were found at necropsy. No evidence of gross or 
histological alteration was seen in tissues from major organs of eight male and eight female rats or in 
the livers and kidneys of the remaining seven animals. The only level tested (5.0 mg/kg bw/day) has 
been taken as a NOAEL (Oser, 1970b). 
bis(2-Methyl-3-furyl) tetrasulphide [FL-no: 13.017] 
Groups of 15 male and 15 female weanling Wistar rats were administered the test substance bis(2-
methyl-3-furyl) tetrasulphide dissolved in acetone and blended into a basal laboratory diet to give a 
daily dose approximating to 0.56 mg/kg bw for 90 days. Controls received the basal laboratory diet 
admixed with acetone. The acetone was evaporated from the diets before presentation to the animals. 
Daily observations of appearance, behaviour, appetite, elimination, gross signs of adverse effects and 
mortality showed no differences among test and control animals. Weekly measurement of body weight 
and food consumption also showed no significant differences between test animals and controls. 
Haematological, blood chemical and urine analyses performed during weeks 6 and 12 on eight males 
and eight females from each group gave normal values. No differences in absolute or relative weights 
of the liver or kidneys were found at necropsy. No treatment-related gross abnormalities were seen in 
tissues from major organs of eight male and eight female rats or in the livers and kidneys of the 
remaining seven animals. Although histopathological examination of these tissues was reported to be 
carried out, the test report did not include these findings, and the absence of treatment-related 
histopathological changes could not be confirmed. However, bis(2-methyl-3-furyl) tetrasulphide had 
no significant effect on organ weights and the structurally related supporting substance bis(2-methyl-
3-furyl)disulfide [FL-no: 13.016] did not produce treatment-related histopathological changes in two 
comparable 90-day studies providing intakes of 5.0 mg/kg bw/day and  0.45 mg/kg bw/day 
respectively. The only level tested (0.56 mg/kg bw/day) has been taken as a NOAEL (Morgareidge 
and Oser, 1970f). 
Repeated dose toxicity data are summarised in Annex IV, Table IV.2. 
8.3. Developmental / Reproductive Toxicity Studies 
Developmental and reproductive toxicity data are available for one candidate substance (2-furoic acid 
[FL-no: 13.136]) and one supporting substance (furfural [FL-no: 13.018]) included in main group I. 
No data are available for main group II.  
Developmental/reproductive toxicity data are summarised in Annex IV, Table IV.3. 
8.4. Genotoxicity Studies 
Genotoxicity studies were available only on some of the candidate substances included in main group 
I or on their related supporting substances. For subgroup Ia, data on in vitro genotoxicity were 
provided for the two candidate substances 5HMF [FL-no: 13.139] and furoic acid [FL-no: 13.136] as 
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well as for five supporting substances. Data on in vivo genotoxicity were only provided on two of the 
supporting substances from subgroup Ia. New genotoxicity data on the candidate substance 5HMF 
have become available and will be considered in this revision of FGE.13. 
For the one candidate substance [FL-no: 13.155] in subgroup Ib no genotoxicity data are available, but 
in vitro and in vivo genotoxicity data are available for the supporting substance 2-acetylfuran [FL-no: 
13.054]. 
For subgroup Ic, data on in vitro genotoxicity were provided for two supporting substances. Data on in 
vivo genotoxicity were only provided for one of the two supporting substances [FL-no: 13.029 and 
13.030]. Since the supporting substance for subgroup Ib gives information on genotoxic properties of 
putative metabolites of the candidate substances in subgroup Ic, the information given for the 
evaluation of subgroup Ib is also relevant for subgroup Ic. 
No genotoxicity data were available on candidate- or on structurally related substances in main group 
II. 
Subgroup Ia 
Candidate substances: 
5-Hydroxymethyl furfural [FL-no: 13.139] 
In the in vitro tests, 5HMF gave negative results in the traditional Ames test in strains TA98, TA100, 
TA104, TA1535 and TA1537 in five and positive results in two studies. The validity of these two 
studies could not be assessed. In one of these two studies (Omura et al, 1983) the positive response 
was observed in strain TA100, but not in TA 98 and the mutagenic potential was higher in the absence 
of S9 than in the presence of S9. In the other study (Shinohara et al., 1986) mutagenicity was only 
observed in strain TA100 in the presence of metabolic activation (see Table IV.4). A positive result 
was obtained also in the Umu assay, although only at high concentrations, resulting in reduced cell 
viability (Janzowski et al., 2000) and in a Rec assay on B. subtilis (Shinohara et al., 1986). In V79 
cells, 5HMF induced a small (although statistically significant) increase in chromosomal aberrations, a 
reduction in mitotic index and, only at high concentrations, resulting in reduced cell viability, also 
HPRT mutations (Janzowski et al., 2000). In TK6 human lymphoblast cells, 5HMF gave negative 
results in the HPRT and TK assay (Surh & Tannenbaum, 1994).  
In an Ames test with TA104 strain upon inclusion of PAPS, a sulpho-group donor, and rat liver 
cytosol into the experimental model, 5HMF gave a positive result, suggesting that it can be activated 
to reactive metabolites following sulphation, with formation of sulphate-ester (SMF). Indeed, the 
mutagenic effect could be partly suppressed by the addition of sulphotransferase inhibitors. In 
accordance, SMF in TA104 was genotoxic in the absence of any metabolic system (cytotoxicity not 
specified); the effect was reduced by addition of Glutathione (GSH) and GSH-transferases and 
restored when this latter enzyme was inhibited (Lee et al., 1995b).  
The formation of SMF was supported by the detection of an unstable conjugate, which disappeared 
within 60 minutes, when 5HMF was incubated with 35S-PAPS and liver cytosol. The exact nature of 
SMF was not elucidated, but its molecular mass was consistent with that of the sulphate-ester of 
5HMF (Surh & Tannenbaum, 1994). 
When the genotoxicity of chemically synthesised SMF was tested in Salmonella strain TM677 (8-AG-
resistance), without any metabolic activation, a clear positive response was obtained at concentrations 
that reduced cell survival to < 60 %. Genotoxicity was also observed with SMF in human 
lymphoblasts at the TK and HPRT loci, at concentrations (> 40 microgram/ml) reducing cell survival 
to > 63 %. No genotoxicity was observed with 5HMF, with its acetate ester or with the sulphation 
product of 2-methyl furfuryl alcohol, suggesting that the genotoxicity of SMF requires the presence of 
both a reactive sulphate group and a free aldehyde group. 
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An assay for primary DNA damage (“Comet assay”) did not show an effect of 5HMF in V79 and 
Caco-2 cells up to cytotoxic concentrations (80 mM). 5HMF causes a slight but significant increase in 
DNA single strand breaks in primary rat hepatocytes at cytotoxic levels (40 – 100 mM), whereas in 
human colon biopsy material the same effect was seen in the absence of cytotoxicity. 5HMF at non 
cytotoxic concentrations induced a substantial concentration-related GSH depletion in V79, Caco-2 
and rat liver cells. The effect of sulphate conjugation was not directly studied, but since this activity is 
present at least in primary hepatocytes, it might have contributed to the depletion of GSH and to 
induction of DNA strand breaks in these cells. However, this study was not considered appropriate to 
evaluate the possible mutagenic activity of SMF in mammalian cells and consequently of 5HMF in 
vivo (Janzowski et al., 2000). 
To support the genotoxic potential of 5HMF, some indications for tumorigenic activities of 5HMF 
have been obtained with rats and mice. It has been reported that 5HMF may act as both an initiator and 
a promoter in the induction of colonic aberrant cryptic foci in rats (Archer et al., 1992; Bruce et al., 
1993; Zang et al., 1993). In addition induction of skin papillomas has been described after topical 
application of doses of 10 or 25 micromol 5HMF to mice (Surh et al., 1994). 
Newly submitted data on 5-hydroxymethylfurfural9(Table IV.5 and IV.7) 
Weak mutagenic activity was reported in S. typhimurium TA100 strain in the absence of metabolic 
activation, while no mutagenicity was observed in strains TA97, TA98, TA102 and TA1535 in a range 
of concentrations of 100 - 10,000 micrograms/plate; however, negative results were reported in 
another study with TA98 and TA100 strains and E. coli WP2 uvrA/pKM101 in a range of 
concentrations of 1,500 - 10,000 micrograms/plate (NTP, 2010c). 
At the end of a 3-month toxicity study, peripheral blood samples were obtained from male and female 
B6C3F1 mice receiving 0, 47, 188, 375 or 750 mg/kg bw/day of 5HMF via gavage. Slides were 
scanned to determine the frequency of micronuclei in 1000 normochromatic erythrocytes (NCEs) in 
10 animals per sex per treatment group. In addition, the percentage of polychromatic erythrocytes 
(PCE) in a population of 1,000 erythrocytes was determined as a measure of bone marrow toxicity. No 
increases in the frequency of micronucleated erythrocytes were observed; in addition, no significant 
dose-related changes in the percentage of immature PCE were observed, suggesting that the chemical 
did not exhibit bone marrow toxicity (NTP, 2010c). 
The DNA-damaging potential of 5HMF was tested in vitro in the Comet assay with the following five 
cell lines with various degree of SULT1A1 expression (Durling et al., 2009): two human lines (Caco-
2, no detectable 1A1 activity; HEK293, high 1A1 activity); two cell lines from Chinese hamster (V79, 
no detectable 1A1 activity and V79-hp-PST, high 1A1 activity) and a one mouse lymphoma line 
(L5178Y, no detectable activity). The cell lines were incubated with 0, 2.5, 7.5, 25, 50 or 100 mM (ca. 
0, 0.3, 1.0, 3.3 6.3 or 12.6 mg/ml) of 5HMF for three hours and subjected to a Comet assay to study 
DNA damage. 
DNA damage was observed at the highest concentration (100 mM) in all cell lines, with significant 
reduction in cell viability (from 11 to 30 %), The concentration of 100 mM is ten times higher than the 
highest concentration (10 mM or 5000 micrograms/ml) recommended by OECD guidelines for in vitro 
testing with mammalian cells. 100 mM was the lowest effective concentration for three cell lines: 
Caco-2, HEK293 and L5178Y. In the V79 (lowest SULT1A1) and V79-hp-PST (highest SULT1A1) 
DNA damage was induced also at lower concentrations (lowest effective concentration: 25 mM or 
3193 micrograms/ml), without a reduction in cell viability. Surprisingly, the positive control (HMP, 
0.01 mM) induced significant damage in Caco-2, V79 and V79-hp-PST cells, but not in HEK293. The 
                                                     
 
9 An in vivo micronucleus test in mouse bone marrow with neofuraneol was also submitted, but an adequate identification of 
the substance studied was not possible due to incomplete reporting. The study did not show an effect of neofuraneol on the 
occurrence of micronuclei. Since no target organ toxicity was seen, this evidence provided by this study is of very limited 
relevance. For these two reasons the study is not further discussed. 
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authors (Durling et al., 2009) concluded that DNA damage induced in all cell lines was unrelated to 
the expression of SULT1A1 but they mentioned that the SULT1A1 activities in these three cell lines 
(Caco-2, HEK293 and L5178Y) were much lower than those that can be found in human gut and liver. 
The possibility was left open that SULT1A1 activity was too low to efficiently bioactivate 5HMF also 
in the cell line with highest SULT1A1 activity. In V79 cells without SULT1A1 activity and in V79-
hp-PST with SULT1A1 activity at the same level as in human gut and liver, no difference in extent of 
DNA-damage could be observed. This would indicate absence of a significant contribution of sulphate 
conjugation in the DNA-damaging activity of 5HMF.  
These results are in conflict with the results of Glatt et al. (Glatt et al., 2005) who reported induction of 
SCE in 5HMF-exposed genetically modified V79 cells expressing high levels of human CYP2E1 and 
SULT1A1. They are also in conflict with the observations by Sommer et al. (Sommer et al., 2003) 
reporting the mutagenicity of 5HMF in a S. typhimurium strain genetically modified and expressing 
human SULT1A1. According to Durling et al. (2009), the reasons of these discrepancies are unknown; 
one possibility is the different sensitivity of the COMET assay compared to other systems. Durling et 
al. (Durling et al., 2009) concluded that other important mechanisms for the observed DNA damage 
should be investigated, but that under the conditions of the test, 5HMF is a rather weak DNA-
damaging agent. 
In a new publication by Severin et al. (2010), a dose dependent increase in DNA damage was 
observed in an COMET assay with HepG2 cells exposed to 5HMF (0, 5.35, 7.87, 11.57, 17, 25, 36.6 
mM) for 20 hours, with a significant increase from 7.87 to 36.6 mM 5HMF. Cytotoxicity was 
observed at the two highest doses (25 and 36.6 mM), with estimated IC50 of 38 mM. HepG2 cells 
express both CYP and SULT enzymes. In the same publication no effect of 5HMF was found in an in 
vitro micronucleous assay in the same cell line exposed to similar doses of 5HMF (20 hours). 5HMF 
was also tested in an Ames test performed according to the OECD guidelines 471. No increase in 
mutants was observed in S. typhimurium strains TA 98, TA 100, TA1535 and TA 1537 exposed to 
5HMF at 0.5 µg/mL up to 5000 µg/mL with or without metabolic activation (S9). However, no 
additional PAPS was added to the test system (Severin et al., 2010).  
However, while 5HMF was unable to induce micronuclei in vivo, in the NTP 3-months study in mice 
by gavage, and in vitro, using the Hep-G2 human cell line expressing both CYP and SULT enzymes, 
its metabolite SMF has been reported to induce micronuclei in peripheral erythrocytes in mice 
(Dahlberg, 2004 as cited by Glatt and Sommer, 2006 (no further data were available). 
According to Glatt and Sommer, incubation of DNA with SMF in a cell-free system led to the 
formation of DNA adducts that could be detected by the 32P-postlabelling technique. No adducts were 
formed in incubations with 5HMF instead of SMF. In subsequent experiments, the authors searched 
for these adducts in mammalian and bacterial cells treated with SMF and in SULT-proficient cells 
treated with 5HMF. Although mutations were induced, adducts were not seen in these cells under the 
same conditions (no data are available to be listed in the genotoxicity table). The authors hypothesized 
that the lack of DNA adducts might be due to technical problems, since generally DNA adducts are a 
more sensitive endpoint than mutations as observed with many other compounds (Glatt and Sommer, 
2006). 
In conclusion, with respect to the genotoxicity 5HMF, taking into account additional data on 
metabolism, the following picture emerges. The substance is negative in the conventional Ames test. 
Mutagenicity is observed only upon inclusion of PAPS, a sulpho-group donor and liver cytosol into 
the metabolic system, suggesting the formation of a sulphate-ester (SMF). In accordance, SMF was 
mutagenic in the absence of any metabolic activation system. In an in vitro assay, 5HMF induced 
dose-dependent increase in DNA damage (Comet assay), but this study has major drawbacks and 
inconsistencies and has to be considered of limited validity. A major limitation is the use of too high 
concentrations that can produce unpredictable effects, not related to the real genotoxic potential of 
5HMF, and this is particularly true for a test like the Comet assay. Furthermore, as also stated by the 
authors, DNA damage was unrelated to the expression of SULT1A1 activity. Also in another Comet 
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assay in HepG2 cells, able to express both CYP and SULT enzymes, indications for DNA damage 
were observed, but the substance did not induce clastogenic or aneugenic effects (micronucleus assay) 
in the same cell system. In vivo, a non-standard micronucleus assay in peripheral blood erythrocytes 
associated to a sub-chronic study in mice, provided no indication of a genotoxic potential, but this 
study has limited validity since no bone marrow cell toxicity was observed. 
Metabolic studies indicate that in vivo, in mice B6C3F1 and rats, the principal route of metabolism is 
oxidation of 5HFM to 5-hydroxymethylfuroic acid, followed by glycine conjugation and rapid 
elimination in the urine. However, a recent pharmacokinetic study in FVB/N mice has shown that 
SMF has been detected in plasma from animals given 5HMF, intravenously. This indicates that there 
is a competition for the substrate 5HMF between the oxidation pathway leading to the furoic acid 
derivative and the sulphonation pathway leading to the SMF metabolite. The Panel noted that SMF is 
very hydrophilic and therefore will have problems crossing the cell membrane and entering cells. 
Therefore SMF is more likely to induce mutation at the site of formation, mainly the liver. In addition, 
the half life was reported to be 4.2 minutes, and it is not likely that this metabolite will manage to 
reach the bone marrow and give any positive effect in an in vivo micronucleous test, taking into 
account that SMF will most likely be formed in the liver. However, 5HMF has been found unable to 
induce micronuclei also in vitro, using the HepG2 human cell line, expressing both CYP and SULT 
enzymes. In the rodent bioassays no carcinogenic response was observed and from this it may be 
concluded that the formation of the SMF metabolite is too low to result in a carcinogenic response. 
Assuming that in humans the ratio between the two competing pathways is not more favourable for the 
formation of SMF than in rodents, no gentoxicity or carcinogenicity is expected in humans either.  
 
Furoic acid [FL-no: 13.136] 
Furoic acid gave negative results in three studies in the Ames test in strains TA98 and TA100. Fluoric 
acid was also negative in DNA repair test in E. coli and in a UDS assay using primary rat hepatocytes. 
Supporting substances: 
In vitro genotoxicity data were available for five supporting substances (furfuryl acetate, furfuryl 
alcohol, furfural, 5-methylfurfural and methyl-2-furoate) and in vivo genotoxicity data for the two 
supporting substances furfuryl alcohol and furfural. Most studies were negative, although some 
positive results were reported.  
However, the genotoxicity of furfural has been re-evaluated by the AFC panel, which concluded that 
furfural did not induce gene mutations in vivo, on the basis of new studies with transgenic mice 
(EFSA, 2004c). 
Overall, the genotoxicity data available on the candidate furoic acid and on supporting substances do 
not give rise to concern with respect to genotoxicity of nine candidate furfural-related candidate 
substances included in subgroup Ia [FL-no: 13.011, 13.102, 13.122, 13.127, 13.129, 13.130, 13.132, 
13.133 and 13.136]. Based on newly submitted data on the mutagenic activity of 5HMF [FL-no: 
13.139] the concern for genotoxicity which was raised because of genotoxic properties of one of its 
metabolites (SMF) is overcome. Thus there are no further concerns for genotoxicity of the candidate 
substances in subgroup Ia, which could preclude their evaluation through the Procedure. 
Subgroup Ib 
No data are available for the one candidate substance in subgroup Ib ([FL no: 13.155]). However, 
several studies have been carried out with a structurally related flavouring substance, 2-acetylfuran  
[FL-no: 13.054] (2-furyl methyl ketone).  
In vitro studies 
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For the supporting substance 2-acetylfuran [FL-no: 13.054] data were found showing an increased 
mutation frequency in a bacterial reverse gene mutation test in S. typhimurium TA98 with metabolic 
activation, but not in TA100. The study has limited validity. The increase was not dose-related and no 
clear data on cytotoxicity were presented, but a decrease in the number of revertants was observed at 
the highest concentrations, which could indicate cytotoxicity. A second trial was not performed 
(Shinohara et al., 1986). Also with this substance a positive result was obtained in the rec-assay 
(Shinohara et al., 1986) and in an SOS-chromo test for bacterial DNA-repair (Eder et al., 1993), but 
the predictive value of these test systems is considered to be limited. With [FL-no: 13.054] also 
chromosomal abberations in chinese hamster ovary cells have been reported in a limited study by 
Stich et al. (Stich et al., 1981b). 
2-Acetylfuran [FL-no: 13.054] was evaluated for induction of unscheduled DNA synthesis (UDS) in 
human hepatocytes following OECD guidelines. Human (sex not given) hepatocytes from two batches 
purchased from a commercial provider were incubated with concentrations of the compound (purity 
not given) of between 2.19 and 280 μg/ml for 16 hours, and UDS was measured autoradiographically. 
No UDS was elicited, in contrast to the positive control, 2-acetylaminofluorene (Durward, 2007a) 
In vivo studies 
2-Acetylfuran [FL-no: 13.054] was also evaluated for induction of sister chromatid exchanges (SCE) 
in bone marrow of female Swiss albino mice. Groups of two per dose per exposure regimen were 
administered compound (99 % pure) at 0, 1000, 2000 or 3000 mg/l via gavage either once or for 5 
consecutive days. 5-Bromodeoxyuridine was injected intraperitoneally to label chromatids. The mice 
were sacrificed at 12, 24 or 48 hours after receiving the last dose, and slides of bone marrow were 
prepared and processed for differential staining. A dose-related increase up to about 2-fold in SCE was 
observed for the 12- and 24-hours groups of both the single-dose regimen and the multiple-dose 
regimen (Sujatha, 2007). This study was considered valid. In an earlier study by the same group 
(Sujatha et al., 1993) this substance was reported to cause chromosomal aberrations in mouse bone 
marrow at oral dose levels up to 60 mg/kg bw/day. Also this study was consided valid. 
2-Acetylfuran was evaluated for induction of UDS in hepatocytes isolated from livers of dosed male 
Sprague-Dawley rats. The assay was conducted according to GLP and OECD guidelines. In a 
preliminary range-finding toxicity study, lethality was observed at 30 mg/kg bw and greater, and signs 
of toxicity were observed at 20 mg/kg bw. No sex differences were observed, and therefore only males 
were used in the main study. Groups of four rats were administered compound (purity not given) at 0, 
7 or 21 mg/kg bw via gavage. In experiment 1, the hepatocytes were isolated 16 hours post-dosing; in 
experiment 2, hepatocytes were isolated 2 hours post-dosing and cultured for autoradiographic 
measurement of UDS. No UDS was observed in either experiment (Durward, 2007b). 
The candidate and supporting substance in this subgroup are alpha,beta-unsaturated ketones. This 
stuctural characteristic has been considered as an additional reason for concern for genotoxic potential 
of these substances. However, due to structural similarity with acetophenone (i.e. the alpha,beta 
unsaturated double bond is part of an aromatic system and therefore less reactive) the concern for 
genotoxicity, resulting from the formation of such alpha,beta-unsaturated ketones has been lifted. 
Nevertheless, the experimentally obtained genotoxicity data indicate that the supporting substance 
may give rise to DNA damage, which may result in chromosomal aberrations rather than gene 
mutations. Also from chapter 4 and Annex III, the formation of DNA-reactive metabolites may be 
anticipated. In combination with this, the available genotoxicity data are sufficiently strong to raise a 
concern, which would preclude the evaluation of the candidate substance in subgroup Ib through the 
Procedure. 
Subgroup Ic 
No data are available on the genotoxic properties of the two candidate substances in this subgroup. 
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Several studies were found with the supporting substances 2-methylfuran [FL-no: 13.030] and 2,5-
dimethylfuran [FL-no: 13.029]. Negative results were obtained in a limited bacterial reverse gene 
mutation test with S. Typhimurium (TA97 and TA100 strains only, no data on cytotoxicity, no 
duplicate trial (Shinohara et al., 1986)). However, a clear dose-related positive response with limited 
validity (e.g. no clear data on cytotoxicity; no clear description of scoring criteria) was obtained with 
both substances in a chromosome aberration test in Chinese hamster ovary cells with and without 
metabolic activation in presence or absence of metabolic activation (Stich et al., 1981b). Both 
substances also gave a positive response in a rec-assay for bacterial DNA-repair (Shinohara et al., 
1986), but the predictive value of this test system is considered to be limited.  
For 2-alkyl- and 2,5-dialkyl-substituted furans, formation of reactive ring opening products cannot be 
excluded (see chapter 4 and Annex III). These reactive intermediates can bind covalently to DNA, 
which might result in genotoxic events. In an alternative metabolic pathway, these flavouring 
substances may also be converted to ketones which are structurally related to the substances in 
subgroup Ib and for these substances a concern for genotoxicity has been identified. Therefore, owing 
to the anticipated metabolism of the two candidate substances in subgroup Ic into possible genotoxic 
metabolites a concern for genotoxicity cannot be excluded. For the two candidate substances in 
subgroup Ic [FL-no: 13.125 and 13.162] this concern for genotoxicity would preclude their evaluation 
through the procedure.   
Main group II 
No genotoxicity data were available on any of the 14 sulphur-containing candidate substances in main 
group II, nor on their related supporting substances. As it is anticipated that the predominant metabolic 
attack for these substances will be on the sulphur atom(s), for the candidate substances in main group 
II, ring opening is not considered to be a major metabolic route. The lack of data on the 14 sulphur-
containing candidate substances included in main group II or on related supporting substances does 
not allow to conclude on their potential for genotoxicity. However, this would not preclude the 
evaluation of these 14 candidate substances from subgroup II using the Procedure. 
Genotoxicity data are summarised in Annex IV, Table IV.4 to Table IV.7. 
 
9. Conclusions 
The present revision of FGE.13, FGE.13Rev2, concerns the evaluation, in total, of  27 candidate 
flavouring substances; two more than in the previous revision of this FGE. New data included are 
additional data submitted on 5-hydroxymethylfurfural (5HMF) [FL-no: 13.139] in response to 
genotoxicity data requested in FGE.13, consideration of additional data on the stereoisomeric 
composition for two substances [FL-no: 13.185 and 13.199] and inclusion of two more candidate 
substances [FL-no: 13.130 and 13.155]. Also the evaluation of substance [FL-no: 13.135] has been re-
considered. 
Three of the 27 flavouring substances possess a chiral centre [FL-no: 13.127, 13.185 and 13.199] 
Industry has informed that the commercial substances are the racemates in all three cases. Two of the 
27 substances can exist as geometrical isomers [FL-no: 13.011 and 13.129] and in both cases Industry 
has informed that the commercial substances are the (E)-isomers.  
Eight of the candidate substances are classified into structural class II [FL-no: 13.122, 13.130, 13.136, 
13.139, 13.145, 13.155, 13.125 and 13.162] and 19 candidate substances are classified into structural 
class III [FL-no: 13.011, 13.102, 13.108, 13.113, 13.114, 13.124, 13.127, 13.129, 13.132, 13.133, 
13.135, 13.141, 13.143, 13.144, 13.146, 13.149, 13.178, 13.185 and 13.199]. 
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Nineteen of the flavouring substances in the present group have been reported to occur naturally in a 
wide range of food items. For seven flavouring substances, no data on natural occurrence have been 
reported. 
According to the default MSDI approach, the 27 flavouring substances in this group have intakes in 
Europe from 0.0012 to 37 microgram/capita/day, which are below the thresholds of concern for both 
structural class II (540 microgram/person/day) and structural class III (90 microgram/person/day) 
substances.  
On the basis of the reported annual production volumes in Europe (MSDI approach), the total 
estimated combined intake of candidate and supporting substances would be 885 and 60 
microgram/capita/day for structural class II and III, respectively. The total combined daily per capita 
intake of 885 microgram exceeds the threshold of concern of 540 microgram/person/day for structural 
class II substances. However, 50 % of the combined daily per capita intake of 885 microgram results 
from furfural for which, together with the furfural component of furfural diethyl acetal, an ADI of 0.5 
mg/kg bw has been established by EFSA. The total combined intake for the class III substances of 60 
microgram/capita/day does not exceed the threshold for the structural class of 90 
microgram/person/day. 
Genotoxicity studies were only available on some of the candidate substances included in main group 
I or on related supporting substances. For subgroup Ia, data on in vitro genotoxicity were provided for 
the two candidate substances 5HMF [FL-no: 13.139] and furoic acid [FL-no: 13.136] as well as for 
five supporting substances. Data on in vivo genotoxicity were provided for one candidate substance 
[FL-no: 13.139] and for two of the supporting substances. For the candidate substance in group Ib, in 
vitro and in vivo genotoxicity data were available for one supporting substance. For subgroup Ic, data 
on in vitro genotoxicity were provided for two supporting substances. For one of these, also data on in 
vivo genotoxicity were provided. In addition, data for a supporting substance for subgroup Ib 
contribute to the evaluation of the genotoxic potential of substances in subgroup Ic due to structural 
similarity of metabolites of the Ic candidates with the substances in subgroup Ib. 
In subgroup Ia the data available do not indicate a concern for genotoxicity. For the one candidate 
substance in subgroup Ib [FL-no: 13.155] and the two candidate substances in subgroup Ic [FL-no: 
13.125 and 13.162], metabolism studies on closely related substances indicate a potential for DNA-
binding of metabolites. In addition, in several in vitro studies with related substances, indications for 
genotoxic activity were obtained. These data preclude the evaluation through the Procedure of the 
three candidate flavouring substances in subgroup Ib and Ic. 
No genotoxicity data were available on candidate substances or on structurally related substances in 
main group II. The lack of data on the sulphur-containing candidate substances from main group II, or 
on the related supporting substances, does not allow concluding on their genotoxicity, but would not 
preclude the evaluation of these substances through the Procedure. 
The metabolism of non-sulphur-containing furfuryl alcohol derivatives in FGE.13 [FL-no: 13.127, 
13.129, 13.130, 13.132 and 13.133] includes the formation of furfural, a known reactive aldehyde, that 
may lead to hepatotoxicity. Furfural will be further metabolised to furoic acid [Fl no: 13.136] and 
furanacrylic acid, the hydrolysis product of [FL-no: 13.011]. In addition the two furoate esters [FL-no: 
13.102 and 13.122] and furoic acid itself [FL-no: 13.136], which is the main metabolite of furfural, 
may be metabolised to CO2, with the opening of the furan ring, producing reactive intermediates. 
Therefore, it is concluded that the candidate substances included in subgroup Ia cannot be predicted to 
be metabolised to innocuous compounds. In addition, 5HMF [FL-no: 13.139] has a free aldehyde 
function (cf. furfural) and can be anticipated to be reactive. In addition, this substance may be 
bioactivated to reactive intermediates by sulphotransferases for which genotoxicity has been reported. 
However, the available genotoxicity and carcinogenicity data for this substance do not indicate a 
concern for this substance. Extensive ring-opening with formation of intermediates reactive towards 
DNA has been reported for 2-alkyl-substituted furans in subgroup 1c [FL-no: 13.125 and 13.162]. In 
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addition, these compounds may be metabolised to ketones (subgroup 1b; [FL-no: 13.155]), for which 
genotoxicity may be anticipated. 
Based on the metabolism of other sulphur-containing compounds, the candidate furfuryl and furan 
monosulphides are expected to be subject to oxidation mainly to sulphoxides and sulphones. Given the 
reactivity of thiol groups, whether free or from di- or trisulphides, and the importance of thiol groups 
in cell physiology, it cannot be excluded that these substances interfere with normal cell function. 
Therefore, it is concluded that none of the candidate substances included in main group II can be 
predicted to be metabolised to innocuous substances.  
Short-term and long-term toxicity studies are available for two candidate substances included in 
subgroup Ia, namely 2-furoic acid [FL-no: 13.136] and 5HMF [FL-no: 13.139] and for three related 
supporting substances. For the candidate substances structurally related to furfuryl alcohol or furfural, 
these studies indicate that the liver is the critical target for their toxicity. EFSA has established an ADI 
value of 0.5 mg/kg/d bw for furfural and the furfural component of furfural diethyl acetal. For 5-
hydroxymethylfurfural [FL-no: 13.139], substance-specific data indicate that the kidney of the male 
mouse was the target organ, and for this substance a BMDL of 14.4 mg/kg bw/day could be derived, 
based on the results of a 13-weeks oral toxicity study.  
No toxicity data are available on the sulphur-containing furan-derived candidate substances included 
in subgroups IIa-d. However, results from toxicity studies on 14 supporting substances have been 
reported. Many of the available studies were performed either with a single dose level or multiple dose 
levels that produced no effects; the doses producing no adverse effects ranged from 0.45 to 10 mg/kg 
bw/day.  
It was considered on the basis of the default MSDI approach that for the 24 candidate substances [FL-
no: 13.011, 13.102, 13.108, 13.113, 13.114, 13.122, 13.124, 13.127, 13.129, 13.130, 13.132, 13.133, 
13.135, 13.136, 13.139, 13.141, 13.143, 13.144, 13.145, 13.146, 13.149, 13.178, 13.185 and 13.199], 
it could be concluded, at step B4 of the Procedure, that these 24 candidate substances do not pose a 
safety concern when used as flavouring substances at the estimated levels of intake based on the MSDI 
approach. 
The Panel has reservations for three substances [FL-no: 13.125, 13.155 and 13.162] which could not 
be evaluated through the Procedure due to concern of genotoxicity in vitro. For these three substances 
additional date are required. 
For three candidate substances [FL-no: 13.122, 13.136 and 13.139] in structural class II, evaluated 
through the Procedure, the mTAMDI range from 1400 to 3900 microgram/person/day, which are 
above the threshold of concern for this Cramer class. For one substance [FL-no: 13.145] the mTAMDI 
is 160 microgram/person/day, which is below the class threshold of 540 microgram/person/day. For 
substance [FL-no: 13.130, no use levels were provided, so no mTAMDI can be calculated. 
The estimated intakes for 16 [FL-no: 13.011, 13.102, 13.108, 13.113, 13.114, 13.127, 13.129, 13.132, 
13.133, 13.135, 13.141, 13.143, 13.146, 13.149, 13.178 and 13.185] of the 19 substances evaluated 
through the Procedure and assigned to structural class III, based on the mTAMDI, range from 160 to 
3900 microgram/person/day, which are above the threshold of concern for structural class III 
substances of 90 microgram/person/day. For the remaining three substances from structural class III 
[FL-no: 13.124, 13.144 and 13.199] the mTAMDIs range from 49 to 78 microgram/person/day, which 
is below the threshold of concern. 
Thus, for 20 of the candidate substances, evaluated using the Procedure, further information is 
required. This would include more reliable intake data and then, if required, additional toxicological 
data. On the basis of such additional data, these flavouring substances should be reconsidered along 
the steps of the Procedure. Following this procedure additional toxicological data might become 
necessary.  
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In order to determine whether the conclusion for the 24 candidate substances evaluated through the 
Procedure can be applied to the material of commerce, it is necessary to consider the available 
specifications. Adequate specifications including complete purity criteria and identity for the materials 
of commerce have been provided for all 24 flavouring substances evaluated through the Procedure.  
For these 24 candidate substances [FL-no: 13.011, 13.102, 13.108, 13.113, 13.114, 13.122, 13.124, 
13.127, 13.129, 13.130, 13.132, 13.133, 13.135, 13.136, 13.139, 13.141, 13.143, 13.144, 13.145, 
13.146, 13.149, 13.178, 13.185 and 13.199] the Panel concluded that they would be of “No safety 
concern at estimated levels of intake as flavouring substances” based on the MSDI approach. 
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TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FGE.13REV2 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 13, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification 
comments 
13.011 
 
Ethyl furfuracrylate 
O
O
O
 
 
545 
623-20-1 
Liquid 
C9H10O3 
166.18 
Practically 
insoluble or 
insoluble 
Freely soluble 
229 
14 
MS 
95 % 
1.544-1.550 
1.092-1.098 
 
Register name to be 
changed to (E)-Ethyl 
furfuracrylate 
(EFFA). 
CASrn in Register 
does not specify (Z) 
or (E) isomer. 
CASrn in Register 
to be changed. 
13.102 
 
Butyl 2-furoate O
O
O
 
 
583-33-5 
Liquid 
C9H12O3 
168.19 
Practically 
insoluble or 
insoluble 
Freely soluble 
233 
 
MS 
95 % 
1.469-1.475 
1.052-1.058 
 
 
13.108 
 
4,5-Dihydro-3-mercapto-2-
methylfuran 
O
SH
4683 
 
26486-13-5 
Liquid 
C5H8OS 
116.18 
Slightly 
soluble 
Freely soluble 
160 
 
MS 
95 % 
1.497-1.503 
1.047-1.053 
 
 
13.113 
 
2,5-Dimethyl-3-
(methyldithio)furan 
O
S
S
 
 
61197-06-6 
Solid 
C7H10OS2 
174.28 
Practically 
insoluble or 
insoluble 
Freely soluble 
284 
45 
MS 
95 % 
n.a. 
n.a. 
 
 
13.114 
 
2,5-Dimethyl-3-(methylthio)furan O
S
 
 
63359-63-7 
Liquid 
C7H10OS 
142.22 
Practically 
insoluble or 
insoluble 
Freely soluble 
63 (13 hPa) 
 
MS 
95 % 
1.503-1.509 
1.042-1.048 
 
 
13.122 
 
Ethyl 2-furoate O
O
O
 
10588 
614-99-3 
Solid 
C7H8O3 
140.14 
Practically 
insoluble or 
insoluble 
Freely soluble 
196 
36 
MS 
99 % 
n.a. 
n.a. 
 
 
13.124 
 
Ethyl furfuryl sulfide 
S
O  
 
2024-70-6 
Liquid 
C7H10OS 
142.22 
Slightly 
soluble 
Freely soluble 
73 (13 hPa) 
 
MS 
1.509-1.515 
1.047-1.053 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 13, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification 
comments 
95 % 
13.125 
 
2-Ethyl-5-methylfuran O
 
 
10942 
1703-52-2 
Liquid 
C7H10O 
110.16 
Practically 
insoluble or 
insoluble 
Freely soluble 
118 
 
MS 
95 % 
1.443-1.449 
0.890-0.896 
 
 
13.127 
 
Furfuryl 2-methylbutyrate 
O
O
O
 
 
10643 
13678-61-0 
Liquid 
C10H14O3 
182.22 
Practically 
insoluble or 
insoluble 
Freely soluble 
263 
 
MS 
95 % 
1.455-1.461 
1.009-1.015 
 
Racemate, Register 
name to be changed 
to Furfuryl 2-
methylbutyrate 
(EFFA). 
13.129 
 
Furfuryl but-2-enoate O
O
O
 
 
 
59020-84-7 
Liquid 
C9H10O3 
166.17 
Practically 
insoluble or 
insoluble 
Freely soluble 
245 
 
NMR 
95 % 
1.491-1.497 
1.034-1.040 
 
Register name to be 
changed to Furfuryl 
but-2(E)-enoate 
(EFFA). 
(Z) or (E) isomer not 
specified by CASrn 
in Register. 
CASrn in Register 
to be changed. 
13.130 
759 
Furfuryl butyrate 
O
O
O  
638 
623-21-2 
Liquid 
C9H12O3 
168.19 
Insoluble 
Miscible 
212 
 
IR 
99 
1.457-1.462 
1.051-1.057 
 
 
13.132 
 
Furfuryl hexanoate O
O
O
 
 
39252-02-3 
Liquid 
C11H16O3 
196.25 
Practically 
insoluble or 
insoluble 
Freely soluble 
224 
 
MS 
98 % 
1.452-1.458 
1.003-1.013 
 
 
13.133 
 
Furfuryl isobutyrate 
O
O
O
 
10641 
6270-55-9 
Liquid 
C9H12O3 
168.19 
Practically 
insoluble or 
insoluble 
Freely soluble 
85 (20 hPa) 
 
MS 
95 % 
1.497-1.503 
1.028-1.034 
 
 
13.135 
 
1-(2-Furfurylthio)propanone O
S
O  
4676 
 
58066-86-7 
Liquid 
C8H10O2S 
170.04 
Insoluble 
Soluble 
240.4 (1.2Torr) 
n.a. 
IR NMR 
95 % 
1.525-1.531 
1.146-1.154 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 13, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification 
comments 
13.136 
 
2-Furoic acid 
O
OH
O  
10098 
88-14-2 
Solid 
C5H4O3 
112.08 
Slightly 
soluble 
Freely soluble 
231 
132 
MS 
95 % 
n.a. 
n.a. 
 
 
13.139 
 
5-Hydroxymethylfurfuraldehyde O
OHO
 
 
11112 
67-47-0 
Solid 
C6H6O3 
126.11 
Slightly 
soluble 
Freely soluble 
154 (16 hPa) 
34 
MS 
95 % 
n.a. 
n.a. 
 
 
13.141 
 
Methyl (2-furfurylthio)acetate O
S
O
O  
 
 
108499-33-
8 
Liquid 
C8H10O3S 
186.23 
Practically 
insoluble or 
insoluble 
Freely soluble 
287 
 
MS 
95 % 
1.510-1.520 
1.195-1.205 
 
 
13.143 
 
Methyl 3-(furfurylthio)propionate O
OS
O
 
 
94278-26-9 
Liquid 
C9H12O3S 
200.25 
Practically 
insoluble or 
insoluble 
Freely soluble 
310 
 
MS 
95 % 
1.509-1.519 
1.160-1.170 
 
 
13.144 
 
Methyl 5-methylfurfuryl disulfide O
S
S
 
 
 
78818-78-7 
Solid 
C7H10OS2 
174.28 
Practically 
insoluble or 
insoluble 
Freely soluble 
279 
32 
NMR 
95 % 
n.a. 
n.a. 
 
 
13.145 
 
Methyl 5-methylfurfuryl sulfide 
S
O
 
 
11522 
13679-60-2 
Liquid 
C7H10OS 
142.22 
Slightly 
soluble 
Freely soluble 
84 (20 hPa) 
 
NMR 
95 % 
1.509-1.515 
1.048-1.054 
 
Register name to be 
changed to Methyl 
5-methylfurfuryl 
sulphide. 
13.146 
 
Methyl furfuryl trisulfide 
S
S
S
O
 
 
 
66169-00-4 
Solid 
C6H8OS3 
192.32 
Practically 
insoluble or 
insoluble 
Freely soluble 
320 
43 
NMR 
95 % 
n.a. 
n.a. 
 
 
13.149 
 
5-Methyl-2-furanmethanethiol O
SH
 
 
 
59303-05-8 
Liquid 
C6H8OS 
128.19 
Slightly 
soluble 
Freely soluble 
62 (17 hPa) 
 
MS 
95 % 
1.523-1.529 
1.041-1.047 
 
 
13.155 
 
2-Methyl-5-propionylfuran 
O
O  
11158 
10599-69-6 
Liquid 
C8H10O2 
138.17 
Practically 
insoluble or 
insoluble 
Freely soluble 
73 (13 hPa) 
 
MS 
95 % 
1.502-1.508 
1.038-1.044 
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Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation 13, Revision 2 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in 
ethanol 2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification 
comments 
13.162 
 
2-Octylfuran O
 
 
10965 
4179-38-8 
Liquid 
C12H20O 
180.29 
Practically 
insoluble or 
insoluble 
Freely soluble 
103 (16 hPa) 
 
MS 
95 % 
1.313-1.319 
0.892-0.898 
 
 
13.178 
 
3-(Furfuryldithio)-2-methylfuran O
O
S
S
 
 
 
109537-55-
5 
Solid 
C10H10O2S2 
226.32 
Practically 
insoluble or 
insoluble 
Freely soluble 
398 
122 
NMR 
95 % 
n.a. 
n.a. 
 
Register name to be 
changed to Furan, 3-
[(2-
furanylmethyl)dithio
]-2-methyl-. 
13.185 
 
2-Furfuryl 3-oxo-2-butyl 
disulphide O
S
S
O
 
 
 
 
Solid 
C9H12O2S2 
216.32 
Practically 
insoluble or 
insoluble 
Freely soluble 
374 
77 
NMR 
95 % 
n.a. 
n.a. 
 
Racemate  (EFFA, 
2010a). CASrn to be 
introduced in 
Register 159113-17-
4. Register name to 
be changed to: 2-
butanone, 3-[(2-
furanylmethyl)dithio
]- (EFFA).  
13.199 
 
3-[(2-Methyl-3-furyl)thio]-
butanal 
o
s O
4501 
 
915971-43-
6 
Liquid 
C9H12O2S 
184.26 
Practically 
insoluble 
Soluble 
n.a. 
decomp at 198°C 
IR NMR MS 
98% 
1.5122-1.5222 
1.101-1.121 
 
Racemate (EFFA, 
2010a). 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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TABLE 2A: SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH) 
Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation 
remarks 
13.122 
 
Ethyl 2-furoate O
O
O
0.39 
 
Class II 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.130 
759 
Furfuryl butyrate 
O
O
O 0.24 
 
Class II 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.136 
 
2-Furoic acid 
O
OH
O 0.013 
 
Class II 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.139 
 
5-
Hydroxymethylfurfuraldehyde 
O
OHO
0.39 
 
Class II 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.145 
 
Methyl 5-methylfurfuryl sulfide 
S
O 0.0024 
 
Class II 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.155 
 
2-Methyl-5-propionylfuran 
O
O 0.011 
 
Class II 
No evaluation 
  a) 
13.125 
 
2-Ethyl-5-methylfuran O 0.011 
 
Class II 
No evaluation 
  b) 
13.162 
 
2-Octylfuran O 0.011 
 
Class II 
No evaluation 
  b) 
13.011 
 
Ethyl furfuracrylate 
O
O
O 0.12 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation 
remarks 
13.102 
 
Butyl 2-furoate O
O
O
0.12 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.108 
 
4,5-Dihydro-3-mercapto-2-
methylfuran 
O
SH
37 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.113 
 
2,5-Dimethyl-3-
(methyldithio)furan 
O
S
S
0.0012 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.114 
 
2,5-Dimethyl-3-
(methylthio)furan 
O
S
0.0024 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.124 
 
Ethyl furfuryl sulfide 
S
O 0.18 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.127 
 
Furfuryl 2-methylbutyrate 
O
O
O
0.73 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.129 
 
Furfuryl but-2-enoate O
O
O
0.11 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.132 
 
Furfuryl hexanoate O
O
O
0.58 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
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Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named 
compound 
[ 4) or 5] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation 
remarks 
13.133 
 
Furfuryl isobutyrate 
O
O
O
0.89 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.135 
 
1-(2-Furfurylthio)propanone O
S
O
0.61 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.141 
 
Methyl (2-furfurylthio)acetate O
S
O
O
0.011 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.143 
 
Methyl 3-
(furfurylthio)propionate 
O
OS
O
0.011 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.144 
 
Methyl 5-methylfurfuryl 
disulfide 
O
S
S 0.0024 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.146 
 
Methyl furfuryl trisulfide 
S
S
S
O 0.0024 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.149 
 
5-Methyl-2-furanmethanethiol O
SH
0.37 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.178 
 
3-(Furfuryldithio)-2-
methylfuran 
O
O
S
S 0.24 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.185 
 
2-Furfuryl 3-oxo-2-butyl 
disulphide O
S
S
O 0.011 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
13.199 
 
3-[(2-Methyl-3-furyl)thio]-
butanal 
o
s O
1.2 
 
Class III 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
4) 6)  
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1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
a) Additional genotoxicity data required. 
b) Genotoxic in vitro. 
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TABLE 2B: EVALUATION STATUS OF HYDROLYSIS PRODUCTS OF CANDIDATE ESTERS 
Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
 Methanol OH  Not evaluated as flavour  Not in EU Register 
 2-Furanacrylic acid 
O
OH
O Not evaluated as flavour  Not in EU Register 
 2-Furfurylthioacetic acid O
S
OH
O
Not evaluated as flavour  Not in EU Register 
 3-Furfurylthiopropionic acid 
O
S OH
O Not evaluated as flavour  Not in EU Register 
02.004 Butan-1-ol 
85 
OH  Category 1 a) No safety concern b) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
02.078 Ethanol 
41 
OH  Category 1 a) No safety concern d) 
 
 
 
No evaluation 
At the forty-sixth JECFA meeting (JECFA, 
1997a), the Committee concluded that 
ethanol posed no safety concern at its current 
level of intake when ethyl esters are used as 
flavouring agents. 
08.005 Butyric acid 
87 
OH
O
 
Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
 
08.006 2-Methylpropionic acid 
253 
O
OH
Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake below threshold 
 
08.009 Hexanoic acid 
93 
O
OH
Category 1 a) 
No safety concern b) 
Category A c) 
Class I 
A3: Intake above threshold, A4: 
Endogenous 
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Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
 
08.046 2-Methylbutyric acid 
255 
O
OH
Category 1 a) 
No safety concern b) 
Category A c) 
 
Class I 
A3: Intake below threshold 
 
08.072 But-2-enoic acid (cis and 
trans) 
 OH
O
(E)-isomer shown
 
 
 
FGE.05 
Class I 
A3: Intake below threshold 
 
13.019 Furfuryl alcohol 
451 
O
OH
 
 
No safety concern e) 
Category B c) 
 
Class II 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
 
13.026 2-Furanmethanethiol 
1072 
O
SH
 
 
No safety concern f) 
Category A c) 
 
Class II 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
 
13.136 2-Furoic acid 
 O
OH
O  
 
 
FGE.13 
Class II 
B3: Intake below threshold, B4: 
Adequate NOAEL exists 
 
1) Category 1: Considered safe in use;   Category 2: Temporarily considered safe in use;   Category 3: Insufficient data to provide assurance of safety in use;   Category 4): Not acceptable due to evidence of toxicity. 
2) No safety concern at estimated levels of intake. 
3) Category A: Flavouring substance, which may be used in foodstuffs Category B: Flavouring substance which can be used provisionally in foodstuffs. 
4) Threshold of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
5) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
a) (SCF, 1995). 
b) (JECFA, 1999b). 
c) (CoE, 1992). 
d) (JECFA, 1997a). 
e) (JECFA, 2001a). 
f) (JECFA, 2002c). 
ND: Not detected. 
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TABLE 3: SUPPORTING SUBSTANCES SUMMARY 
Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
13.001 5-Methylfurfural O
O
2702 
119 
620-02-0 
745 
JECFA specification 
(JECFA, 2002d) 
180  
No safety concern a) 
Category B b) 
 
13.002 Methyl 2-furoate 
O
O
O 2703 
358 
611-13-2 
746 
JECFA specification 
(JECFA, 2000d) 
30  
No safety concern a) 
Deleted b) 
GrADI: 0.5 (JECFA, 
2001a). Deleted CoE 
(CoE, 1992) 
13.003 Propyl 2-furoate O
O
O
2946 
359 
615-10-1 
747 
JECFA specification 
(JECFA, 2000d) 
0.061  
No safety concern a) 
Deleted b) 
GrADI: 0.5 (JECFA, 
2001a). Deleted CoE 
(CoE, 1992) 
13.005 Hexyl 2-furoate O
O
O
2571 
361 
39251-86-0 
749 
JECFA specification 
(JECFA, 2001c) 
0.061  
No safety concern a) 
Deleted b) 
GrADI: 0.5 (JECFA, 
2001a). Deleted CoE 
(CoE, 1992) 
13.015 bis-(2,5-Dimethyl-3-furyl) 
disulfide 
O
S
S
O
3476 
722 
28588-73-0 
1067 
JECFA specification 
(JECFA, 2002d) 
0.012  
No safety concern c) 
Category A b) 
 
13.016 bis-(2-Methyl-3-furyl) 
disulfide 
O
S
S
O
3259 
723 
28588-75-2 
1066 
JECFA specification 
(JECFA, 2002d) 
0.27  
No safety concern c) 
Category A b) 
 
13.017 bis-(2-Methyl-3-furyl) 
tetrasulfide 
O
OS
S
S
S
3260 
724 
28588-76-3 
1068 
JECFA specification 
(JECFA, 2002d) 
0.97  
No safety concern c) 
Category A b) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
13.018 Furfural O
O
2489 
2014 
98-01-1 
450 
JECFA specification 
(JECFA, 2000d) 
440 Category 4 d) 
No safety concern a) 
Category B b) 
GrADI: 0-0.5 (JECFA, 
2001a). EFSA opinion, 
2004. 
13.019 Furfuryl alcohol O
OH
2491 
2023 
98-00-0 
451 
JECFA specification 
(JECFA, 2000d) 
180  
No safety concern a) 
Category B b) 
GrADI: 0.5 (JECFA, 
2001a) 
13.025 Pentyl 2-furoate O
O
O
2072 
2109 
1334-82-3 
748 
JECFA specification 
(JECFA, 2001c) 
0.36  
No safety concern a) 
Deleted b) 
GrADI: 0.5 (JECFA, 
2001a). Deleted CoE 
(CoE, 1992) 
13.026 2-Furanmethanethiol O
SH
2493 
2202 
98-02-2 
1072 
JECFA specification 
(JECFA, 2002d) 
29  
No safety concern c) 
Category A b) 
 
13.029 2,5-Dimethylfuran O  
2208 
625-86-5 
1488 
JECFA specification 
(JECFA, 2006b) 
0.012  
No evaluation e) 
Deleted b) 
f) 
13.030 2-Methylfuran O 4179 
2209 
534-22-5 
1487 
JECFA specification 
(JECFA, 2006b) 
0.21  
No evaluation e) 
Category B b) 
f) 
13.032 Furfuryl isopropyl sulfide 
O
S
3161 
2248 
1883-78-9 
1077 
JECFA specification 
(JECFA, 2002d) 
0.0012  
No safety concern c) 
Category B b) 
 
13.038 2-Phenyl-3-carbethoxyfuran 
O
O
O
3468 
2309 
50626-02-3 
752 
JECFA specification 
(JECFA, 2002d) 
0.012  
No safety concern a) 
Category B b) 
 
13.050 Difurfuryl disulfide 
S
SO
O
3146 
11480 
4437-20-1 
1081 
JECFA specification 
(JECFA, 2002d) 
3.3  
No safety concern c) 
 
 
13.053 Methyl furfuryl sulfide 
S
O 3160 
11482 
1438-91-1 
1076 
JECFA specification 
(JECFA, 2002d) 
0.97  
No safety concern c) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
13.054 2-Acetylfuran 
O
O 3163 
11653 
1192-62-7 
1503 
JECFA specification 
(JECFA, 2006b) 
46  
No evaluation e) 
 
f) 
13.055 2-Methylfuran-3-thiol O
SH
3188 
11678 
28588-74-1 
1060 
JECFA specification 
(JECFA, 2002d) 
0.52  
No safety concern c) 
 
 
13.056 Difurfuryl sulfide 
S
OO 3238 
11438 
13678-67-6 
1080 
JECFA specification 
(JECFA, 2002d) 
0.73  
No safety concern c) 
 
 
13.057 Furfuryl isovalerate O
O
O
3283 
10642 
13678-60-9 
743 
JECFA specification 
(JECFA, 2001c) 
0.024  
No safety concern a) 
 
GrADI: 0.5 (JECFA, 
2001a) 
13.059 2-Pentylfuran O 3317 
10966 
3777-69-3 
1491 
JECFA specification 
(JECFA, 2006b) 
0.18  
No evaluation e) 
 
f) 
13.062 Furfuryl propionate O
O
O
3346 
10646 
623-19-8 
740 
JECFA specification 
(JECFA, 2001c) 
1.7  
No safety concern a) 
 
GrADI: 0.5 (JECFA, 
2001a) 
13.064 Methyl furfuryl disulfide 
S
SO 3362 
11513 
57500-00-2 
1078 
JECFA specification 
(JECFA, 2002d) 
0.85  
No safety concern c) 
 
 
13.065 2-Methyl-5-
(methylthio)furan 
O S 3366 
11550 
13678-59-6 
1062 
JECFA specification 
(JECFA, 2002d) 
1.1  
No safety concern c) 
 
 
13.066 3-Acetyl-2,5-dimethylfuran O
O
3391 
10921 
10599-70-9 
1506 
Tentative JECFA 
specification (JECFA, 
2006b) 
ND  
No evaluation e) 
 
f) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
13.067 Furfuryl octanoate O
O
O
3396 
10645 
39252-03-4 
742 
JECFA specification 
(JECFA, 2001c) 
0.012  
No safety concern a) 
 
GrADI: 0.5 (JECFA, 
2001a) 
13.068 Furfuryl valerate O
O
O
3397 
10647 
36701-01-6 
741 
JECFA specification 
(JECFA, 2001c) 
0.24  
No safety concern a) 
 
GrADI: 0.5 (JECFA, 
2001a) 
13.069 2-Heptylfuran O 3401 
10952 
3777-71-7 
1492 
JECFA specification 
(JECFA, 2006b) 
0.012  
No evaluation e) 
 
f) 
13.070 2-Hexanoylfuran 
O
O 3418 
11180 
14360-50-0 
1512 
JECFA specification 
(JECFA, 2006b) 
ND  
No evaluation e) 
 
f) 
13.071 2,5-Dimethylfuran-3-thiol O
SH
3451 
11457 
55764-23-3 
1063 
JECFA specification 
(JECFA, 2002d) 
0.024  
No safety concern c) 
 
 
13.073 Octyl 2-furoate O
O
O
3518 
10864 
39251-88-2 
750 
JECFA specification 
(JECFA, 2001c) 
2.2  
No safety concern a) 
 
GrADI: 0.5 (JECFA, 
2001a) 
13.075 2,6-Dimethyl-3-((2-methyl-3-
furyl)thio)heptan-4-one 
O
S
O
3538 
11915 
61295-51-0 
1086 
JECFA specification 
(JECFA, 2002d) 
1.8  
No safety concern c) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
13.077 3-((2-Methyl-3-
furyl)thio)heptan-4-one 
O
S
O
3570 
11922 
61295-41-8 
1085 
JECFA specification 
(JECFA, 2002d) 
2.9  
No safety concern c) 
 
 
13.078 4-((2-Methyl-3-
furyl)thio)nonan-5-one 
O
S
O
3571 
11923 
61295-50-9 
1087 
JECFA specification 
(JECFA, 2002d) 
0.73  
No safety concern c) 
 
 
13.079 Methyl 2-methyl-3-furyl 
disulfide 
O
S
S
3573 
11924 
65505-17-1 
1064 
JECFA specification 
(JECFA, 2002d) 
0.73  
No safety concern c) 
 
 
13.082 Propyl 2-methyl-3-furyl 
disulfide 
O
S
S
3607 
 
61197-09-9 
1065 
JECFA specification 
(JECFA, 2002d) 
0.12  
No safety concern c) 
 
 
13.083 2-Acetyl-5-methylfuran 
O
O 3609 
11038 
1193-79-9 
1504 
JECFA specification 
(JECFA, 2006b) 
0.37  
No evaluation e) 
 
f) 
13.092 2-Ethylfuran O 3673 
11706 
3208-16-0 
1489 
JECFA specification 
(JECFA, 2006b) 
0.061  
No evaluation e) 
 
f) 
13.093 Ethyl 3-(2-
furfurylthio)propionate 
OS
O
O 3674 
 
94278-27-0 
1088 
JECFA specification 
(JECFA, 2002d) 
0.012  
No safety concern c) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
13.101 2-Acetyl-3,5-dimethylfuran 
O
O 4071 
 
22940-86-9 
1505 
JECFA specification 
(JECFA, 2006b) 
0.0012  
No evaluation e) 
 
f) 
13.103 2-Butylfuran O 4081 
10927 
4466-24-4 
1490 
JECFA specification 
(JECFA, 2006b) 
0.24  
No evaluation e) 
 
f) 
13.105 2-Butyrylfuran 
O
O 4083 
11045 
4208-57-5 
1507 
JECFA specification 
(JECFA, 2006b) 
0.12  
No evaluation e) 
 
f) 
13.106 2-Decylfuran O 4090 
 
83469-85-6 
1493 
JECFA specification 
(JECFA, 2006b) 
0.0012  
No evaluation e) 
 
f) 
13.126 Furfural diethyl acetal 
O
O
O
 
 
13529-27-6 
 
 
0.085  
 
 
Furfural diethyl acetal, 
structurally related to 
the substances in 
subgroup IA, has been 
evaluated by the AFC 
Panel (EFSA, 2004c) 
13.128 Furfuryl acetate O
O
O
2490 
2065 
623-17-6 
739 
JECFA specification 
(JECFA, 2000d) 
16  
No safety concern a) 
Category B b) 
GrADI: 0.5 (JECFA, 
2001a) 
13.151 2-Methyl-3,5 and 6-
(furfurylthio)pyrazine 
2 or 5 or 6 -Methyl-3-(furfurylthio)pyrazine
N
N
O
S
3189 
2287 
65530-53-2 
1082 
JECFA specification 
(JECFA, 2002d) 
0.37  
No safety concern c) 
Category B b) 
 
13.152 2-Methyl-3-
(methylthio)furan 
O
S
3949 
 
63012-97-5 
1061 
JECFA specification 
(JECFA, 2002d) 
1.2  
No safety concern c) 
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Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
Comments 
13.160 2-Methyltetrahydrofuran-3-
thiol 
O
SH
3787 
 
57124-87-5 
1090 
JECFA specification 
(JECFA, 2002d) 
3.5  
No safety concern c) 
 
 
13.163 2-Pentanoylfuran 
O
O 4192 
 
3194-17-0 
1509 
JECFA specification 
(JECFA, 2006b) 
0.061  
No evaluation e) 
 
f) 
13.193 2,5-Dimethyltetrahydro-3-
furanthiol 
O
SH
3971 
 
26486-21-5 
1091 
JECFA specification 
(JECFA, 2002d) 
0.024  
No safety concern c) 
 
 
13.196 4-(Furfurylthio) pentan-2-one 
O
S
O 3840 
 
180031-78-1 
1084 
JECFA specification 
(JECFA, 2002d) 
0.012  
No safety concern c) 
 
 
13.197 Furyl propyldisulfide O
S
S 3979 
 
252736-36-0 
1079 
JECFA specification 
(JECFA, 2002d) 
0.024  
No safety concern c) 
 
 
1) EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity. 
3) No safety concern at estimated levels of intake. 
4) Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
a) (JECFA, 2001a). 
b) (CoE, 1992). 
c) (JECFA, 2002c). 
d) (SCF, 1995). 
e) (JECFA, 2009c.) 
f) The procedure could not be applied to this furan-substituted substance due to concern with respect to available genotoxicity data, formation of possible toxic metabolites and structural similarity to furan which is 
carcinogenic (JECFA, 2006b). 
ND)  No intake data reported. 
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ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), named the "Procedure", is shown in schematic 
form in Figure I.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 
2 December 1999 (SCF, 1999a), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA, 
1996a; JECFA, 1997a; JECFA, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 microgram/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996a). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products10 (Step 2)?  
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
• are the flavourings or their metabolites endogenous11 (Step A4)?  
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions. 
 
                                                     
 
10 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the 
estimated intakes of the flavouring agent” (JECFA, 1997a). 
 
11 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
(JECFA, 1997a). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety 
evaluation
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is  high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
  Substance would not be    
expected to be of safety concern
Is the substance or are its metabolites endogenous?
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4.
 Yes No
 Yes 
 No 
No
No
Yes
No
Yes
Yes
Yes
 No
Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
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ANNEX II: USE LEVELS / MTAMDI 
II.1 Normal and Maximum Use Levels 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000a). According to the Industry the 
”normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th 
percentile of reported usages (EFFA, 2002i). The normal and maximum use levels in different food 
categories have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 2004e). 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
 
The “normal and maximum use levels” are provided by Industry for 26 of the 27 candidate substances in the 
present flavouring group (EFFA, 2003g; EFFA, 2004y; EFFA, 2007a; Flavour Industry, 2009b) (Table 
II.1.2). 
Table II.1.2 Normal and Maximum use levels (mg/kg) for candidate substances in FGE.13Rev1 (EFFA, 2003g; 
EFFA, 2004y; EFFA, 2007a; Flavour Industry, 2009b). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
13.011 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
13.102 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
13.108 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
13.113 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
13.114 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
13.122 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
13.124 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,3 
0,2 
1 
0,4 
2 
0,1 
0,5 
13.125 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
13.127 7 5 10 7 - 10 5 10 2 2 - - 5 10 5 10 20 5 
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Table II.1.2 Normal and Maximum use levels (mg/kg) for candidate substances in FGE.13Rev1 (EFFA, 2003g; 
EFFA, 2004y; EFFA, 2007a; Flavour Industry, 2009b). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
35 25 50 35 - 50 25 50 10 10 - - 25 50 25 50 100 25 
13.129 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
13.130 - 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
13.132 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
13.133 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
5 
25 
10 
50 
20 
100 
5 
25 
13.135 0 
0 
0 
0 
0 
0 
0 
0 
- 
- 
2 
7 
0 
0 
1,5 
6 
1,1 
6 
0 
0 
- 
- 
- 
- 
0 
0 
0 
0 
1,5 
7 
0,5 
2 
1,5 
7 
0 
0 
13.136 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
5 
25 
2 
10 
- 
- 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
5 
25 
5 
25 
2 
10 
13.139 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
2 
10 
4 
20 
5 
25 
2 
10 
13.141 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
1 
5 
0,4 
2 
13.143 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
13.144 0,2 
1 
0,1 
0,5 
0,2 
1 
0,2 
1 
- 
- 
0,2 
1 
0,1 
0,5 
0,2 
1 
0,1 
0,2 
0,1 
0,2 
- 
- 
- 
- 
0,1 
0,5 
0,2 
1 
0,1 
0,3 
0,2 
1 
0,4 
2 
0,1 
0,5 
13.145 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
13.146 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
13.149 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
13.155 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
13.162 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
13.178 0,4 
2 
0,2 
1 
0,4 
2 
0,3 
1,5 
- 
- 
0,4 
2 
0,2 
1 
0,4 
2 
0,1 
0,4 
0,1 
0,4 
- 
- 
- 
- 
0,2 
1 
0,4 
2 
0,2 
1 
0,4 
2 
1 
5 
0,2 
1 
13.185 0,5 
2,5 
0,2 
1 
0,5 
2,5 
0,4 
2 
- 
- 
1 
5 
0,2 
1 
2 
10 
0,2 
1 
0,2 
1 
- 
- 
- 
- 
0,3 
1,5 
0,5 
2,5 
0,2 
1 
1 
5 
2 
10 
0,4 
2 
13.199 0,00
5 
0,01 
0,05 
0,1 
0,00
1 
0,00
3 
0,00
1 
0,00
3 
0,00
1 
0,00
3 
0,00
5 
0,01 
0,00
5 
0,01 
0,05 
0,1 
0,05 
0,2 
0,05 
0,1 
- 
- 
- 
- 
0,05 
0,1 
0,00
5 
0,01 
0,00
2 
0,00
5 
0,00
5 
0,01 
2 
10 
0,00
5 
0,01 
II.2 mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is 
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may consume 
the amount of flavourable foods and beverages listed in Table II.2.1. These consumption estimates are then 
multiplied by the reported use levels in the different food categories and summed up.  
Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
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The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as outlined in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) and reported by the Flavour Industry in the 
following way (see Table II.2.2): 
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000a) 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 16 
(EC, 2000a) 
• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000a) 
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000a) 
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000a) 
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000a) 
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be 
placed in categories 01.0 - 15.0 
Food   
 
The mTAMDI values are presented for 26 of the 27 flavouring substances in the present flavouring group, 
for which Industry has provided use and use levels (EFFA, 2003g; EFFA, 2004y; EFFA, 2007a; Flavour 
Industry, 2009b). The mTAMDI values are only given for highest reported use levels (see Table II.2.3). 
TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
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13.122 Ethyl 2-furoate 3900 Class II 540 
13.130 Furfuryl butyrate  Class II 540 
13.136 2-Furoic acid 1400 Class II 540 
13.139 5-Hydroxymethylfurfuraldehyde 1600 Class II 540 
13.145 Methyl 5-methylfurfuryl sulfide 160 Class II 540 
13.155 2-Methyl-5-propionylfuran 420 Class II 540 
13.125 2-Ethyl-5-methylfuran 420 Class II 540 
13.162 2-Octylfuran 420 Class II 540 
13.011 Ethyl furfuracrylate 3900 Class III 90 
13.102 Butyl 2-furoate 3900 Class III 90 
13.108 4,5-Dihydro-3-mercapto-2-methylfuran 160 Class III 90 
13.113 2,5-Dimethyl-3-(methyldithio)furan 160 Class III 90 
13.114 2,5-Dimethyl-3-(methylthio)furan 160 Class III 90 
13.124 Ethyl furfuryl sulfide 78 Class III 90 
13.127 Furfuryl 2-methylbutyrate 3900 Class III 90 
13.129 Furfuryl but-2-enoate 3900 Class III 90 
13.132 Furfuryl hexanoate 3900 Class III 90 
13.133 Furfuryl isobutyrate 3900 Class III 90 
13.135 1-(2-Furfurylthio)propanone 780 Class III 90 
13.141 Methyl (2-furfurylthio)acetate 400 Class III 90 
13.143 Methyl 3-(furfurylthio)propionate 420 Class III 90 
13.144 Methyl 5-methylfurfuryl disulfide 78 Class III 90 
13.146 Methyl furfuryl trisulfide 160 Class III 90 
13.149 5-Methyl-2-furanmethanethiol 160 Class III 90 
13.178 3-(Furfuryldithio)-2-methylfuran 160 Class III 90 
13.185 2-Furfuryl 3-oxo-2-butyl disulphide 420 Class III 90 
13.199 3-[(2-Methyl-3-furyl)thio]-butanal 49 Class III 90 
 
ANNEX III: METABOLISM 
III.1. Introduction 
The candidate substances in FGE.13Rev2 are furan derivatives which can be divided into two main groups (I 
and II). Ten candidate substances in subgroup Ia are furfuryl alcohol derivatives. In subgroup Ib, there is 
only one candidate substance, an alkoyl-substituted furan. The two candidate substances in subgroup Ic are 
alkyl-substituted furans, without functional groups in the side chains  
The 14 candidate substances in main group II are furan derivatives, containing sulphur substituents as mono-, 
di- and tri-sulphides (subgroups IIa, IIc and IId) or free thiol groups (subgroup IIb). The candidate substance 
4,5-dihydro-3-mercapto-2-methylfuran [FL-no: 13.108] in subgroup IIb is a non-aromatic furan derivative. 
The subgrouping has been presented in Table 4.1 (Section 4). Further details on the structural properties of 
the substances in these two subgroups are presented in the respective sections of this Annex. 
III.2. Main Group I – Non-sulphur-containing Furan Derivatives 
Furfuryl alcohol derivatives (Ia), alkoyl-substituted furans (Ib) and alkyl-substituted furans (Ic) 
The candidate substances in subgroup I are furan derivatives such as esters of furfuryl alcohol, 2-furoic acid 
or furanacrylic acid. One substance 5-hydroxymethylfurfuraldehyde (5HMF) [FL-no: 13.139] is a furfural 
derivative with a hydroxymethyl side chain at C5 position of the furan ring. Several candidate substances are 
alpha-beta unsaturated alcohols, aldehydes or ketones, or precursors thereof. These are esters of furfuryl 
alcohol [FL-no: 13.127, 13.129, 13,130, 13.132, 13.133], and 5-hydroxymethylfurfuraldehyde [FL-no: 
13.139]. For a number of candidate or supporting substances, among which furfural itself, metabolism data 
are available. An evaluation of the metabolism of several supporting substances can be found in 
JECFA/WHO (JECFA, 2001b). 
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III.2.1. Hydrolysis of esters 
Five of the candidate substances in subgroup I [FL-no: 13.127, 13.129, 13.130, 13.132 and 13.133] are esters 
of furfuryl alcohol [FL-no: 13.019] and two [FL-no: 13.122 and 13.102] are esters of 2-furoic acid [FL-no: 
13.136]. One candidate substance is an ester of furanacrylic acid [FL-no: 13.011]. 
The furfuryl alcohol esters (i.e. candidate substances furfuryl butyrate [FL-no: 13.130], furfuryl hexanoate 
[FL-no: 13.132], furfuryl isobutyrate [FL-no: 13.133], furfuryl 2-methylbutyrate [FL-no: 13.127] and 
furfuryl but-2-enoate [FL-no: 13.129]) are expected to be hydrolysed to furfuryl alcohol and the 
corresponding aliphatic carboxylic acid. Furoate esters (i.e. the candidate substances ethyl 2-furoate [FL-no: 
13.122] and butyl 2-furoate [FL-no: 13.102]) are hydrolysed to candidate substance 2-furoic acid [FL-no: 
13.136] and the corresponding saturated aliphatic alcohol. Upon hydrolysis, candidate substance [FL-no: 
13.011] will produce furanacrylic acid and ethanol. 
Hydrolysis is catalysed by classes of enzymes recognised as carboxylesterases or esterases, the most 
important are the B-esterases. In mammals, B-esterases occur in most tissues throughout the body, but 
predominate in the hepatocytes (Heymann, 1980). 
While no hydrolysis data have been provided for the candidate esters of the present group of flavourings, 
there are in vitro hydrolysis data for some structurally related esters. Also some indirect evidence from an in 
vivo study is available. 
Concentrations of 27 µl/L isoamyl furylpropion-1-ate or 40 µl/L ethyl furylpropion-1-ate were reported to be 
completely hydrolysed within two hours by pancreatin (Grundschober, 1977). Furoylglycine, the glycine 
conjugate of 2-furoic acid [FL-no: 13.136], has been reported to be the major metabolite in the urine of rats 
given a 50 to 66 mg/kg oral dose of furfuryl diacetate, furfuryl propionate or 3-furanacrylate methyl ester, 
which demonstrates that these esters are hydrolysed in vivo to form furfuryl alcohol, the metabolic precursor 
of 2-furoic acid [FL-no: 13.136]. After giving 3-furanacrylate methylester orally to rats, some parent 
substance was detected in the urine, which may indicate that for this substance the hydrolysis is not complete 
(Paul et al., 1949). 
In summary: 
Based on the data on supporting substances, it can be expected that in humans the eight candidate esters in 
subgroup Ia will be hydrolysed to their corresponding acids and alcohols within a relatively short time, 
possibly prior to gastrointestinal absorption or otherwise during their passage through the liver. The expected 
hydrolysis products for these esters and their evaluation status, when used as flavouring substances, are 
shown in table 2b. Ester hydrolysis is not an issue for the substances in subgroups Ib an Ic. 
III.2.2. Absorption, distribution and elimination 
Subgroup Ia 
Since enteric bacterial strains are capable of converting furfural to furfuryl alcohol under both aerobic and 
anaerobic conditions, both furfuryl alcohol and furfural are anticipated to be present in the gastrointestinal 
tract of animals given furfural. Enteric bacterial strains are also capable of reducing 5-
hydroxymethylfurfuraldehyde (5HMF) [FL-no: 13.139] to a compound postulated to be 5-
hydroxymethylfurfuryl alcohol under both aerobic and anaerobic conditions during an 8-hours incubation 
period (Boopathy et al., 1993). Therefore, 5HMF and 5-hydroxymethylfurfuryl alcohol are anticipated to be 
present in the gastrointestinal tract of animals given 5HMF. Biotransformation of 5HMF was accomplished 
by co-metabolism in the presence of glucose and peptone as main substrates (Boopathy et al., 1993). 
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However, these enteric bacteria did not transform 2-furoic acid [FL-no: 13.136] under the experimental 
conditions. 
At doses in the range from 0.1 mg/kg bw to 200 mg/kg bw, furfuryl alcohol and furfural are rapidly absorbed 
from the gastrointestinal tract, metabolised and excreted primarily in the urine (Nomeir et al., 1992; Parkash 
& Caldwell, 1994). 
More than 86 % of 0.275, 2.75 or 27.5 mg [carbonyl-14C]-furfuryl alcohol/kg bw or 0.127, 1.15 or 12.5 mg 
[carbonyl-14C]-furfural/kg bw given to F344 rats (4/group) by gavage in corn oil is rapidly absorbed from the 
gastrointestinal tract and excreted. At all dose levels, 83 - 89 % of the dose was excreted in the urine and 2 - 
4 % in the faeces. The majority of radioactivity was excreted within the first 24 hours following dosing. 
Approximately 7 % of the 12.5 mg/kg bw dose of furfural was exhaled as 14CO2. Other 14C-containing 
volatile substances in the exhaled air could not be demonstrated. At 72 hours following administration, 
residual radioactivity was distributed primarily to the liver and kidney, with tissue radioactivity generally 
proportional to the dose. Total radioactivity in the carcass comprised about 0.5 % of the dose at 72 hours 
(Nomeir et al., 1992). 
[Carbonyl-14C]-furfural was given in single oral doses of 0.1, 10 and 60 mg /kg bw to F344 rats or at 1, 20 
and 200 mg [14C]furfural/kg bw to CD1 mice. For both species both sexes were studied. More than 90 % of 
the dose was recovered within 72 hours. The major route of elimination was the urine (> 76 % in rats and > 
60 % in mice within 24 hours). Faecal elimination (1 - 7 % in 72 hours for all dose groups) and expired CO2 
(5 % in high dose male mice and 4 % in low dose female mice after 24 hours; no other CO2 measurements 
were taken) constituted minor routes of excretion (Parkash & Caldwell, 1994). Only minor differences in 
elimination were observed between the two sexes. 
Results of inhalation and dermal absorption studies indicate that humans efficiently and rapidly absorb 
furfural through the lungs and skin. Dermal absorption of vapours corresponds to approximately 20 – 30 % 
of the dose retained by the lungs. The biological half-life of furfural in humans is 2 – 2.5 hours, and mean 
pulmonary retention is approximately 80 %. Pulmonary retention is independent of the concentration of 
furfural vapour or the duration of exposure. About 1 % of the amount of furfural retained after inhalatory 
exposure was eliminated via expiration, while no free furfural could be demonstrated in the urine. Urinary 
elimination of metabolites was complete within 24 hours after the beginning of the exposure to furfural 
vapours (Flek & Sedivec, 1978). 
A similar pattern of absorption, distribution and excretion is reported for 5HMF [FL-no: 13.139]. Groups of 
male F344 rats and male B6C3F1 mice were administered 5, 10, 100 or 500 mg [U-14C]-5HMF/kg bw via 
oral gavage. In both species, 5HMF-derived radioactivity was rapidly cleared from all major tissues, with no 
evidence of accumulation in any tissue, but some covalent binding could be demonstrated in liver, kidney 
and possibly the GI-tract at 8 and 24 hours. Tissue concentrations varied with dose in both species at most 
time points. Within 48 hours, 70 - 82 % of the administered dose was excreted in the urine of rats, while 8 – 
12 % was excreted in the faeces. In mice, 61 - 77 % was excreted in the urine and 15 - 26 % in the faeces 
within the same time period. In both species 80 - 100 % of the total amount of radioactivity excreted via the 
urine was recovered within the first 24 hours post dosing. It was stated that 14CO2 was not exhaled (Godfrey 
et al., 1999). 
Fasted male Sprague-Dawley rats were administered single oral gavage doses of [U-14C]-5HMF [FL-no: 
13.139] at 0.08, 1.3, 13 or 330 mg/kg. After 24 hours, less than 1 % of the radioactivity was retained in the 
body-cavity organs and faeces. Over the dose range studied, 85 % of the radioactivity was eliminated after 8 
hours and 95 - 100 % of the radioactivity was eliminated after 24 hours, almost exclusively via urine. No 
significant differences in the rate of urinary elimination of [U-14C]-5HMF were observed over the 
administered dose range. Distribution of [U-14C]-5HMF and its metabolites was determined by whole-body 
autoradiography of rats fasted overnight. One hour after oral administration, radioactivity was observed 
mainly in the kidney and bladder, as well as the liver. After 24 hours, no accumulation of radioactivity was 
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observed in the body indicating essentially complete elimination of the test substances and its metabolites 
(Germond et al., 1987). 
Subgroup Ic 
Alkylfuran derivatives also exhibit rapid uptake, metabolism and excretion. Male Sprague-Dawley rats 
administered 100 mg [14C]-2-methylfuran/kg bw in sesame oil via intraperitoneal injection showed 
radiolabelled 2-methylfuran [FL-no: 13.030] metabolites in the 12-hours urine (Ravindranath & Boyd, 
1991). Maximal hepatic radioactivity was detected at 4 hours post-administration.  
Tissue distribution of 50 - 200 mg [14C]-2-methylfuran/kg bw over 24 hours showed the presence of 
radiolabel from greatest to least as follows: liver > kidney > lung > blood. The maximal amount of radiolabel 
was detected in the liver at 8 hours post administration, followed by a steady decline up to 24 hours 
(Ravindranath et al., 1986). 
Based on these data, the members of this group of furan-substituted aliphatic hydrocarbons, alcohols, 
aldehydes, ketones, carboxylic acids and related esters are anticipated to be rapidly absorbed, distributed 
through key organs involved in metabolic processes and then eliminated, primarily in the urine. 
III.2.3. Biotransformation 
Subgroup Ia: 
The glycine conjugate of 2-furoic acid [FL-no: 13.136] was detected in rat urine, collected for six hours after 
a single oral dose of 50 - 66 mg/kg bw of furfuryl alcohol, furfural, 2-furoic acid, furfuryl diacetate, furfuryl 
propionate, furanacrylic acid or 3-furanacrylate methyl ester (Paul et al., 1949). 
In F344 male rats (4/group) oral doses of 0.275, 2.75 or 27.5 mg [14C]-furfuryl alcohol [FL-no: 13.019]/kg 
bw or 0.127, 1.15 or 12.5 mg [14C]-furfural [FL-no: 13.018]/kg bw (radiolabel on carbonyl C) are oxidised to 
2-furoic acid [FL-no: 13.136], which is excreted mainly in the urine either free (1 - 6 %) or as the glycine 
conjugate (73 - 80 %). In addition, the glycine conjugate of furanacrylic acid (3 - 8 %) was found, while up 
to 1.5 % of the dose was excreted as an unidentified urinary metabolite. In rats receiving 12.5 mg furfural/kg 
bw, 7 % was exhaled as CO2. Carbon dioxide measurements were not taken for any other dose group. The 
authors stated that the percentage of furfural or furfuryl alcohol exhaled as CO2 is unlikely to vary 
significantly with the dose, based on the argument that over the dose ranges studied, the extent of 
metabolism and relative amounts of metabolites were independent on the dose level, while rates of excretion 
were linear to dose (Nomeir et al., 1992). 
Single oral doses of 0.1, 10 and 60 mg [14C]furfural [FL-no: 13.018]/kg bw given to male and female F344 
rats or 1, 20 and 200 mg [14C]furfural/kg bw given to male and female CD1 mice were metabolised to the 
glycine conjugates of 2-furoic acid [FL-no: 13.136] (76 - 84 % in rats and 65 - 89 % in mice within 24 
hours) and 2-furanacrylic acid (16 - 24 % in rats and 11 - 35 % in mice within 24 hours). About 5 % of the 
radiolabel was expired as 14CO2 in the high-dose group (males) and 4 % was expired in the low dose group 
(female) of mice. Expired 14CO2 was not determined in any other dose group. In urine from all male rat dose 
groups and in the high-dose male mice 1.5 - 3 % of the dose was recovered as an unidentified, polar 
metabolite, not conjugated to sulphate or glucuronide. The absorption, tissue distribution, extent of 
metabolism, and rates of excretion in rodents were linear over the dose ranges investigated (0.1 mg/kg bw to 
200 mg/kg bw) (Parkash & Caldwell, 1994). 
It was suggested by the authors that 2-furanacrylic acid is generated from 2-furoic acid by condensation with 
acetyl-CoA, rather than that it is the product of direct aldol condensation of furfural with acetate as suggested 
in other papers e.g. (Nomeir et al., 1992). According to Parkash and Caldwell, it is more likely that the 
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thioester-CoA derivatives of furanacrylic acid and furoic acid are in a dynamic equilibrium favouring the 
CoA-thioester of 2-furoic acid. This is supported by the following observations: 
2-Furoic acid is excreted in the urine of rats or dogs given 2-furanacrylic acid (Paul et al., 1949; Friedmann, 
1911), which shows that the reverse reaction (reverse to furanacrylic acid formed out of furoic acid) does 
also occur, thereby suggesting that these two acids are interconvertible. 
Analogous conversions have been shown for other aromatic carboxylic acids (e.g. benzoic acid and cinnamic 
acid) (Nutley et al., 1994). 
Parkash and Caldwell (Parkash & Caldwell, 1994) suggested that an observed decrease in the extent of 
glycine conjugation would result in an increase in the percentage of the dose of furfural that was excreted as 
free furoic or free furanacrylic acids. The small shift in the urinary metabolite pattern would suggest that, 
similar to what has been observed for benzoic acid, glycine conjugation may be capacity limited, probably 
by the supply of endogenous glycine (Gregus et al., 1993), but for furfural, the shift was limited to a few 
percents of the dose, if any, even at dose levels up to 60 mg/kg bw in rats or 200 mg/kg bw in mice. 
When human volunteers were exposed to furfural vapour at concentrations of 15 to 31 mg/m3 for 8 hours, the 
following metabolites could be identified in the urine: 2-furoylglycine (major) and 2-furanacryloylglycine 
(minor). In contrast to what has been seen in animals, no free 2-furoic acid was observed, and the authors 
suggested that this might be due to the low level of furfural to which the volunteers had been exposed (max. 
~ 2 mg/kg bw) (Flek & Sedivec, 1978). 
The formation of labelled CO2 from radioactive furfural or furfuryl alcohol in rats and mice may occur via 
decarboxylation of 2-furoic acid; not directly at the C2 position but rather after ring opening. Koenig and 
Andreesen (Koenig & Andreesen, 1990) have shown that the microorganism Pseudomonas putida is capable 
of hydroxylation of 2-furoic acid (or rather 2-furoyl-CoA) at the C5 position followed by ring opening to 
yield the citric acid cycle intermediate alpha-ketoglutaric acid. 
Using 2-methylfuran in rat lung and liver microsomal preparations, ring opening of the furan ring was 
inferred from the formation of the reactive intermediate 4-keto-pent-2-enal (= acetylacrolein) (Ravindranath 
& Boyd, 1985). This is a conversion similar to the one described above for the metabolism of 2-furoic acid in 
bacteria, but whether in the bacterial pathway an aldehyde is also formed as intermediate is not clear.  
However, there is no evidence of ring oxidation and opening in humans at low levels of exposure. 
Essentially all absorbed furfural (ca. 2 mg/kg bw) in a human inhalation study was excreted in the urine as 
furoylglycine and furanacrylic acid. Because of a virtually complete mass balance between the amount of 
metabolites in the urine and the amount absorbed via the lungs, it was concluded that no important 
elimination routes had been missed, which may be interpreted in the way that in humans, in contrast to 
animals, no evidence of furfural decarboxylation was obtained (Flek & Sedivec, 1978). However, the 
evidence is rather indirect and based on a small number of individuals. 
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Figure III.1. Biotransformation of furfuryl alcohol and furfural. Formation of glycine conjugates are major pathways in mammals. 
Formation of carbon dioxide also occurs in mammals. The pathway via alpha-ketoglutaric acid has been described for micro-
organisms, and might occur in mammals, as well. 
 
In rats, 5-methylfurfural [FL-no: 13.001] exhibits a metabolic fate similar to that of furfural. Two urinary 
metabolites were identified when rats were given an oral dose of an aqueous solution containing 80, 120 or 
160 mg 5-methylfurfural/kg bw. The principal metabolite was the glycine conjugate of 5-methylfuroic acid 
(> 40 % of the dose) accompanied by about 7 - 8 % of 5-methylfuryl methyl ketone. 5-Methylfuryl methyl 
ketone was also a urinary metabolite of 5-methylfuroic acid, but not of 2-methylfuran, suggesting that both 
side chains to the furan ring are essential and that the ketone is formed from the acid (Jodynis-Liebert, 1985; 
Jodynis-Liebert, 1988). From this observation, it may be inferred that similar to the formation of 2-
furanacrylic acid from furfural, the CoA-thioester of 5-methylfuroic acid condenses with acetyl-CoA to form 
a beta-ketothioester (corresponding intermediate not shown in Figure III.1), which sequentially undergoes 
hydrolysis and decarboxylation to form 5-methylfuryl methyl ketone. 
Male Sprague-Dawley rats were fasted overnight and then administered single oral gavage doses of 5HMF 
[FL-no: 13.139] at 0.08, 1.3, 13 or 330 mg/kg, which contained 8 microCi [U-14C]-5HMF. After 24 hours, 
less than 1 % of the radioactivity was exhaled as 14CO2. Over the dose range studied, 85 % of the 
radioactivity was eliminated within 8 hours and 95 - 100 % of the radioactivity was eliminated within 24 
hours, almost exclusively via urine. Two major urinary metabolites were identified as 5-hydroxymethyl-2-
furoic acid (5HMFA) and its glycine conjugate [N-(5-hydroxymethyl-2-furoyl)glycine, 5HMFG]. A third, 
minor polar metabolite was not further identified. 
The ratio of 5HMFA to 5HMFG concentrations increased at higher doses of [U-14C]5HMF. Up to a dose of 
1.3 mg/kg of [U-14C]-5HMF, the HMFA-to-HMFG ratio was about 1, increasing to a maximum ratio of 15 - 
20 in the first two hours after a dose of 330 mg/kg of [U-14C]-5HMF, but then falling to about 5 after 8 
hours. When a 3 g/kg bw supplementation with glycine was given shortly before the high dose of 5HMF, the 
increase in the 5HMFA/5HMFG ratio was much less pronounced, indicating that the availability of free 
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glycine may limit the rate of conjugation at higher doses of 5HMF. Distribution of [U-14C]-5HMF and its 
metabolites was determined by whole-body autoradiography of rats fasted overnight. One hour after oral 
administration, radioactivity was observed mainly in the kidney and bladder, as well as the liver. After 24 
hours, no accumulation of radioactivity was observed in the body indicating essentially complete elimination 
of the test substances and its metabolites (Germond et al., 1987). 
In a more recent study, the disposition of uniformly labelled candidate substance 5HMF (i.e. [U-14C]-5HMF 
[FL-no: 13.139]) was investigated in male F344 rats and B6C3F1 mice following oral gavage administration 
of 5, 100 or 500 mg (rats) and 10, 100 or 500 mg (mice) [U-14C]-5HMF/kg at approximately 10 µCi/animal. 
Total radioactivity recovered in excreta in the 48 hours following administration was 82 - 91 % in rats and 
80 - 92 % in mice. No radioactivity was exhaled. In both species the urinary excretion of metabolites 
accounted for the major part of the elimination. At a dose of 5 mg [U-14C]-5HMF/kg to rats, the cumulative 
excretion of radioactivity at 24 hours as percent of initial dose was 73.0 % in urine and 6.7 % in faeces. In 
mice relatively more radioactivity was excreted in faeces (approximately 13 % at 24 hours) than in rats. 
5-Hydroxymethyl-2-furoic acid (5HMFA) was the major urinary metabolite in both species and accounted 
for 78 - 85 % of the recovered radioactivity of each administered dose. Excretion of the glycine conjugate, 
N-(5-hydroxymethyl-2-furoyl)-glycine (5HMFG) accounted for 5 - 8 % of the dose in the mice. In rats the 
excreted amount of this metabolite was inversely proportional to dose, possibly due to glycine depletion (6 
% at the low dose and 1.3 % at the high dose). 2,5-Furan dicarboxylic acid (FDCA) accounted for only 2 - 4 
% of the recovered radioactivity in mice and 4 - 6 % in rats. The identified metabolites result from initial 
oxidation of the aldehyde followed by either conjugation of the resulting carboxylic acid (major pathway) or 
oxidation of the alcohol group (minor pathway) (Godfrey et al., 1999). 
The pathways involved in the metabolism of 5HMF to animals have been presented in Figure III.2 
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Figure III.2 Metabolic pathways for 5-hydroxymethylfurfuraldehyde. Glycine conjugation will require transient coupling to CoA 
(see Figure III.1) 
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In humans, furoylglycine and 2,5-furandicarboxylic acid can be found in the urine, and it has been 
demonstrated that these are derived from precursors in food. Heat-sterilised aqueous solutions of fructose 
and glucose may be rich in e.g. 5HMF, which after i.v. administration may be excreted as 5-hydroxymethyl-
2-furoic acid or as 2,5-furandicarboxylic acid (Jellum et al., 1973; Pettersen & Jellum, 1972). 
In addition to the above mentioned pathways, 5HMF has been shown to be bioactivated in vitro to 5-
[(sulphoxy)methyl] furfural (SMF), through sulphonation of its allylic hydroxyl functional group, catalyzed 
by sulphotransferases. In the resulting ester, the sulphate is a good leaving group, thus producing a highly 
electrophilic allyl carbocation (Glatt, 1997), which could be stabilized by distribution of charges on the furan 
ring. The subsequent interaction of this reactive intermediate with critical cellular nucleophiles (i.e. DNA, 
RNA and proteins) maybe result in toxic and mutagenic effects. This sulphate conjugate has not been 
observed in vivo, since it appears to be too unstable to allow its excretion as such and detection in urine. 
Indeed, when 5HMF was incubated with 35S-PAPS, a sulpho-group donor, and liver cytosol an unstable 
conjugate was formed, which disappeared within 60 minutes. The time dependent decline in the amount of 
the reaction product appears to be associated with its hydrolysis in an aqueous environment (Surh & 
Tannenbaum, 1994). Moreover, 5HMF was mutagenic in tests with Salmonella typhimurium in the presence 
of rat hepatic cytosol enriched with the sulpho-group donor PAPS; the effect was markedly lessened by 
sulphotransferase inhibitors, clearly suggesting that 5HMF can be metabolically bioactivated to an allylic 
sulphate with genotoxic potential (Lee et al., 1995b). 
Twelve weeks old FVB/N mice (n = 28) were given an intravenous injection of 100 mg/kg bw 5HMF in 
isotonic saline. Two blood samples were taken from each animal, and blood samples from different animals 
were combined to give information on 5HMF and SMF pharmacokinetics. SMF was detected in plasma from 
animals given 5HMF, and the half life of SMF was calculated to be 4.2 minutes (Monien et al., 2009). 
As part of the NTP program 3-weeks and 3-months sub-chronic toxicity studies, male and female F344/N 
rats and B6C3F1 mice were administered 5HMF at different dose levels up to 1,500 mg/kg bw per day (see 
section 8.2). At various time points during the studies, urine of the animals was collected for 24 hours and 
analyzed for the presence of 5-(hydroxymethyl)-2-furoic acid and the corresponding glycine conjugate 5-
(hydroxymethyl)-furoyl glycine. In male mice and in rats in both sexes, the percentages of the dose 
recovered following the last exposure increased during the exposure period. In female mice no such 
induction was observed. Also in male mice the percentage recovered as the glycine conjugate amounted to 
10 - 20 % of the urinary metabolites, while in the females the proportion of the glycine conjugate was only 
ca. 5 %. The proportion of the glycine conjugate was not dependent on the dose level. In male rats, the 
fraction of the dose excreted as glycine conjugate was ~ 10 % at the lower end of the dose range and this 
percentage fell to below 2 % at the high end of the dose range, due to saturation of the glycine conjugation 
pathway. In female rats a similar phenomenon was observed, but in the females the proportion of the glycine 
conjugate remained at about 3 - 5 % of the total amount in urine. Excretion of SMF was not studied (NTP, 
2010c). 
Subgroups Ib and Ic: 
No data were available on the candidate substances in these groups. However, some data on supporting 
substances have been summarised by the JECFA (JECFA, 2009a). The following text is based on this 
JECFA evaluation in which some modifications have been included after consultation of the original 
publications. 
The candidate substance in subgroup Ib [FL-no: 13.155] is an alkoyl-substituted furan which has a keto 
group in the C1-position of the furan ring substituent. It is considered that the alpha,beta-unsaturated ketone 
structure in this substance is structurally related and comparable to the structure in acetophenone (EFSA, 
2008am). It is anticipated that the ketone in the C1 position of the sidechain will undergo reduction to the 
corresponding secondary alcohol which subsequently is excreted after conjugation (JECFA, 2006d). For this 
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substance also ring oxidation followed by ring opening may be anticipated (see subgroup Ic) (JECFA, 
2009a). 
For the candidate substances in subgroup Ic it is of relevance that alkyl-substituted furan and benzofuran 
derivatives may undergo cytochrome P450–mediated side-chain oxidation to yield an alcohol functional 
group located at the position bonded directly to the furan ring. The resulting secondary alcohol may be 
excreted in the urine primarily as the glucuronic acid or sulphate conjugate, or it may be converted to the 
corresponding ketone, which may also be excreted in the urine. This kind of side-chain oxidation, preferably 
at the C1’ position of furan, is similar to that observed with other alkyl-substituted heterocyclic derivatives 
(e.g. pyridine derivatives and indoles) (Hawksworth & Scheline, 1975; Thornton-Manning et al., 1993). It is 
noted that the resulting secondary furyl alcohol forms an α,β-unsaturated carbonyl system with the double 
bonds in the furan ring. In addition to side-chain oxidation, the furan ring can undergo cytochrome P450-
induced oxidation followed by opening of the ring to yield reactive 2-enal or 2-enedial intermediates. It is 
not entire clear if in these reactions also epoxide intermediates are involved, but if so, there have to be very 
unstable. The 2-en(edi)al intermediates have been shown to form protein and DNA adducts. They also may 
conjugate readily with GSH, but as their GSH conjugates are unstable, this conjugation offers no protection. 
However, conjugation with cysteine results in a stable non-reactive product (Ravindranath et al., 1983; 
Ravindranath et al., 1984; Ravindranath & Boyd, 1985; Ravindranath et al., 1986; Ravindranath & Boyd, 
1991). 
The metabolic fate of a 2-ethylbenzofuran derivative has been investigated in humans, rats and dogs. Two 
healthy male subjects were each given an oral 100 mg dose of [3-14C]-benzarone [3-(4-hydroxybenzoyl) 2-
ethylbenzofuran] in two gelatine capsules. Approximately 73 % of the radioactivity was excreted in the urine 
over 5 days, with more than 59 % being excreted in the first 24 hours. Approximately 19 % of the 
radioactivity was excreted in the faeces over 5 days. The principal metabolites included benzarone 
hydroxylated at the C1’ position of the furan ring and a glucuronic acid conjugate either of the C1’ hydroxyl 
or the phenolic hydroxyl group. In the dog or rat, more than 80 % of a 0.5 or 2 mg/kg bw dose of [3-14C]-
benzarone was excreted in the faeces during the first 48 hours. In the rat or dog, most (> 70 %) of the 
absorbed dose was eliminated by direct conjugation of the administered substance, whereas in humans, >70 
% was hydroxylated before conjugation. The authors speculated that the benzarone glucuronic acid 
conjugate was excreted directly into the bile more readily in rats and dogs than in humans, thereby 
minimizing further hydroxylation in the liver (Wood et al., 1987). 
Two healthy male volunteers were administered a single oral daily dose of 100 mg benzbromarone [(3,5-
dibromo-4-hydroxyphenyl) (2-ethyl-3-benzofuranyl)methanone]12 for 8 consecutive days (De Vries et al., 
1993). The major metabolites were formed by C1’-hydroxylation to yield the corresponding 1’-
hydroxybenzbromarone and by hydroxylation of the fused benzene ring to yield 6-hydroxybenzbromarone. 
The corresponding C1’ ketone (= 1’-oxobenzbromanone) formed by oxidation of the 1’-hydroxy group was 
also identified in the urine. The ratio of C1’ enantiomers of 1’-hydroxybenzbromarone was 2.12 in the plasma 
and 7.32 in the urine. These metabolic data support the conclusion that alkyl-substituted furan and 
benzofuran derivatives undergo side-chain oxidation to yield the corresponding alcohol metabolite, followed 
by excretion in the urine. As no comparison was made between urinary metabolites before and after 
treatment with glucuronidase/sulphatase the study does not provide information on the extent of conjugation 
of benzbromanone metabolites.  
Initial in vitro experiments in rat microsomal preparations suggested that high concentrations of alkyl-
substituted furans are partly metabolized to reactive acetylacrolein1-type intermediates (Ravindranath et al., 
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1983, 1984). Acetylacrolein is a potent microsomal mixed-function oxidase inhibitor that has been reported 
to bond covalently and irreversibly to the oxidizing enzyme, thus inactivating it (Ravindranath & Boyd, 
1985). 
Acetylacrolein (= 4-oxo-pent-2-enal) is a potent microsomal mixed-function oxidase inhibitor which has 
been reported to bind covalently and irreversibly to the oxidizing enzyme, thus deactivating it (Ravindranath 
and Boyd, 1985). Significant protein binding (> 55 nmol/mg protein) was reported when 10 mmol/l of [2-
14C]-methylfuran were incubated with rat hepatic microsomes in the presence of NADPH and oxygen. In the 
absence of oxygen or NADPH, little binding was observed (< 2 nmol/mg protein). These findings suggest 
that NADPH-dependent oxidation of 2-methylfuran is a prerequisite for protein binding. Increased protein 
binding (> 80 nmol/mg protein) was also reported when Sprague-Dawley rats were pre-treated with 
phenobarbital, a cytochrome P450 inducer, while decreased or no protein binding was observed in the 
presence of piperonyl butoxide or N-octyl imidazole, both of which inhibit cytochrome P450. The Vmax and 
Km for 2-methylfuran metabolism in phenobarbital pre-treated rats were 0.81 μmol/2 mg microsomal protein 
per min and 0.463 mmol/l, respectively, and those in rats without phenobarbital pre-treatment were 0.53 
μmol/2 mg microsomal protein per min and 1.417 mmol/l, respectively. These values suggest that 2-
methylfuran undergoes cytochrome P450-mediated oxidation to yield a reactive metabolite (i.e. 
acetylacrolein) which binds covalently to protein (Ravindranath & Boyd, 1985). With 3-methylfuran a 
similar ring opening product (3-methyl-but-2-enedial) has been found (Ravindranath et al., 1983). 
In the same study, when acetylacrolein at 0.25 mmol/l (24.5 μg/ml) was added to the incubation mixture, 
microsomal metabolism of 2-methylfuran was almost completely inhibited (covalent binding was 1.5 % of 
the control incubation). At a concentration of 0.5 mmol acetylacrolein/l (49.1 μg/ml), no metabolism of 2-
methylfuran was detectable, suggesting that acetylacrolein inhibits cytochrome P450-mediated oxidation, 
probably through direct covalent bonding with the enzyme. Thus, 2-methylfuran is a suicide substrate for 
this enzyme. Conjugation of the reactive metabolite with sulphydryl trapping agents, including cysteine (10 
mmol/l) and GSH (10 mmol/l), showed a marked decrease in microsomal protein binding, suggesting that 
sulphydryl conjugation plays a role in the detoxication of acetylacrolein. Cysteine was the better trapping 
agent for the prevention of microsomal protein binding when compared with GSH, semicarbazide, lysine or 
N-acetylcysteine. The authors postulated that cysteine forms a stable cyclic conjugate with alpha,beta-
unsaturated aldehydes, whereas the ability of GSH to form stable conjugates with alpha,beta-unsaturated 
aldehydes varies (Esterbauer et al., 1975; Esterbauer et al., 1976; Ravindranath & Boyd, 1985). 
Other in vitro experiments support the conclusion that cytochrome P450-mediated oxidation of 2-methyl-
furan is directly related to its toxicity. This was studied in hepatocytes isolated from adult male Wistar rats 
that were untreated or treated with phenobarbitone (0.1 % in drinking-water for 5 days) or beta-
naphthoflavone (80 mg/kg bw by intraperitoneal injection daily for 3 days). The cultured hepatocytes were 
incubated with 2-methylfuran at 0, 100, 300, 600 or 1000 μmol/l (0, 8.2, 24.6, 49.3 and 82.1 μg/ml, 
respectively) for 24 hours. The median lethal concentrations (LC50 values) for untreated, phenobarbitone-
treated or β-naphthoflavone-treated hepatocytes were 794, 34 and 57 μmol/l (65.2, 2.8 and 4.7 μg/ml), 
respectively, indicating that enzyme induction increased the toxicity of 2-methylfuran (Hammond and Fry, 
1991). 
Male Sprague-Dawley rats (150 - 200 g) were administered a single dose of 50, 100, 200 or 400 mg 2-
methylfuran/kg bw in sesame oil by intraperitoneal injection and were sacrificed 24 hours later. The 50 
mg/kg bw group did not show any evidence of liver necrosis, but they exhibited endothelial injury, with 
blebbing of the endothelium into the vascular lumen of the central veins. Animals given 100, 200 or 400 mg 
2-methylfuran/kg bw showed a dose-related increase in the severity of hepatocellular injury (e.g. 
eosinophilic cytoplasm, vacuolation), centrilobular necrosis, and necrosis and sloughing of the bronchiolar 
epithelium, which, at the high dose, resulted in complete obliteration of numerous respiratory and terminal 
bronchioles. Dose-related increases in serum glutamic pyruvic transaminase (GPT) were observed up to 200 
mg 2-methylfuran/kg bw; however, the levels of serum GPT in the animals given 50 mg 2-methylfuran/kg 
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bw were not significantly higher than those of the control rats. Free GSH levels in the liver, lungs and 
kidneys, investigated over a period of 0.5 - 36 hours after administration of 100 mg 2-methylfuran/kg bw, 
were initially decreased (67.5 % of control in the liver and 87 % of control in the kidneys at 0.5 hours), but 
then reached or exceeded control levels within 8 - 24 hours (137 % of control in the kidneys and 130 % of 
control in the lungs at 12 hours). Tissue distribution and covalent binding studies were conducted over a 
period of 0.5 - 24 hours after an intraperitoneal dose of 100 mg [14C]-2-methylfuran/kg bw. The radiolabelled 
[14C]-2-methylfuran covalently bound to protein was detected at the highest concentration in the liver, 
followed by the kidney, lung and blood. Liver and kidney DNA also showed covalent binding of 14C label. 
Maximal covalent binding to DNA was observed in the liver at 1 hour and in the kidney at 4 hours. With 
phenobarbital pretreatment a 2-fold increase in binding in the liver was observed. Conversely, N-
octylimidazole pretreatment decreased the level of covalent binding of the 14C label to proteins and DNA in 
the liver, lung and kidney. Increased and decreased protein binding and hepatotoxicity measured as serum 
GPT levels were observed in rats pretreated with phenobarbital and N-octylimidazole, respectively. 3-
Methylcholanthrene or piperonyl butoxide pretreatment did not affect either covalent binding or 
hepatotoxicity. These results provide evidence that bioactivation of 2-methylfuran by a CYP system is a 
prerequisite for tissue necrosis in rats (Ravindranath et al., 1986). 
In a study examining GSH and cysteine conjugation on the toxic potential of 2-methylfuran, male Sprague-
Dawley rats were treated subcutaneously with a 900 mg/kg bw dose of buthionine sulphoximine 1.5 hours 
prior to intraperitoneal administration of 100 mg [14C]2-methylfuran/kg bw prepared in sesame oil. Marked 
decreases in covalent DNA and protein binding in the liver and reduced hepatotoxicity, as indicated by lower 
serum GPT levels, were observed. Buthionine sulphoximine treatment revealed a transient increase in plasma 
cysteine levels, concurrent with a decrease in GSH levels. However, administration of 100 mg 2-
methylfuran/kg bw 1.5 hours after buthionine sulphoximine administration significantly reduced plasma 
cysteine levels and increased (20 %) urinary elimination of 2-methylfuran-labelled metabolites compared 
with the control group ([14C]-2-methylfuran only). Subcutaneous pretreatment with diethylmaleate, a 
depletor of liver GSH, at 0.4 ml/kg bw increased binding to liver proteins and increased hepatotoxicity, as 
indicated by a rise in serum GPT levels compared with rats that received only 2-methylfuran. Subcutaneous 
pretreatment of rats with GSH synthesis promoter L-2-oxothiazolidine-4-carboxylate at a dose of 1000 
mg/kg bw resulted in a marked increase of covalent protein binding in the liver and potentiated 
hepatotoxicity (increased serum GPT levels compared with rats that received only 2-methylfuran). When rats 
were pretreated with both buthionine sulphoximine and L-2-oxothiazolidine-4-carboxylate, a marked 
decrease in covalent protein binding in the liver and hepatotoxicity, as indicated by a reduction in serum 
GPT levels, was observed. No unchanged 2-methylfuran was observed in the urine, indicating that 
pretreatment did not inhibit metabolic processes (Ravindranath & Boyd, 1991). The authors proposed that 
buthionine sulphoximine pretreatment indirectly aids in the detoxication of 2-methylfuran through a 
reduction of GSH supply and an increase in the availability of cysteine, which forms a more stable conjugate 
with acetylacrolein than GSH. 
Adult male Swiss albino mice (10 - 15 per group) were administered 2-ethylfuran (commercial grade, FL-no: 
13.092) at 200 mg/kg bw in sesame oil via intraperitoneal injection with or without phenobarbital, piperonyl 
butoxide or cobalt(II) chloride pretreatment. The mortality rates were 1/10, 2/10, 3/15 and 2/11 for the 
untreated, phenobarbital pretreatment, piperonyl butoxide pretreatment and cobalt(II) chloride pretreatment 
groups, respectively. 2-Ethylfuran produced a moderate necrosis of the liver and mild to moderate necrosis 
of the kidneys. The kidney necrosis was described as a coagulative lesion of the proximal convoluted tubules 
of the outer cortex, without damage to the glomerular or medullary cells. Piperonyl butoxide and cobalt(II) 
chloride decreased the severity of necrosis in the liver and kidney (McMurtry et al., 1977). 
In the same study, mice were injected intraperitoneally with 70 mg 2-acetylfuran [FL-no: 13.054] 
(commercial grade)/kg bw in 0.9 % sodium chloride, with and without phenobarbital pretreatment, and 80 
mg 2-acetylfuran/kg bw, with and without cobalt(II) chloride pretreatment. The mortality rates were 1/12, 
0/12, 0/12 and 0/12 for the 70 mg 2-acetylfuran/kg bw, 70 mg 2-acetylfuran/kg bw plus phenobarbital, 80 
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mg 2-acetylfuran/kg bw, and 80 mg 2-acetylfuran/kg bw plus cobalt(II) chloride treatment groups, 
respectively. Mice treated with 2-acetylfuran showed no evidence of toxicity in the kidneys. Hepatic 
necrosis, described as midzonal-centrilobular necrosis of the parenchymal hepatocytes, was mild in severity 
with cobalt(II) chloride pretreatment, showing a marked decrease in the incidence and severity of necrosis 
(McMurtry et al., 1977). 
Ten male ICR mice were injected intraperitoneally with 2-ethylfuran (analytical reagent grade) at 2.6 
mmol/kg bw (250 mg/kg bw) in sesame oil. Histopathology of tissues collected 24 hours later revealed 
extensive proximal tubular necrosis of the kidneys and focal hydroptic degeneration of the liver. Significant 
increases in the plasma urea nitrogen level (approximately 5 times control level) and GPT level were 
reported (Wiley et al., 1984). 
Severe bronchiolar necrosis was reported when 2-ethylfuran (2.6 mmol/kg bw or 250 mg/kg bw) in sesame 
oil was administered by intraperitoneal injection to male ICR mice. Administration of 1.56 mmol 2-
ethylfuran/kg bw (150 mg/kg bw) via intraperitoneal injection to five male ICR mice showed approximately 
a doubling, compared with control values, of the amount of [14C]-thymidine incorporation into pulmonary 
DNA measured at 3 days after dosing, which indicates increased cell replication and lung repair (Gammal et 
al., 1984). 
In a study of the tumour-inhibiting properties of 2-heptylfuran [FL-no: 13.069], increased cytosolic 
glutathione S-transferase activity was observed in tissue preparations of the liver, forestomach and small 
bowel mucosa isolated from 7-weeks old female A/J mice (five mice per group) that received doses of 12, 
25, 50 or 80 μmol of 2-heptylfuran dissolved in cottonseed oil via gavage every other day for a total of three 
doses. A 50 μmol dose of 2-heptylfuran showed a significant increase in acid-soluble sulphydryl levels, 
which is a good measure of GSH content in tissues, in all four tissue types (liver, small bowel mucosa, 
forestomach and lung) when compared with controls. At lower dose levels the increases became inconsistent. 
At the highest dose level the increase was lower than at 50 μmol probably because of the toxicity of the 
substance (Lam & Zheng, 1992).  
In summary, 2-alkyl-substituted furans can be metabolized by side-chain oxidation to initially yield the 1’-
alcohol derivative, which can be either conjugated and excreted or oxidized to the corresponding (α,β,-
unsaturated) ketone. The conversion to the ketone is anticipated to be reversible, in which case the ketones 
are reduced to the corresponding alcohols and excreted mainly in the urine. In a second pathway, the furan 
ring can be oxidized and may undergo rapid ring opening to yield reactive 2-ene-1,4-dicarbonyls (e.g. 
acetylacrolein) possibly through an unstable epoxide intermediate. These reactive 2-ene-1,4-dicarbonyls can 
be conjugated with available sulphydryl trapping agents, such as GSH and cysteine, or can be covalently 
bound to proteins and DNA. 
III.2.4. Summary 
Subgroup Ia: 
The non-furan containing component alcohols and carboxylic acids (C2 - C8) formed by ester hydrolysis of 
the candidate furfuryl esters and furoic acid esters participate in fatty acid β-oxidation and the citric acid 
cycle to eventually yield CO2 and H2O. The metabolism of aliphatic alcohols and carboxylic acids has been 
discussed extensively in previous Flavouring Group Evaluations e.g. FGE.01, 02, 03 and 05 and will not be 
discussed here any further. 
Following hydrolysis of furfuryl esters, furfuryl alcohol is oxidised to furfural, which is subsequently 
oxidised to 2-furoic acid. In the major metabolic detoxication pathway, the CoA-thioester of 2-furoic acid is 
either conjugated with glycine and excreted in the urine, or condensed with acetyl-CoA to form the CoA 
thioester of 2-furanacrylic acid. This compound, 2-furanacryloyl CoA, is also conjugated with glycine and 
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excreted primarily in the urine. At high dose levels, the availability of glycine might limit the rate of 
conjugation, resulting in the excretion of free furoic acid. The same detoxication pathways have been 
demonstrated to be present in humans. In a minor pathway that has been reported in rodents, CO2 is 
produced presumably via oxidation and opening of the furan-ring, in which a reactive intermediate may be 
involved. Apart from the formation of CO2 similar reactions have been observed with 5HMF, which can be 
additionally bioactivated to an allylic sulphuric acid ester. 
Metabolism data confirm that for 5HMF the principal route of metabolism in mice and rats is oxidation to the 
furoic acid derivative followed by glycine conjugation and rapid elimination in the urine. 5HMF has been 
shown to be bioactivated in vitro to 5-(sulphoxy)-methyl furfural (SMF), through sulphonation of its allylic 
hydroxyl functional group, catalyzed by sulphotransferases. Recent data have also shown that SMF can be 
formed in vivo upon intravenous administration of 5HMF. The half-life was reported to be 4.2 minutes 
indicating that this sulphate conjugate is very unstable. Nevertheless, the formation of SMF raises a concern 
for genotoxicity, which needs specific data on genotoxicity to be overcomed. 
Subgroups Ib and Ic: 
The candidate substance in subgroup Ib [FL-no: 13.155] is an alkoyl furan which has a keto group in the 1-
position of the furan ring substituent. It is considered that the alpha,beta-unsaturated structure in this 
substance is structurally related and comparable to the structure in acetophenone (EFSA, 2008am). It is 
anticipated that the ketone in the C1 position of the sidechain will undergo reduction to the corresponding 
secondary alcohol which subsequently is excreted after conjugation (JECFA, 2006d). For this substance also 
ring oxidation followed by ring opening may be anticipated (see subgroup Ic). 
The mono-alkyl furans from subgroup Ic, such as the candidate substance 2-octylfuran [FL-no: 13.162], may 
undergo oxidation (possibly epoxidation of the unsubstituted double bond) and rearrangement to an alkyl 
substituted dialdehyde. For several 2-alkylsubstituted furans reactivity of these dialdehydes towards proteins 
and DNA has been demonstrated, resulting in toxicity to liver and kidneys. In addition, oxidation of the C1’-
carbon of the alkyl substituent may result in the formation of an α,β-unsaturated ketone, for which 
genotoxicity might be anticipated. No data on metabolism of 2,5-dialkyfurans were available, but for this 
substance also oxidation of the side chain may be anticipated. It is not clear if this substance would be 
subject to ring-opening. 
III.3. Main Group II – Furan derivatives with sulphur substitution  
The candidate substances in main group II are sulphur-substituted furan derivatives. These substances are 
further divided in four subgroups, based on the structural properties of the sulphur-containing functional 
group. The sulphur is present, either: 
• as sulphides [FL-no: 13.114, 13.124, 13.135, 13.141, 13.143, 13.145 and 13.199] (subgroup IIa), 
• as free thiol group: [FL-no: 13.108 and 13.149] (subgroup IIb), 
• as disulfides [FL-no: 13.113, 13.144, 13.178 and 13.185] (subgroup IIc), 
• as trisulfide [FL-no: 13.146] (subgroup IId). 
 
In candidate substance [FL-no: 13.178] the disulfide bridge forms a link between two furan rings. In the 
other members of this main group II, only one furan ring is present. One of the candidate substances in 
Flavouring Group Evaluation 13, Revision 2
 
 
80 EFSA Journal 2011; 9(8):2313 
subgroup IIb is 4,5-dihydro-3-mercapto-2-methylfuran [FL-no: 13.108]; the only compound containing a 
non-aromatic ring. 
For none of the candidate substances, absorption, distribution, metabolism or elimination studies were found 
in the published or (submitted) unpublished literature, but it is anticipated that these substances will be 
absorbed from the GI tract at least to some extent. An evaluation of the metabolism of several supporting 
substances can be found in JECFA/WHO (JECFA, 2003a). For two of the supporting substances, some data 
on hydrolysis and oxidation in the gastro-intestinal tract were found. These data are presented below. 
III.3.1 Hydrolysis and spontaneous oxidation in the gastro-intestinal tract 
Approximately 96 % ester hydrolysis was observed when 3-(furfurylthio)propionic acid ethyl ester [FL-no: 
13.093] was incubated in simulated intestinal fluid for one hour (Bio-Research Laboratory, 1980), while only 
14 % was hydrolysed after six hours of incubation in simulated gastric fluid. This supporting substance is a 
normal ester and thus the ester hydrolysis is relevant for the two candidate substances [FL-no: 13.141, 
13.143] in subgroup IIa.  
When the supporting substance 2-methyl-3-tetrahydrofuranthiol [FL-no: 13.160] was incubated in intestinal 
fluid for four hours, as a result of oxidation, 18 % bis-(2-methyl-3-tetrahydrofuryl)disulphide was formed 
(Salzer, 1991). This observation is relevant for the candidate substances in subgroup IIb. 
III.3.2 Biotransformation 
Although no in vivo studies are available for the candidate substances in this group, thiofurans and 
thiofurfuryl derivatives are likely metabolised via reactions of the divalent sulphur atom, similar to other 
substances containing a sulphur substituent. An extensive review of the possible reactions for a number of 
different sulphur-containing chemicals (mainly pharmaceuticals) has been presented by Damani (Damani, 
1987). An overview of the possible metabolic conversions of organic thiols and sulphides is given in Figure 
III.3 
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Figure III.3 Metabolism of organic sulphur compounds. A panel: metabolism of thiols and disulphides. B panel: metabolism of 
thioethers. Structures in bold are major excretion products. TDE = Thiol-Disulphide Exchange 
 
Metabolism of sulphides (subgroup IIa): 
The major reactions by which simple sulphides can be metabolised involve oxidation of the sulphor (S) to 
give sulphoxides, which can be further converted to sulphones. Alternatively, sulphides can undergo 
oxidation of the carbon alpha to the -S-, resulting in the formation of an unstable hydroxyalkyl intermediate, 
which can be split to give an aldehyde and a free thiol. The aldehyde can be oxidised to its corresponding 
acid. This reaction may also occur with a free thiol group, and in that case the sulphur is finally released as 
sulphate (see Figure III.3, Panel A) (Damani, 1987; Richardson et al., 1991). For dipropyl sulphide it was 
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demonstrated that the sulphoxide was the most important metabolite. Formation of dipropyl sulphone was 
much less important and complete oxidation, resulting in excretion of free sulphate accounted for less than 3 
% of the dose (Nickson & Mitchell, 1994). These authors also indicated that with diethyl and dimethyl 
sulphides, sulphur oxidation to the sulphones was more important than for dipropylsulphide. No metabolism 
occurred in other parts of the molecule. 
Metabolism of free thiol groups (subgroup IIb): 
Thiols are highly reactive in vivo mainly because most thiols exist in the ionised form at physiologic pH. 
Thiols are oxidised to unstable sulphenic acids, which are further oxidised to the corresponding sulphinic and 
sulphonic acids (Damani, 1987). Methylation of thiols primarily by methyl-S-transferases, which require S-
adenosyl methionine as a co-factor, yields methyl sulphides, which then are readily oxidised to sulphoxides 
and sulphones. Substances which contain free thiol groups may also react with endogenous thiol-containing 
compounds such as proteins or glutathione to form mixed disulphides or, alternatively, with glucuronic acid 
to give thio-beta-D-glucuronide conjugates (Dutton & Illing, 1972; Maiorino et al., 1989; McBain & Menn, 
1969; Richardson et al., 1991). Sulphoxides and sulphones are physiologically stable and are excreted 
unchanged in the urine (Nickson & Mitchell, 1994; Nickson et al., 1995; McBain & Menn, 1969). 
The oxidation to sulphoxides is mainly catalysed by two enzyme systems, cytochromes P450 and Flavine-
containing Mono Oxygenase (FMO) (Renwick, 1989; Nnane & Damani, 1995). Any organosulphur 
compound may be a substrate for both the enzyme systems, although with different affinity, essentially 
dependent on the electromolecular environment in which the sulphur is located: the more nucleophilic, 
divalent sulphur are primarily oxidised by FMO and to a lesser extent by P450. This is the case for simple 
aliphatic (e.g. diethyl sulphide), alicyclic (e.g. thiolane) and aromatic (e.g., ethyl p-tolyl sulphide) sulphides 
(Damani, 1987; Hoodi & Damani, 1984). Moreover, another important determinant is the tissue-specific 
distribution of the two different enzymatic systems, especially in extrahepatic tissues, as well as the 
differential presence of single isoforms, with different catalytic activities. 
Metabolism of disulphides (subgroup IIc):  
The labile nature of the S-S bond also presents a variety of metabolic options for detoxication. Disulphides 
can be either symmetrical (i.e. the two moieties at either side of the S-S bridge are the same) or mixed (i.e. 
the two moieties on both sides of the S-S bridge are different). The disulphide bond may be rapidly reduced 
to yield the corresponding thiol or thiols (i.e. mercaptans) in a reversible reaction in vivo. Therefore, the 
metabolic options available to thiols are also available to disulphides.  
Thiol-disulphide exchange (TDE) reactions occur in vivo and result from nucleophilic substitution by 
sulphur. TDE reactions with endogenous cellular thiols (GSH) and disulphides (GSSG) produce mixed 
disulphides that may also undergo reduction. In these TDE reactions, also –SH groups from proteins may be 
involved and in many cases such interactions affect the biological function of the proteins involved. Under 
normal conditions, TDE reactions control the cellular concentrations of endogenous thiols (e.g. GSH) and 
disulfides (i.e. GSSG) and maintenance of an adequate GSH/GSSG ratio is essential for cell survival and 
function (Cotgreave et al., 1989; Brigelius, 1985; Sies et al., 1987). 
2-Furfuryl 3-oxo-2-butyl disulphide [FL-no: 13.185], which also carries a keto group in the side chain, might 
be subject to keto-reduction after which the resulting hydroxyl group could be conjugated. However, there is 
no data to support this observation.  
Metabolism of tri-sulphides (subgroup IId) 
Trisulphides may react with endogenous thiols such as reduced glutathione (GSH) or cysteine forming a thiol 
and a hydropersulphide or perthiol (RSH + R’SSH or R’SSSH or R’SxH, respectively). (Münchberg et al., 
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2007) Compared to thiols, perthiols may be strong reducing agents, reacting rapidly with oxidants to form 
reactive products.  
In the literature it is discussed that trisulphides are readily cleaved by GSH to form an equimolar mixture of 
thiol and perthiol, while tetrasulphides are symmetrically cleaved forming two molecules of perthiol. Redox 
cycling and production of “active oxygen” may be expected with tri-, tetra- and polysulphides. In this 
context the chain of reduction is proposed to start with GSH, which reduces the polysulphide and continues 
via the perthiol and haemoglobin to O2 which is reduced to H2O2. Experiments with a synthetic persulphide, 
benzyl hydrodisulphide (benzyl-SSH), gave evidence that persulphides may produce reactive oxygen species 
(O2*-, H2O2 and HO*) under physiologically relevant conditions. This was proposed to be the mechanism 
behind the cytotoxicity of some naturally occurring products (Chatterji et al., 2005). These interactions have 
been discussed to greater extent in FGE.08Rev1 (EFSA, 2009z). 
Summary 
The fourteen representatives of main group II are all furan derivatives containing sulphur substituents as free 
thiol groups, mono-, di- and tri-sulphides. Substances bearing a free thiol group (subgroup IIb), can directly 
react with endogenous sulphur-containing substances, e.g. glutathione and proteins. These free thiol groups 
can be metabolised by methylation, after which the sulphur can be further oxidised to give sulphoxides or 
sulphones, which can be readily excreted. Alternatively, conjugation with glutathione may occur resulting in 
a mixed disulphide, which can be reduced to give the free thiols. These can be oxidised to give 
thiosulphinates or thiosulphones or can undergo thiol-disulphide exchange, either with free thiol groups of 
proteins or with free thiol groups in endogenous substances. The reactions with proteins may affect their 
biochemical functions, thus triggering adverse effects. The simple sulphides (subgroup IIa) may undergo 
sulphur oxidation reactions, similar to the methylether conjugates of free thiol groups; in additions thiols 
may be formed. Disulphides (subgroup IIc) can be reduced to give the free thiols, or can be oxidised to give 
thiosulphinates or thiosulphones. For the one trisulphide candidate substance (in subgroup IId) no direct 
information on biotransformation was available. However, it has been described that tri and higher sulphides 
may be cleaved upon reaction with GSH, resulting in the formation of reactive perthiols.  
III.4. Summary 
The candidate substances in FGE.13Rev2 are all furan derivatives which can be divided into two main 
groups and several subgroups. 
Main group I - Non-sulphur Containing Furan Derivatives 
The 13 candidate substances in  main group I are ten furfuryl alcohol derivatives such as esters of furfuryl 
alcohol, furoic acid, or furanacrylic acid, in addition to furoic acid and 5-hydroxymethylfurfuraldehyde 
(5MHF), a furfural with an additional hydroxymethyl side chain at C5 of the furan ring. These ten substances 
have been allocated to subgroup Ia. One candidate substance is an alkoyl-substituted furan, allocated to 
subgroup Ib, and two substances in subgroup Ic are alkylsubstituted furans. 
Subgroup Ia 
The esters of furfuryl alcohol [FL-no: 13.127, 13.129, 13.130, 13.132 and 13.133] are expected to be 
hydrolysed to furfuryl alcohol and the corresponding saturated aliphatic carboxylic acid. Furoate esters [FL-
no: 13.102 and 13.122] are directly hydrolysed to candidate substance 2-furoic acid [FL-no: 13.136] and the 
corresponding saturated aliphatic alcohol. The candidate substance [FL-no: 13.011] is expected to be 
hydrolysed to furanacrylic acid (a known metabolite of furfural) and ethanol. It can be anticipated that the 
substances in both subgroups or there hydrolysis products are rapidly absorbed after oral exposure. The non-
furan containing component alcohols and carboxylic acids formed by ester hydrolysis of the candidate 
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furfuryl alcohol and furoic acid esters, participate in fatty acid β-oxidation and the citric acid cycle to yield 
CO2 and water. 
Furfuryl alcohol, furanacrylic acid, 5HMF and their derivatives in rodents participate in pathways involved 
in the detoxication of furfural, a known reactive aldehyde that may lead to hepatotoxicity. The oxidation of 
the alcohol or aldehyde group to the candidate 2-furoic acid [FL-no: 13.136] can be followed by conjugation 
with glycine or acetyl-CoA (leading to furanacryloyl,-CoA) which are readily excreted in the urine. The 
same detoxication pathways have been demonstrated to be present in humans. In a minor pathway which has 
been reported in rodents, the two furoate esters [FL-no: 13.102 and 13.122] and 2-furoic acid itself [FL-no: 
13.136], which is the main metabolite of furfural, may be metabolised to CO2 presumably via oxidation and 
opening of the furan-ring, in which production of reactive intermediate(s) may be involved. 
In addition to the above mentioned pathway, 5HMF [FL-no: 13.139] has been shown to be bioactivated in 
vitro by sulphotransferases to SMF, a reactive intermediate. The same metabolism has been demonstrated in 
vivo after intravenous administration, but the SMF has a very short half-life. This metabolite raises a concern 
for genotoxicity and therefore additional data on genotoxicity of 5HMF need to be present to overcome this 
concern.  
Subgroups Ib and Ic 
The alkyl furans from subgroup Ic, such as the candidate substance 2-octylfuran [FL-no: 13.162], may 
undergo oxidation (possibly epoxidation of the unsubstituted double bond) and rearrangement to an alkyl 
substituted dialdehyde (a ring-opening product). For several 2-alkylsubstituted furans reactivity of these 
dialdehydes towards proteins and DNA has been demonstrated, resulting in toxicity to liver and kidneys. In 
addition, oxidation of the C1’-carbon of the alkyl substituent may result in the formation of a ketone, with a 
structure similar to the candidate and supporting substances in subgroup Ib. Although such ketons may 
undergo keto-reduction and subsequent conjugation and excretion, it cannot be excluded that a significant 
part of the dose may also be subject to ring oxidation and opening, similar to the substances in subgroup Ic. 
No data on metabolism of 2,5-dialkylfurans were available, but for these substances also oxidation of the 
side chain may be anticipated. It is not clear if these substances would be subject to ring-opening. 
Main group II - Sulphur-containing Furan Derivatives 
The fourteen representatives of main group II are all sulphur-substituted furan derivatives, containing 
sulphur substituents as free thiol groups, mono-, di- and tri-sulphides. The substance 4,5-dihydro-3-
mercapto-2-methylfuran [FL-no: 13.108] is the only candidate containing a non aromatic ring, in contrast to 
the other 13 candidate substances in this group. 
Substances bearing a free thiol group (subgroup IIb), can directly react with endogenous sulphur-containing 
substances, e.g. glutathione and proteins. These free thiol groups can be metabolised by methylation, after 
which the sulphur can be further oxidised to give sulphoxides or sulphones, which can be readily excreted. 
Alternatively, conjugation with glutathione may occur resulting in a mixed disulphide, which can be reduced 
to give the free thiols. These can be oxidised to give thiosulphinates or thiosulphones or can undergo thiol-
disulphide exchange either with free thiol groups of proteins or with free thiol groups in endogenous 
substances. The reactions with proteins may affect their biochemical functions, thus triggering adverse 
effects. The simple sulphides (subgroup IIa) may undergo sulphur oxidation reactions, similar to the 
methylether conjugates of free thiol groups; in additions thiols may be formed. Disulphides (subgroup IIc) 
can be reduced to give the free thiols, or can be oxidised to give thiosulphinates or thiosulphones. For the 
one trisulphide candidate substance (in subgroup IId), no direct information on biotransformation was 
available. However, it has been described that tri and higher sulphides may be cleaved upon reaction with 
GSH, resulting in the formation of reactive perthiols. 
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From the above text it is anticipated that the predominant metabolic attack for these substances in main 
group II will be on the sulphur atom(s) and ring opening is not considered to be a major metabolic route. 
III.5. Conclusion 
Based on the available information, it is concluded that the candidate substances included in subgroup Ia, as 
far as their metabolism includes formation of furfural [FL-no: 13.127, 13.129, 13.130, 13.132 and 13.133], a 
known hepatotoxic reactive aldehyde, cannot be predicted to be metabolised to innocuous or endogenous 
compounds. The two furoate esters in this subgroup [FL-no: 13.102 and 13.122] and 2-furoic acid itself [FL-
no: 13.136], which is the main metabolite of furfural, may be metabolised in rodents to CO2, with opening of 
the furan ring, producing reactive intermediates. Data available do not allow to rule out the presence of this 
pathway in humans. Therefore, it cannot be predicted that these candidate substances are metabolised to 
innocuous products. The same would apply to the candidate substance [FL-no: 13.011]. In addition, to the 
above mentioned pathways, 5HMF [FL-no: 13.139], the remaining substance in subgroup Ia, has been shown 
to be bioactivated in vitro to a reactive intermediate, SMF, by sulphotransferases. The same metabolism has 
been demonstrated in vivo after intravenous administration, but the SMF has a short half-life. This metabolite 
raises a concern for genotoxicity and therefore additional data on genotoxicity of 5HMF need to be present 
to overcome this concern. 
In contrast to the substances in subgroup Ia, the candidate substances in subgroups Ib and Ic do not have 
options for rapid oxidation and subsequent conjugation to innocuous glycine conjugates. For these 
substances, oxidation and opening of the furan ring, which results in the formation of very reactive 
metabolites, can be anticipated to be much more important that for the furan derivatives in subgroup Ia. 
Given the reactivity of thiols groups, whether free or as obtained from the metabolism of did- or trisulphides, 
and the importance of thiols groups in cell physiology, it cannot be excluded that these substances interfere 
with normal cell function. In addition, for the trisulphide candidate substance formation of very reactive 
partial-metabolites has to be anticipated. Therefore, it is concluded that the following candidate substances 
cannot be predicted to be metabolised to innocuous products: 
[FL-no: 13.114, 13.124, 13.135, 13.141, 13.143, 13.145 and 13.199,] included in subgroup IIa;  
[FL-no: 13.108 and 13.149,] included in subgroup IIb;  
[FL-no: 13.113, 13.144, 13.178 and 13.185] included in subgroup IIc; and 
[FL-no: 13.146] included in subgroup IId.  
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ANNEX IV: TOXICITY 
Oral acute toxicity data are available for three candidate substances of the present flavouring group evaluation from chemical group 14, and for 17 supporting 
substances evaluated by the JECFA at the 55th and 59th meetings. The supporting substances are listed in brackets. 
TABLE IV.1: ACUTE TOXICITY 
Chemical Name [FL-no:]  Species  Sex  Route  LD50 
(mg/kg bw) 
Reference  Comments 
Main group I – Non-sulphur-containing Furan Derivatives 
(Furfural [13.018]) Rat  M, F  Gavage M: 145 – 204 
F: 90 - 119 
(Brown, 1982)   
5-Hydroxymethylfurfuraldehyde [13.139]  Rat  NR  Oral  3100  (Simonyan, 1969) Article in Russian 
Rat  M, F  Gavage  2500  (Warf Institute, 1977)  
Mouse  NR  Oral  1910  (Simonyan, 1969) Article in Russian 
Mouse  NR  Oral  > 2000  (Czok, 1970)  
(5-Methylfurfural [13.001]) Rat NR Oral 2200 (Moreno, 1978g)  
(Methyl-2-furoate [13.002]) Rat  M, F  Gavage  300  (Great Lakes Chemical Corp., 
1998) 
 
Rat  NR  IP injection 100  (Phatak & Emerson, 1936)  
Ethyl 2-furoate [13.122] Rat  NR  IP injection 75 – 100  (Phatak & Emerson, 1936) Questionable route of exposure.  
(Propyl 2-furoate [13.003]) Rat  NR  IP injection 75 – 100  (Phatak & Emerson, 1936)  
Butyl 2-furoate [13.102] Mouse  NR  Oral  1500  (Stasenkova & Shchirskaya, 
1967) 
 
Rat  NR  IP injection 100 – 150  (Phatak & Emerson, 1936) Questionable route of exposure. 
(Amyl 2-furoate [13.025]) Rat  NR  IP injection 250 – 500  (Phatak & Emerson, 1936)  
Main group II – Sulphur-containing Furan Derivatives 
(2-Methyl-3-furanthiol [13.055])  Mouse  M, F  Gavage  100  (Oser, 1969a)  
Mouse  M, F  Gavage  100  (Moran et al., 1980)  
(Methyl 2-methyl-3-furyl disulfide [13.079]) Mouse  M, F  Gavage  142  (Moran et al., 1980)  
(Propyl 2-methyl-3-furyl disulfide [13.082]) Mouse  M, F  Gavage  284  (Moran et al., 1980)  
(Bis(2-methyl-3-furyl) disulfide [13.016]) Mouse  M, F  Gavage  106  (Oser, 1969b)  
(2,5-Dimethyl-3-furanthiol [13.071])  Mouse  M, F  Gavage  < 544  (Fogleman & Suppers, 1973a)  
Mouse  M, F  Gavage  360  (Moran et al., 1980)  
(Furfuryl mercaptan [13.026]) Mouse  M  IP  injection 100 – 200 (Doull et al., 1962)  
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TABLE IV.1: ACUTE TOXICITY 
Chemical Name [FL-no:]  Species  Sex  Route  LD50 
(mg/kg bw) 
Reference  Comments 
(2-Methyl-3-tetrahydrofuranthiol [13.160]) Mouse  NR  Gavage  1860  (Oser, 1970c)  
(Bis(2-methyl-3-furyl) tetrasulfide [13.017]) Mouse M, F Gavage 220 (Oser, 1970c)  
 Mouse  M, F  Gavage  220  (Moran et al., 1980)  
(2,5-Dimethyl-3-furyl thioisovalerate [13.041]) Mouse  M, F  Gavage  580  (Fogleman & Suppers, 1974a)  
Mouse  M, F  Gavage  720  (Fogleman & Suppers, 1973b)  
Mouse  M, F  Gavage  580  (Moran et al., 1980)  
(2,5-Dimethyl-3-thiofuroylfuran [13.040])  Mouse  M, F  Gavage  625  (Fogleman & Suppers, 1974b)  
Mouse  M, F  Gavage  625  (Fogleman & Suppers, 1973a)  
Mouse  M, F  Gavage  540  (Moran et al., 1980)  
(3-[(2-Methyl-3-furyl)thio]-4-heptanone [13.077]) Mouse M, F Gavage 425 (Moran et al., 1980)  
(Ethyl 3-(furfurylthio)propionate [13.093]) Mouse M, F Oral > 5000 (Griffiths & Babish, 1977a)  
NR = Not reported.  
M = Male; F = Female. 
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Subacute / subchronic / chronic / Carcinogenic toxicity data are available for two of the candidate substances of the present flavouring group evaluation from 
chemical group 14 and for 17 supporting substances and two structurally related substances evaluated by the JECFA at the 55th and 59th meetings. The 
supporting and related substances are listed in brackets 
TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no:] Species; Sex 
No./Group 
Route Dose levels 
mg/kg bw/day 
Duration NOAEL 
(mg/kg /day) 
Reference Comments 
Main group I – Non-sulphur-containing Furan Derivatives 
(Furfural [13.018]) Mouse; M, F 
10 
Gavage 0, 25, 50, 100, 
200, 400 
16 days 400 (NTP, 1990a)  
Mouse; M, F  
20 
Gavage 0, 75, 150, 300, 
600, 1200 
13 weeks M: 75  
 F: < 75 
(NTP, 1990a)  
Mouse; M, F  
100 
Gavage 0, 50, 100, 175 2 years 50 (NTP, 1990a)  
Rat; M, F 
10 
Gavage 0, 15, 30, 60, 
120, 200 
16 days 120 (NTP, 1990a)  
Rat; M, F 
20 
Gavage 0, 11, 22, 45, 90, 
180 
13 weeks 45 (NTP, 1990a)  
Rat; M, F 
100 
Gavage 0, 30, 60 2 years > 60 (NTP, 1990a)  
Rat; M 
6 
Diet 0, 20-30 7  150 days < 30 (Shimizu et al., 1989)  
Rat; M 
48 
Diet 0, 20-30-40 
(ml/kg/d)8 
105 days < 40 ml/kg (Shimizu & Kanisawa, 
1986) 
 
Rat; M, F 
20 
Diet1 0, 30, 60, 90, 
180 
13 weeks 60 (Jonker, 2000b)  
Rat; M, F 
100 
Gavage 0, 30, 60 2 years 30 (NTP, 1990a)  
Hamster; M, F  
70 
Oral 0, 25 36 weeks 252 (Feron, 1972)  
5-Hydroxymethylfurfur-
aldehyde [13.139] 
Rat; NR 
NR 
Diet 0, 1000 100 days < 1 %3 
(1000) 
(Archer et al., 1992) Meeting Abstract. Due to 
lack of experimental details 
the validity could not be 
evaluated. 
Rat; NR 
NR 
Drinking 
water 
0, 0.16, 1.6 6 months 1.62 (Simonyan, 1969) Article in Russian (only the 
abstract in english) Due to 
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TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no:] Species; Sex 
No./Group 
Route Dose levels 
mg/kg bw/day 
Duration NOAEL 
(mg/kg /day) 
Reference Comments 
lack of experimental details 
the validity could not be 
evaluated. 
Rat; M 
19 
Diet 0, 250 40 weeks 2502 (Lang et al., 1970)  
Rat; NR 
NR 
Gavage 0, 40, 80, 160 11 months 80 (Zaitzev et al., 1975) Article in Russian (only the 
abstract in english) Due to 
lack of experimental details 
the validity could not be 
evaluated. 
Mouse; M, F 
10 
Gavage 0, 94, 188, 375, 
750, 1500;  
22 days 750 (NTP, 2010c) Dosing 5 day/week. 
Mouse; M, F  
20 
Gavage 0, 47, 94, 188, 
375, 750 
13 weeks 20.2 (NTP, 2010c) Dosing 5 day/week; the 
reported value under 
NOAEL is actually a BMDL 
(see section 8.2). 
Mouse; M, F  
100 
Gavage 0, 188, 375, 750 2 years < 188 (NTP, 2010c) Dosing 5 day/week. 
Rat; M, F 
10 
Gavage 0, 94, 188, 375, 
750, 1500;  
22 days 750 (NTP, 2010c) Dosing 5 day/week. 
Rat; M, F 
20 
Gavage 0, 94, 188, 375, 
750, 1500; 5d/w 
13 weeks < 188 (NTP, 2010c) Dosing 5 day/week. 
Rat; M, F  
100 
Gavage 0, 188, 375, 750 2 years < 188 (NTP, 2010c) Dosing 5 day/week. 
2-Furoic acid [13.136] Rat; M 
NR 
Orally 0, 20 14 days 204 (Hall et al., 1993) Only the hypolipodemic 
effects have been tested. No 
other end-point has been 
considered. 
 Mouse; M 
NR 
Orally 0, 20, 40, 80 14 days 20 (Hall et al., 1993) The study was not 
extensively reported but can 
be considered valid. 
(2-
Benzofurancarboxaldehyde 
[13.031]) 
Rat; M, F 
32 
Diet 0, 25 90 days M: 252 
F: 272 
(Posternak et al., 1969) Summary publication of 
study using appropriate 
methodology. Nu numerical 
data presented to enable 
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TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no:] Species; Sex 
No./Group 
Route Dose levels 
mg/kg bw/day 
Duration NOAEL 
(mg/kg /day) 
Reference Comments 
verification of NOAEL. 
Otherwise considered valid. 
(2-Phenyl-3-carbethoxy 
furan [13.038]) 
Rat; M, F 
30 
Diet 0, 13 90 days 132 (Posternak et al., 1969) Summary publication of 
study using appropriate 
methodology. Nu numerical 
data presented to enable 
verification of NOAEL. 
Otherwise considered valid. 
(2-Pentylfuran [FL-no: 
13.059]) 
Rat; M, F 
23 
Diet 0, 25.6 (26) 90 days 25.62 (Shellenberger, 1971e)  
Main group II – Sulphur-containing Furan Derivatives 
(2-Methyl-3-furanthiol 
[13.055]) 
Rat; M, F 
30 
Diet 0, 5 90 days 52 (Oser, 1970b) The target dose was 3.96 
mg/kg bw/day; the actual 
dose was 5 mg/kg bw/d. 
(Bis(2-methyl-3-furyl) 
disulfide [13.016]) 
Rat; M, F 
30 
Diet 0, 0.45 90 days 0.456 (Morgareidge and Oser, 
1970e) 
Good quality study. 
Rat; M, F 
30 
Diet 0, 3.96 90 days Not established (Oser, 1970a) Good quality study 
The target dose was 3.96 
mg/kg bw/day; the actual 
dose was 5 mg/kg bw/day. 
(Furfuryl mercaptan 
[13.026]) 
Rat; M, F 
30 
Gavage 0, 1, 3, 30 91 days 3 (Phillips et al., 1977) Good quality study. 
(Furfuryl thioacetate 
[13.033]) 
Rat; M, F 
32 
Diet 0, 0.831 (M); 
 0.812 (F) 
90 days M: 0.8312 F: 
0.8122 
(Posternak et al., 1969) Summary publication of 
study using appropriate 
methodology. Nu numerical 
data presented to enable 
verification of NOAEL. 
Otherwise considered valid. 
(4-[(2-Furanmethyl)thio]-2-
pentanone [13.196]) 
Rat; M, F 
10 
Diet 0, 54.2 (M); 
50.8(F) 
14 days 50.82 (Wnorowski, 1997d)  
(2-Methyl-3-
tetrahydrofuranthiol 
[13.160]) 
Rat; M, F 
10 
Diet 0, 12.5 (M): 11.0 
(F) 
14 days M: 12.5 F: 11.0 (Rush, 1991)  
(2,2'- Rat; M, F Diet 0, 10 14 days 10 (Gill and Van Miller,  
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TABLE IV.2: SUBACUTE / SUBCHRONIC / CHRONIC / CARCINOGENICITY STUDIES 
Chemical Name [FL-no:] Species; Sex 
No./Group 
Route Dose levels 
mg/kg bw/day 
Duration NOAEL 
(mg/kg /day) 
Reference Comments 
(Thiodimethylene)difuran 
[13.056]) 
10 1987b) 
(Bis(2-methyl-3-furyl) 
tetrasulfide [13.017]) 
Rat; M, F 
30 
Diet 0, 0.56 90 days 0.562 (Morgareidge and Oser, 
1970f) 
Taken as a valid study, but 
test report did not contain 
results of carried out 
histopathology. 
(2,5-Dimethyl-3-furyl 
thioisovalerate [13.041]) 
Rat; M, F 
30 
Diet 0, 0.73 90 days 0.732 (Morgareidge et al., 
1974a) 
 
(2,5-Dimethyl-3-
thiofuroylfuran [13.040]) 
Rat; M, F 
30 
Diet 0, 0.74 90 days 0.742 (Morgareidge et al., 
1974b) 
 
(Furfuryl isopropyl sulfide 
[13.032]) 
Rat; M, F 
32 
Diet 0, 1.34 (M): 1.31 
(F) 
90 days M: 1.342
F: 1.312 
(Posternak et al., 1969) Summary publication of 
study using appropriate 
methodology. Nu numerical 
data presented to enable 
verification of NOAEL. 
Otherwise considered valid. 
(2-Methyl-3-, 5-, or 6-
(furfurylthio)pyrazine 
[13.151]) 
Rat; M, F 
32 
Diet 0, 1.66 (M): 1.64 
(F) 
90 days M: 1.662
F: 1.642 
(Posternak et al., 1975) Summary publication of 
study using appropriate 
methodology. Nu numerical 
data presented to enable 
verification of NOAEL. 
Otherwise considered valid. 
(3-[(2-Methyl-3-furyl)thio]-
4-heptanone [13.077]) 
Rat; M, F 
30 
Diet 0, 3.8 90 days 3.82 (Gallo et al., 1976b) Valid study. 
(Ethyl 3-
(furfurylthio)propionate 
[13.093]) 
Rat; M, F 
20 
Diet 0, 5.78, 17.24 90 days 5.782 (Bio-Research 
Laboratory, 1980) 
Limitedly reported, but 
considered valid. 
(2-Methyl-3-thioacetoxy-
4,5-dihydrofuran [13.086]) 
Rat; M, F 
6 
Diet 0, 2.5, 6.5, 12.5, 
25, 37.5, 50 
3 weeks 2.5 (Munday & Gellatly, 
1972) 
 
Rat; M, F 
16 
Diet 0, 1.4, 2.8, 5.5, 
8.3, 13.85, 27.70 
13 weeks 1.4 (Munday & Gellatly, 
1973a) 
Good quality study. 
Rat; M, F 
16 
Diet 0, 13.85, 27.70 16 weeks Not established  (Munday & Gellatly, 
1973b) 
 
Rat; M, F 
16 
Diet Changing during 
the study  
1 year 8.35 (Munday & Gellatly, 
1974) 
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M = Male; F = Female.  
1 Furfural was administered in the diet in microencapsulated form.  
2 This study was performed at either a single dose level or multiple dose levels that produced no adverse effects. 
3 Previously initiated animals administered 1 % 5-hydroxymethylfurfuraldehyde in the diet were found to have double the occurrence of microadenoma in the colon as compared to controls.  
4 NOEL not reported. Dose concentrations of 20 mg/kg day reduced serum cholesterol and triglyceride levels by 50 and 42 %, respectively. 
5 For the first 16-weeks, the animals were maintained on diets containing 1.4, 2.8, 5.55 or 8.3 mg/kg bw of test material. , then they received 8.3 for the rest of the study The authors gave no 
clear explanation for theabsence of effects measured at 13 and 16 weeks. 
6 The study was conducted with the same methodology, test item and rat strain as the study by Oser 1970a , in order to establish a NOAEL. 
7For the first 30 days animals received 20 mg/kg/day; then the dose as increased to 30 mg/kg/day. 
8 The animals received 20 ml/kg/d during the 1st week, 30 ml/kg/d during the 2nd week and 40) ml/kg/d for the rest of the study. 
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Developmental and reproductive toxicity data are available for one candidate substance of the present flavouring group evaluation from chemical group 14 
and for one supporting substance evaluated by JECFA at the 55th meeting. Supporting substance listed in brackets. 
TABLE IV.3: DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
Chemical Name [FL-
no:] 
Study type 
Duration 
Species/Sex 
No/group  
Route  Dose levels 
mg/kg bw/day 
NOAEL (mg/kg/day) 
Including information on 
possible maternal toxicity 
Reference  Comments 
Subgroup I – Non-sulphur-containing Furan Derivatives 
(Furfural [13.018]) Developmental toxicity 
Gestation days 6-15 
Rat; F 
8 
Gavage 0, 10, 50, 100, 
500, 1000 
Maternal: 100 
Foetal: ND 
(Nemec, 1997a)  
 Developmental toxicity 
Gestation days 6-15 
Rat; F 
8 
Gavage 0, 10, 50, 100, 
150, 250, 350 
Maternal: 100 
Foetal: 150 
(Nemec, 1997a)  
 Developmental toxicity 
Gestation days 6-15 
Rat; F 
25 
Gavage 0, 50, 100, 150  Maternal: <50 
Foetal: 100 
(Nemec, 1997b)  
2-Furoic acid [13.136] 3 weeks1 Mouse; F 
6 
Oral 0, 20, 50, 100 Reproductive: 50 (Hall et al., 1993) Very few details 
reported. No 
statistical analysis 
performed. Poor 
quality data. 
ND: Not determined. 
1Animals were exposed for three weeks prior to mating and for three weeks during mating. 
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In vitro mutagenicity/genotoxicity data are available for two candidate substances of the present flavouring group evaluation from chemical group 14 and for 
five supporting substances evaluated by the JECFA at the 55th meeting and three supporting substances evaluated at the 65th and 69th (re-evaluation) meeting. 
Supporting substances are listed in brackets. 
 
TABLE IV.4: GENOTOXICITY (IN VITRO) 
Chemical Name [FL-
no:] 
Test system Test Object  Concentration Result  Reference  Comments 
Main group I – Non-sulphur-containing Furan Derivatives 
(Furfuryl alcohol 
[13.019]) 
Ames test  S. typhimurium TA98, TA100, 
TA1535 and TA1537  
 294 µg/plate  Negative1   (Florin et al., 1980)  
Ames test  S. typhimurium TA98, TA100, 
TA1535 and TA1537 
10000 µg/plate  Negative1 (Mortelmans et al., 
1986) 
(NTP, 1999a) 
 
Ames test  S. typhimurium TA100  2500 - 12500 µg/ml  Negative1 (Stich et al., 1981a)  
Ames test  S. typhimurium TA98, TA100 and 
TA102  
198000 µg/plate  Negative1 (Aeschbacher et al., 
1989) 
 
Ames test  S. typhimurium TA98 and TA100  81 - 323 µg/plate  Negative1 (Shinohara et al., 
1986) 
 
Modified Ames test  S. typhimurium TA1535, TA100 and 
TA1537  
200000 µg/ml  Positive1 (McGregor et al., 
1981) 
 
Rec assay  B. subtilis  2000 - 20000 µg/disk  Positive1 (Shinohara et al., 
1986) 
 
Sister chromatid 
exchange  
CHO cells  245 µg/ml  Positive1 (Stich et al., 1981a)  
Sister chromatid 
exchange  
CHO cells  500 µg/ml  Positive/weakly 
positive2  
Negative3 
(NTP, 1999a)  
Sister chromatid 
exchange  
Human Lymphocytes  Up to196 µg/ml  Negative  (Jansson et al., 1986)  
Sister chromatid 
exchange  
Human  
Lymphocytes  
Up to 970 µg/ml  Negative  (Gomez-Arroyo & 
Souza, 1985) 
 
Chromosomal 
aberration  
CHO cells  2000 µg/ml  Positive  (Stich et al., 1981a)  
Chromosomal 
aberration  
CHO cells  1600 µg/ml  Negative1 (NTP, 1999a)  
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TABLE IV.4: GENOTOXICITY (IN VITRO) 
Chemical Name [FL-
no:] 
Test system Test Object  Concentration Result  Reference  Comments 
SHE test  Syrian hamster embryo cells  NR Negative3  (Kerckaert et al., 
1996) 
 
Gene Conversion 
Assay  
S. cerevisiae strain D7  13500 -16000 µg/ml  Positive2 (Stich et al., 1981b)  
Mammalian cell assay Mouse embryo fibroblast cells (T1) 10 µg/ml  Negative2 (Kowalski et al., 
2001) 
 
p53 – induction assay  Mouse embryo fibroblast cells (NCTC 
929)  
50 µg/ml  Negative2  (Duerksen-Hughes 
et al., 1999) 
 
(Furfuryl acetate 
[13.128]) 
Ames test  S. typhimurium TA1535, TA98 and 
TA100  
33 - 666 µg/plate  Positive2  (Mortelmans et al., 
1986) 
 
(Furfural [13.018]) Ames test  S. typhimurium TA 1535, TA100, 
TA1537, TA1538, TA98  
0.1 – 1000 µg/ml  Negative1 (McMahon et al., 
1979) 
 
Ames test  S. typhimurium TA100, TA98 and 
TA1535  
Up to 3460 µg/plate  
5766 µg/plate  
Negative1  
Positive2 (weak)  
(Loquet et al., 1981)  
Ames test  S. typhimurium TA100, TA98 and 
TA102  
Up to 115320 µg/plate  Negative1  (Aeschbacher et al., 
1989) 
 
Ames test  S. typhimurium TA100 and TA98  15 – 63 µg/plate  Negative1 (Shinohara et al., 
1986) 
 
Ames test  S. typhimurium TA104 5 – 500 µg/plate  Positive3 (Shane et al., 1988)  
Ames test  S. typhimurium TA100 and TA102  5 – 500 µg/plate  Negative3 (Shane et al., 1988)  
Ames test  S. typhimurium TA104 and TA102 96 µg/plate  Negative  (Marnett et al., 
1985a) 
 
Ames test  S. typhimurium TA98, TA100 and 
TA1535  
Up to 6667 µg/plate  Negative1 (Mortelmans et al., 
1986) 
 
Ames test  S.typhimurium TA98, TA100  Up to 1000 µg  Negative2  (Osawa & Namiki, 
1982) 
 
Ames test  S.typhimurium TA98, TA100, 
TA1535, TA1537  
33 – 6666 µg/plate  Negative1  
TA100 
Equivocal2  
(NTP, 1990a)  
Ames test  S. typhimurium TA100  8000 µg/plate  Positive1 (Zdzienicka et al., 
1978) 
 
Ames test  S. typhimurium TA98  8000 µg/plate  Negative1  (Zdzienicka et al., 
1978) 
 
Ames test  S. typhimurium TA100, TA102  100 - 10000 µg/plate  Negative2 (Dillon et al., 1998)  
Ames test  S. typhimurium TA104  100 - 10000 µg/plate  Equivocal2 (Dillon et al., 1998)  
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TABLE IV.4: GENOTOXICITY (IN VITRO) 
Chemical Name [FL-
no:] 
Test system Test Object  Concentration Result  Reference  Comments 
Ames test  S. typhimurium TA102, TA104  100 – 10000 µg/plate  Negative3 (Dillon et al., 1998)  
Ames test  S. typhimurium TA100  100 – 10000 µg/plate  Equivocal3 (Dillon et al., 1998)  
Modified Ames test  S. typhimurium TA100  426 µg/plate  Negative  (Kim et al., 1987b)  
Modified Ames test  S. typhimurium TA100, TA1535 and 
TA1537  
200000 µg/ml  Negative  (McGregor et al., 
1981) 
 
Modified Ames test  E. coli WP2 and WP2 uvrA  0.1 – 1000 µg/ml  Negative1 (McMahon et al., 
1979) 
 
SOS induction  S.typhimurium TA1535/ pSK1002  1932 µg/ml  Negative1 (Nakamura et al., 
1987) 
 
Rec-assay  B. subtilis H17 & M45  Up to 1000 µg  Negative  (Osawa & Namiki, 
1982) 
 
Rec-assay  B. subtilis H17 & M45  0.6 ml  Negative1 (Matsui et al., 1989)  
Rec-assay  B. subtilis strains H17 & M45  1700 - 17000 µg/disk  Positive1 (Shinohara et al., 
1986) 
 
Forward mutation 
assay  
L5178Y tk+/- Mouse Lymphoma Cells 25 - 100 µg/ml  
200 µg/ml  
Negative2  
Positive2  
(McGregor et al., 
1988b)  
 
Sister chromatid 
exchange  
CHO cells  2500 – 4000 µg/ml  Positive1  (Stich et al., 1981a)  
Sister chromatid 
exchange  
CHO cells  Up to 1170 µg/ml  Positive1 (NTP, 1990a)   
Sister chromatid 
exchange  
Human  
Lymphocytes  
Up to 0.035 mM4  
0.07 – 0.14 Mm4  
Negative1  
Positive1  
(Gomez-Arroyo & 
Souza, 1985)  
 
Chromosomal 
aberration  
CHO cells  500 µg/ml  
1000-2000 µg/ml  
Negative  
Positive  
(Nishi et al., 1989)  
Chromosomal 
aberration  
CHO cells  Up to 40 mM (3,840 mg)  Positive1 (Stich et al., 1981a)  
Chromosomal 
aberration  
CHO cells  3000 µg/ml  Positive  (Stich et al., 1981b)  
Chromosomal 
aberration  
CHO cells  375 µg/ml2  
750 µg/ml3  
Positive  (Gudi & Schadly, 
1996) 
 
Chromosomal 
aberration  
CHO cells  Up to 1,230 µg/ml  Positive1 (NTP, 1990a)   
Unscheduled DNA 
Synthesis  
Human liver slices  0.005 – 10 mM  Negative (Adams et al., 
1998b) 
 
DNA-protein cross- EBV- human Burkitt’s lymphoma cells 25 mM Positive5 (Costa, 1997)  
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TABLE IV.4: GENOTOXICITY (IN VITRO) 
Chemical Name [FL-
no:] 
Test system Test Object  Concentration Result  Reference  Comments 
links  
5-Hydroxymethyl-
furfuraldehyde 
[13.139] 
Ames test  S. typhimurium TA98; TA100  0.2-1 μmol/plate  Negative  (Surh et al., 1994) The study is 
considered valid 
Purity 99 %. 
Ames test  S. typhimurium TA98; TA100  0.2-2.0 µg/plate  Positive1  (Omura et al., 1983) Positive dose related 
response inTA100 
only, most potent 
without S9. Purity 
and other 
experimental details 
not reported. The 
validity of the study 
can not be evaluated. 
Ames test  S. typhimurium TA98; TA100  0.17- 0.66 µmol/plate Positive1  (Shinohara et al., 
1986) 
Positive results only 
obtained in TA100 
with S9. Reverse 
dose-respons 
relationship. 
Experimental details 
are lacking.  
Ames test  S. typhimurium TA104  0.1 - 0.8 mM  Negative2  
Positive 
(Lee et al., 1995b) Positive result was 
obtained by inclusion 
of PAPS and rat liver 
cytosol in the assay. 
The study is 
considered valid. 
Ames test  S. typhimurium TA98; TA100;  1 - 50 µl/plate3  Negative1 (Aeschbacher et al., 
1981) 
The study is 
considered valid. 
Ames test  S. typhimurium TA100  4.44 µM/plate  Negative2  (Kim et al., 1987b) Single dose only. 
Ames test  S. typhimurium TA98; TA100; 
TA1535; TA1537  
3 µmol/plate Negative1  (Florin et al., 1980) Spot test. The study 
is considered valid. 
Ames test  S. typhimurium TA100  10 µg/plate  Negative2  (Majeska & 
McGregor, 1992) 
The study is 
considered valid. 
Umu assay  S. typhimurium  
TA1535  
20 mM Positive9  (Janzowski et al., 
2000) 
Positive results were 
only obtained at high 
concentrations 
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TABLE IV.4: GENOTOXICITY (IN VITRO) 
Chemical Name [FL-
no:] 
Test system Test Object  Concentration Result  Reference  Comments 
resulting in reduced 
cell viability and 
growth. The study is 
considered valid but 
interpretation of data 
is questionable. 
Rec assay  B. subtilis  
H 17 rec+; M 45 rec-  
0.25 - 12.5 mg/disk  Positive1  (Shinohara et al., 
1986) 
Experimental details 
are lacking. The 
validity of the study 
cannot be evaluated. 
Chromosomal 
aberration  
Chinese hamster V79 cells  Up to 2000 µg/ml  Positive10  (Nishi et al., 1989) Weak positive 
responses were only 
obtained at high 
concentrations. The 
study is considered 
valid. 
Comet assay  V79, Caco-2, primary human colon 
cells and primary rat hepatocytes  
Up to 80 mM  Negative2  (Janzowski et al., 
2000) 
The study is 
considered valid but 
interpretation of data 
is questionable. 
HPRT assay  V79 cells  Up to 140 mM  Positive1, 11  (Janzowski et al., 
2000) 
Positive responses 
were only obtained at 
high concentrations 
resulting in reduced 
cell viability and 
growth. The study is 
considered valid but 
interpretation of data 
is questionable. 
HPRT and tk assay  TK6 human lymphoblast cells  20 - 75 µg/ml  Negative  (Surh & 
Tannenbaum, 1994)  
The study is 
considered valid. 
(5-Methylfurfural 
[13.001]) 
Ames test S. typhimurium TA1537, TA100 and 
TA1535  
288 µg/plate  Negative1 (Florin et al., 1980)  
Ames test  S. typhimurium TA98, TA100 and 
TA102  
96100 µg/plate  Negative1 (Aeschbacher et al., 
1989) 
 
Ames test  S. typhimurium TA98 and TA100  79 - 316 µg/plate  Negative1 (Shinohara et al.,  
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TABLE IV.4: GENOTOXICITY (IN VITRO) 
Chemical Name [FL-
no:] 
Test system Test Object  Concentration Result  Reference  Comments 
1986) 
Rec-assay  B. subtilis strains H17 & M45  0.55 – 5500 µg/disk  Positive1 (Shinohara et al., 
1986) 
 
Sister chromatid 
exchange  
CHO cells  2200 – 4070 µg/ml  Positive1 (Stich et al., 1981a)  
2-Furoic acid [13.136] Ames test  S. typhimurium TA98; TA100  25 -100 µg/plate  Negative2 (Ichikawa et al., 
1986b) 
The study is 
considered valid. 
Ames test  S. typhimurium TA100   Negative  (Soska et al., 1981) Dose not reported. 
The validity of the 
study can not be 
evaluated. 
Ames test  S. typhimurium TA100  1000 µg/plate  Negative  (Kitamura et al., 
1978) 
The study is 
considered valid. 
DNA repair test  E. coli  
WP2l WP2 uvrA; WP67; WP100; CM 
561; CM 571; CM 611  
1000 µg/disk  Negative  (Soska et al., 1981) The study is 
considered valid. 
Unscheduled DNA 
synthesis  
Primary rat hepatocytes  1000 µg/ml  Negative10, 12  (Aaron et al., 1989) Study performed in 
accordance with 
GLP. The study is 
considered valid. 
(Methyl-2-furoate 
[13.002]) 
Ames test  S. typhimurium TA98; TA100  100 µg/plate  Negative10  (Ichikawa et al., 
1986b) 
 
(2-acetylfuran 
[13.054]) 
  
UDS  Human hepatocytes  2.19, 4.38, 8.75, 17.5, 35, 70, 
140 or 280 µg/ml  
Negative  (Durward, 2007a)  New study submitted 
to JECFA for the 69th 
meeting. 
Reverse mutation  S. typhimurium TA98 and TA100  0.165, 0.330, 0.495 or 0.660 
µmol/plate (13.5, 27.1, 40.6 
or 54.2 µg/plate)20  
Negative/positive
1,21  
(Shinohara et al., 
1986) 
Study reported by 
JECFA at the 65th 
meeting. 
DNA damage  E. coli PQ37 (SOS  chromotest)  Not specified  Slightly positive  (Eder et al., 1993) Study reported by 
JECFA at the 65th 
meeting. 
DNA damage  B. subtilis H17 (rec+) and M45 (rec-)  550, 5500 or 55000 µg/disc  Negative/ 
positive1,22  
(Shinohara et al., 
1986) 
Study reported by 
JECFA at the 65th 
meeting. 
Chromosomal CHO cells 0-112.6 mmol/l  Positive22,23,24 (Stich et al., 1981b) Study reported by 
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TABLE IV.4: GENOTOXICITY (IN VITRO) 
Chemical Name [FL-
no:] 
Test system Test Object  Concentration Result  Reference  Comments 
aberration (0-13220 µg/ml)20   JECFA at the 65th 
meeting. 
(2-Methylfuran  
[13.030]) 
  
Reverse mutation   S .typhimurium  TA98 and TA100  0.165, 0.330, 0.495 or 0.660 
µmol/plate (13.5, 27.1, 40.6 
or 54.2 µg/plate)13  
Negative1   (Shinohara et al., 
1986)  
Study reported by 
JECFA at the 65th 
meeting. 
Reverse mutation   S. typhimurium TA98,  TA100, TA102 
and TA1535  
Up to 10 000 µg/plate   Negative1,14,15  (Zeiger et al., 1992)  Study reported by 
JECFA at the 65th 
meeting. 
Reverse mutation   S. typhimurium TA97 and  TA104  Up to 10 000 µg/plate   Equivocal1,14,15  (Zeiger et al., 1992)  Study reported by 
JECFA at the 65th 
meeting. 
Reverse mutation   S. typhimurium TA98,  TA100 and 
TA102 
11 nmol/plate to 1,1 mmol/ 
plate (0,9-90 310 µg/plate)13   
Negative1   (Aeschbacher et al., 
1989)  
Study reported by 
JECFA at the 65th 
meeting. 
DNA damage   Bacillus subtilis H17 (rec+)  and M45 
(rec˜Ñ)   
0.16, 16 or 1600 µg/disc   Negative/positive
1,16 
(Shinohara et al., 
1986)  
Study reported by 
JECFA at the 65th 
meeting. 
Chromosomal 
aberration  
CHO cells   0-150 mmol/l   
(0-12315 µg/ml)13  
Positive1,17   (Stich et al., 1981b) Study reported by 
JECFA at the 65th 
meeting. 
(2,5-Dimethylfuran  
[13.029]) 
  
Reverse mutation  S. typhimurium TA98 and  TA100   0.165, 0.330, 0.495 or 0.660 
µmol/plate (13.5, 27.1, 40.6 
or 54.2 µg/plate)18  
Negative1   (Shinohara et al., 
1986) 
Study reported by 
JECFA at the 65th 
meeting. 
Reverse mutation   S. typhimurium TA98  and TA100  Not specified   Negative1   (Lee et al., 1994a) Study reported by 
JECFA at the 65th 
meeting. 
Reverse mutation   S. typhimurium TA97,  TA98, TA100 
and TA1535   
Up to 3333 µg/plate   Negative1,14,15 (Zeiger et al., 1992) Study reported by 
JECFA at the 65th 
meeting. 
DNA damage   B. subtilis H17 (rec+)  and M45 (rec-)  190, 1900 or 9500 µg/disc   Negative/positive
1,19   
(Shinohara et al., 
1986) 
Study reported by 
JECFA at the 65th 
meeting. 
Chromosomal 
aberration 
Chinese hamster V79  cells 1 mmol/l (96.13 µg/ml)18   Negative  (Ochi and Ohsawa, 
1985) 
Study reported by 
JECFA at the 65th 
meeting. 
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TABLE IV.4: GENOTOXICITY (IN VITRO) 
Chemical Name [FL-
no:] 
Test system Test Object  Concentration Result  Reference  Comments 
Chromosomal 
aberration 
CHO cells  0-20 mmol/l  (0-1923 
µg/ml)18   
Positive1,17   (Stich et al., 1981b) Study reported by 
JECFA at the 65th 
meeting. 
NR=Not Reported. 
1With and without S9 metabolic activation.  
2 Without S9 metabolic activation.  
3 With S9 metabolic activation. 
4 Concentration that was added to the culture. 
5 Significant increases in % DNA-protein cross-links occurred only when cell viability was 40 % or less (i.e. high incidence of cell death). 
6 TA98 with S9 metabolic activation; TA100 without S9 metabolic activation. 
7 5-Hydroxymethylfurfuraldehyde with 0.05 mol L-tryptophan without the presence of nitrite treatment.  
8 5-Hydroxymethylfurfuraldehyde with 0.05 mol L-tryptophan treated with nitrite.  
9 At concentrations of 12 mmol and greater, positive results were obtained without S9 metabolic activation. The dose dependent results were noted at concentrations known to be cytotoxic.  
10 Metabolic activation not reported.  
11 Effects occurred at concentrations inhibiting cellular growth. 
12 Dose levels above 300 microgram/ml were cytotoxic.  
13
 Calculated using relative molecular mass of 2-methylfuran = 82.1. 
14 Preincubation method. 
15 Occasional incidences of slight to complete clearing of the background lawn at the higher concentrations. 
16 Negative at all concentrations with metabolic activation; positive without metabolic activation. 
17 Clastogenic activity decreased with metabolic activation (statistical significance of results was not specified). 
18 Calculated using relative molecular mass of 2,5-dimethylfuran = 96.13. 
19 Positive at every concentration without metabolic activation; with metabolic activation, negative at 190 μg/disc, but positive at higher concentrations. 
20 Calculated using relative molecular mass of 2-acetylfuran = 110.11. 
21 Positive only in strain TA98 with an increase in the presence of metabolic activation. 
22 Negative at 550 μg/disc; positive at 5500 and 55 000 μg/disc (with and without metabolic activation). 
23 Cytotoxicity was observed at 12 398 μg/ml (112.6 mmol/l) in the presence of metabolic activation. 
24 Clastogenic activity increased with metabolic activation (statistical significance of results was not specified). 
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TABLE IV.5: SUMMARY OF ADDITIONAL GENOTOXICITY DATA ON 5-HMF (IN VITRO) 
 
TABLE IV.5: SUMMARY OF ADDITIONAL GENOTOXICITY DATA ON 5-HYDROXYMETHYLFURFURAL (IN VITRO) 
Chemical name [FL-no:] Test system Test object Concentration Result Reference 
5-Hydroxymethylfurfural 
[13.139] 
Ames S. typhimurium TA97, TA98, TA102, 
TA1535 
100-10,000 µg/plate Negative1 (NTP, 2010c) 
Ames S. typhimurium TA100 100-10,000 µg/plate Weakly positive2 (NTP, 2010c) 
Ames S. typhimurium TA100 and TA98 1,500-10,000 µg/plate Negative1 (NTP, 2010c) 
Ames S. typhimurium TA98, TA100, 
TA1535, TA1537 
at 0.5 µg/mL up to 5000 µg/mL Negative1 (Severin et al., 2010) 
Reverse mutation E. coli WP2 uvrA/pKM101 1,500-10,000 µg/plate Negative1 (NTP, 2010c) 
Micronucleus 
assay 
HepG2 cells 0, 5.35, 7.87, 11.57, 17, 25, 36.6 mM Negative6 (Severin et al., 2010) 
SCE induction V79-hCYP2E1-hSULT1A1 cells 19.8-3808 µM Positive (Glatt et al., 2005) 
SCE induction V79-Mz cells 238-3808 µM, Positive7  (Glatt et al., 2005) 
Comet Assay HepG2 cells 0, 5.35, 7.87, 11.57, 17, 25, 36.6 mM Positive5, 6 (Severin et al., 2010) 
Comet Assay Human Caco-2 cells 3,153-12,611 µg/mL (25-100 mM) Positive3 (Durling et al., 2009) 
Comet Assay Human HEK293 cells 3,153-12,611 µg/mL (25-100 mM) Positive3 (Durling et al., 2009) 
Comet Assay Mouse lymphoma L5178Y cells 3,153-12,611 µg/mL (25-100 mM) Positive3 (Durling et al., 2009) 
Comet Assay Chinese hamster V-79  cells 315-12,611 µg/mL (2.5-100 mM) Positive4 (Durling et al., 2009) 
Comet Assay Chinese hamster V-79-hP-PST cells 315-12,611 µg/mL (2.5-100 mM) Positive4 (Durling et al., 2009) 
Micronucleus 
assay 
Mouse peripheral blood cells 47, 94, 188, 375 or 750 mg/kg bw/d Negative (Durling et al., 2009) 
1 With and without S9 metabolic activation. 
2 Without S9 metabolic activation. 
3 Positive only at the highest concentration tested with significant decrease in cell viability. 
4 Positive at high concentration with significantly reduced cell viability. 
5 Cytotoxic at the two highest doses. 
6 20 hours of exposure. 
7 Weakly positive but statistically significant at each concentration. 
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In vivo mutagenicity/genotoxicity data are not available for any of the candidate substances of the present flavouring group evaluation from chemical group 14 
but for two supporting substances evaluated by the JECFA at the 55th meeting and two supporting substances evaluated at the 65th and 69th (re-evaluation) 
meeting. 
TABLE IV.6: GENOTOXICITY (IN VIVO) 
Chemical Name [FL-no:] Test system Test Object Route Dose Result Reference Comments 
(Furfuryl alcohol [13.019]) Sex-linked recessive 
lethal test  
Drosophila 
melanogaster  
Injection Up to 6500 ppm  Negative  (Rodriquez-Arnaiz et al., 
1989) 
 
Sister chromatid 
exchange  
Adult Human 
Lymphocytes  
Inhalation 
(occupational 
atmosphere) 
32300 mg/m3  Negative (Gomez-Arroyo & Souza, 
1985) 
 
Chromosomal 
aberration assay  
Adult Human 
Lymphocytes  
Inhalation 
(occupational 
atmosphere) 
32300 mg/m3  Negative (Gomez-Arroyo & Souza, 
1985) 
 
Chromosomal 
aberration assay  
Mouse bone 
marrow cells 
Drinking 
water 
0.5 mg/kg  
1 - 2 mg/kg  
Negative  
Positive  
(Sujatha & Subramanyam, 
1994) 
 
Sister chromatid 
exchange  
Mouse bone 
marrow cells  
IP injection 300 mg/kg  Negative (NTP, 1999a)  
Chromosomal 
aberration assay  
Mouse bone 
marrow cells  
IP injection 300 mg/kg  Negative  (NTP, 1999a)  
Micronucleus assay  Mouse bone 
marrow cells 
IP injection 250 mg/kg  Negative  (NTP, 1999a)  
Mouse bioassay  Tg·AC 
transgenic 
mice  
Dermal 
exposure 
1.5 mg; 5 d/week for 20 
weeks  
Negative (Spalding et al., 2000)  
(Furfural [13.018]) Sex-linked recessive 
lethal test  
Drosophila 
melanogaster  
Diet 1000 ppm  Negative  (Woodruff et al., 1985)  
 Sex-linked recessive 
lethal test  
Drosophila 
melanogaster 
Injection 100 ppm  Positive (Woodruff et al., 1985)  
 Sex-linked recessive 
lethal test  
Drosophila 
melanogaster 
Injection Up to 6500 ppm  Negative (Rodriquez-Arnaiz et al., 
1989) 
 
 Chromosome Loss  Drosophila 
melanogaster 
Oral or 
injected 
3750 –5000 ppm. Mated with 
repair-proficient females  
Negative  (Rodriquez-Arnaiz et al., 
1992) 
 
 Chromosome Loss  Drosophila 
melanogaster 
Oral or 
injected 
3750 –5000 ppm. Mated with 
repair-deficient females  
Positive (Rodriquez-Arnaiz et al., 
1992) 
 
 Reciprocal 
translocations  
Drosophila 
melanogaster 
Injection 100 ppm  Negative (Woodruff et al., 1985)  
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TABLE IV.6: GENOTOXICITY (IN VIVO) 
Chemical Name [FL-no:] Test system Test Object Route Dose Result Reference Comments 
 Nondisjunction assay  Drosophila 
melanogaster 
(females)  
Inhalation 1.5 %  Negative1  (Muñoz & Barnett, 1999)  
 Sister chromatid 
exchange  
Mouse bone 
marrow cells  
Injection 50 - 200 mg/kg  Negative (NTP, 1990a)   
 Sperm head 
abnormalities  
Mouse Oral 4000 ppm daily for 5 weeks  Negative (Subramanyam et al., 
1989) 
 
 Somatic chromosome 
mutations  
Swiss albino 
mouse (bone 
marrow cells)  
 1000 – 2000 ppm  
4000 ppm for 5 days  
Negative  
Positive  
(Subramanyam et al., 
1989) 
 
 Sister chromatid 
exchange  
Adult Human 
Lymphocytes  
Inhalation 
(occupational 
atmosphere) 
9454 mg/m3 Negative (Gomez-Arroyo & Souza, 
1985) 
 
 Chromosomal 
aberration assay  
Adult Human 
Lymphocytes  
Inhalation 
(occupational 
atmosphere) 
9454 mg/m3 Negative (Gomez-Arroyo & Souza, 
1985) 
 
 Unscheduled DNA 
synthesis  
Mouse  Oral 50 - 320 mg/kg Negative (Edwards, 1999)  
 Unscheduled DNA 
synthesis  
F344 Rat  Oral 5 - 50 mg/kg Negative (Phillips et al., 1997)  
 Gene mutation in the 
λlacZ-gene in liver 
Transgenic 
mouse  
CD2F1 
(BALB/c x 
DBA/2) 
Oral 75 – 300 mg/kg Negative (CIVO-TNO, 2003)  
(2-acetylfuran [13.054]) SCE   Mouse bone 
marrow   
 1000, 2000 or 3000  mg/l (20, 
40 or 60 mg/   kg bw)2   
Positive   (Sujatha, 2007)   New study submitted 
to JECFA for the 69th 
meeting. 
UDS   Rat liver    7 or 21 mg/kg bw   Negative   (Durward, 2007b)   New study submitted 
to JECFA for the 69th 
meeting. 
Chromosomal 
aberration 
Mouse bone 
marrow 
 1000, 2000 or 3000  mg/l (20, 
40 or 60 mg/  kg bw)2   
Positive3,4 (Sujatha et al., 1993) Study reported by 
JECFA at the 65th 
meeting. 
Chromosomal 
aberration 
Mouse 
spermatocytes 
 1000, 2000 or 3000  mg/l (20, 
40 or 60 mg/ kg bw)2   
Negative5 (Sujatha et al., 1993) Study reported by 
JECFA at the 65th 
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TABLE IV.6: GENOTOXICITY (IN VIVO) 
Chemical Name [FL-no:] Test system Test Object Route Dose Result Reference Comments 
meeting. 
(2-Methylfuran [13.030]) Chromosomal 
aberration 
Mouse bone 
marrow  cells 
and 
spermatocytes 
 1000, 2000 or 4000 mg/kg 
(100, 200 or 400 mg/kg bw 
per day)6   
Negative (Subramanyam et al., 
1989) 
Study reported by 
JECFA at the 65th 
meeting. 
1 Exposure to 1 % solutions did not affect the flies’ behaviour and they had a 95 % survival rate. At dose concentrations of 1.3 and 1.5 % the results indicate a threshold for the induction of 
nondisjunction.  
2
 Two experimental protocols were utilized. In one experiment, animals received single oral dose administrations of the test compound. In the other experiment, the test compound was orally 
administered once per day at the same concentrations as in the single-dose study for 5 consecutive days with 24-h intervals between doses. 
3
 No effects observed at 20 mg/kg bw dose level and only mild, but significant (P < 0.05) effects seen at higher concentrations in bone marrow cells. 
4
 Chromosomal aberrations were observed in the presence of significant mitodepression. 
5
 A single statistically significant occurrence of increased chromosomal aberrations observed 3 weeks following a single dose administration in the 60 mg/kg bw test group; statistically 
significant increases in polyploidy and XY univalents observed at weeks 3 and 4 at 60 mg/kg bw in multipledose-treated rats. 
6 Mice received 2-methylfuran in the diet for 5 consecutive days at 24 hours intervals.  
 
 
 
 
TABLE IV.7: SUMMARY OF ADDITIONAL GENOTOXICITY DATA ON 5-HMF (IN VIVO) 
 
TABLE IV.7: SUMMARY OF ADDITIONAL GENOTOXICITY DATA ON 5-HYDROXYMETHYLFURFURAL (IN VIVO) 
Chemical name [FL-no:] Test system Test object Route Concentration Result Reference EFSA Comments 
5-Hydroxymethylfurfural 
[13.139] 
Micronucleus 
assay 
Mouse peripheral blood 
cells 
Gavage 47, 94, 188, 375 or 750 mg/kg 
bw/d 
Negative (NTP, 2010c) 3-months 
micronucleous 
assay. 
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ANNEX V: DOSE RESPONSE MODELLING FOR 5HMF  
 
In compliance with the Opinion of the EFSA Scientific Committeee on the use of the Bench Mark 
Dose (BMD) approach in Risk Assessment (EFSA, 2011g), the results obtained in the (NTP, 2010c)  
subchronic and chronic bioassays with 5HMF [FL-no: 13.139] have been submitted to statistical dose 
response modelling. The studies performed with rats did not indicate adverse effects at dose levels 
sufficiently low to drive the determination of a point-of-departure. In addition, the effects reported in 
rats appeared to be much more of questionable relevance than the effects reported in the mice (see 
section 8.2 of the main text). Therfore, only the data from the mouse study have been included in this 
analysis. 
For all modelling the statistical package PROAST (version 27.4) has been used. This package is 
available via: http://www.rivm.nl/en/foodnutritionandwater/foodsafety/proast.jsp. Using this statistical 
package, 95 % lower confidence limit (single sided) of the Benchmark doses (BMDLs) were 
calculated (see (EFSA, 2011g)) for the various effects. For each evaluation, all statistical models 
available in PROAST (i.e. the “EPA-models” plus the Exponential and Hill families of models) were 
used. 
All evaluations were carried out with the following settings: 
° Benchmark respons 10 % extra risk (default for quantal data) 
° No restrictions for model parameters to limit e.g. steepness of the fitted dose-response curves 
° Sex was used as a covariate unless effects were only observed in one sex. 
° For all evaluations the following criteria were used to decide on acceptability of modelling output: 
° P-value for goodness of fit: 0.05. 
° The ratio BMDL/BMDU < 10, otherwise the uncertainty in the data and model results is too high 
Dose-response analysis for renal changes in male mice in the NTP (NTP, 2010c) subchronic gavage 
study with 5HMF. 
For the subchronic study in the mouse, the critical effect was the occurrence of cytoplasmic alterations 
in the renal proximal tubule epithelium at 188 mg/kg or above in male mice. 
The following data were extracted from the study report (NTP, 2010c) 
TABLE V.1 
dose (mg/kg bw/d) No of animals affected No of animals per group 
0 1 10 
47 0 10 
94 1 10 
188 6 10 
375 8 10 
750 10 10 
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The results of this analysis are presented in Table V.2. 
TABLE V.2 Results of a BMD analysis of the data from NTP (2010c) on cytoplasmic alterations 
in the renal proximal tubule epithelium in the male mouse subchronic bioassay 
with 5HMF. 
model covar npar loglik acc BMD* BMDL* BMDU*
null NA 1 -41.05 -- NA NA NA 
full NA 6 -18.24 -- NA NA NA 
one-stage -- 2 -22.87 yes 29.5 20.2 45 
two-stage -- 3 -20.24 yes 87.4 68.9 116 
log-logist -- 3 -19.83 yes 95.9 55.5 145 
Weibull -- 3 -20.24 yes 84.3 40.7 145 
log-prob -- 3 -19.64 yes 96 57.4 146 
gamma -- 3 -19.92 yes 92.6 47.1 147 
logistic -- 2 -20.68 yes 84.5 57.1 122 
probit -- 2 -20.73 yes 74.2 62 116 
LVM: E2- -- 2 -20.67 yes 79.6 54.9 115 
LVM: H3- -- 3 -20 yes 90 48.9 143 
*: BMD, BMDL and BMDU are in mg/kg bw/d; 5d/w 
BMR: 0.1 
constraint: no 
P-value GoF: 0.05 
 
From the table it can be concluded that all models gave an acceptable fit. Since none of the models is a 
priori preferable above one of the others, the BMDL, which can be selected from this table, is 20.2 
mg/kg bw/d from the EPA one-stage model. This BMDL is the lowest BMDL calculated. A graphical 
representation of the modelled dose response curve is given in figure V.1. Note that in this plot the 
maximal observed incidence of the effect is normalised to 1. 
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Figure V.1. Plot of EPA one-stage model fitted to the data from NTP (2010c) on cytoplasmic
alterations in the renal proximal tubule epithelium in the male mouse subchronic
bioassay with 5HMF.
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Dose-response analysis for nasal changes in male and femal mice in the NTP (2010c) chronic gavage 
study with 5HMF. 
A spectrum of non-neoplastic nasal lesions considered to be related to administration of 5HMF was 
observed. The following effects extended into the low dose group in either or both sexes:  
° Olfactory epithelial metaplasia, 
° Chronic active olfactory epithelium inflammation, 
° Bowman gland hyperplasia 
° Bowman gland dilatation 
° Chronic active inflamation of Bowman glands 
The following data were extracted from the study report: 
TABLE V.3 
  No of animals / group which showed effect* No of animals 
/ group dose  sex OEM ICA GlH GlD GlCAI 
0 m 1 0 3 16 4 50 
188 m 7 6 7 22 12 50 
375 m 38 18 45 47 34 50 
750 m 43 45 45 45 43 47 
0 f 1 0 0 12 1 49 
188 f 5 1 7 36 6 49 
375 f 30 14 42 48 21 50 
750 f 40 41 43 47 38 50 
 
* OEM: Olfactory epithelial metaplasia; ICA: Chronic active olfactory epithelium inflammation; GlH: Bowman gland hyperplasia; GlD: 
Bowman gland dilatation; GlICAI: Chronic active inflammation of Bowman glands. 
 
For all five effects for which the data were analysed, at least two of the 10 models provided an 
acceptable fit. The data of the statistical analysis are only given for the analysis of the data on chronic 
active inflammation of Bowman glands (GlCAI) for which the lowest BMDL of 62.5 mg/kg for the 
males could be calculated (see Table V.4). The BMDLs for the other effects were 65.6, 142, 152 and 
155 mg/kg for GlD, ICA, OEM and GlH, respectively. 
TABLE V.4 Results of a BMD analysis of the data from NTP (2010c) on chronic active 
inflammation of Bowman glands in the  mouse chronic bioassay with 5HMF. 
model covar npar loglik acc BMD* BMDL* BMDU* 
null NA 1 -266.24 -- NA NA NA 
full NA 8 -171.18 -- NA NA NA 
one-stage b 3 -180.3 no 41.3 NA NA 
two-stage b 4 -174.34 yes 101 62.5 147 
log-logist b 4 -172.5 yes 129 97.2 164 
Weibull b 4 -173.81 yes 105 72.7 140 
log-prob b 4 -172.51 yes 132 101 166 
gamma b 4 -173.14 yes 119 83.2 156 
logistic b 3 -175.67 yes 121 102 142 
probit -- 2 -186 no 168 NA NA 
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LVM: E4- a 4 -172.04 yes 94.9 77.2 116 
LVM: H3- a 4 -172.07 yes 114 81.6 149 
*: BMD, BMDL and BMDU are in mg/kg bw/d; 5d/w 
covariate: sex (no covariate is implemented for the probit model) 
BMR: 0.1 
constraint: no 
P-value GoF: 0.05 
 
From Table V.4 it can be concluded that no acceptable fit could be found for the EPA one-stage model 
and the probit model. All other models gave an acceptable fit. Since none of the accepted models is a 
priori preferable above one of the others, the BMDL, which can be selected from this table is 62.5 
mg/kg bw/d from the EPA two-stage model. This BMDL is the lowest BMDL calculated. A graphical 
representation of the modelled dose response curve is given in figure V.2. Note that in this plot the 
maximal observed incidence of the effects is normalised to 1. 
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Figure V.2. Plot of EPA two-stage model fitted to the data from NTP (2010c) chronic active 
inflammation of Bowman glands in the mouse chronic bioassay with 5HMF. (upper 
curve and triangles males; lower curve and circles: females)
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ABBREVIATIONS 
ADI  Acceptable Daily Intake 
AFC  Food Additives, Flavourings, Processing Aids and Materials in Contact with Food 
AST  Aspartate aminotransferase 
BUN  Blood Urea Nitrogen  
BW  Body weight 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids  
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EC European Commission 
EFSA  The European Food Safety Authority 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
FLAVIS (FL) Flavour Information System (database) 
FMO  Flavine-containing Mono Oxygenase 
GI   Gastrointestinal 
GLP  Good Laboratory Practice 
GPT  Glutamic Pyruvic Transaminase 
GSH  Glutathione 
HMF  Hydroxymethylfurfualdehyde 
HMFA  Hydroxymethyl-2-furoic acid 
ID   Identity 
IP   Intra Peritoneal 
IOFI  International Organization of the Flavour Industry 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50 %; Median lethal dose 
LH  Luteinizing hormone 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NAD  Nicotinamide Adenine Dinucleotide  
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NADP  Nicotinamide Adenine Dinucleotide Phosphate 
NADPH Nicotinamide Adenine Dinucleotide Phosphate, reduced form 
NCE  Normochromatic erythrocytes 
No  Number 
NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
PCE  Polychromatic erythrocytes 
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
SMART  Somatic Mutation and Recombination Test  
TAMDI Theoretical Added Maximum Daily Intake 
TDE  Thiol-disulphide exchange 
UDS  Unscheduled DNA Synthesis  
WHO  World Health Organisation 
 
 
